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Although the main stimuli to Cortisol and aldosterone secretion are ACTH
and All, respectively, increasing evidence has implicated other hormones and
neurotransmitters in the regulation of steroidogenesis. In particular, nerve endings in
close apposition to cortical cells and blood vessels have been demonstrated in
humans (and other species) and a variety of neurotransmitters and neuropeptides
detected within these nerves. Other work has established closer morphological
interactions between cortical and medullary cells than hitherto suspected, with the
possibility of paracrine interactions. Vasoactive intestinal peptide (VIP), which is
present in adrenocortical nerves and chromaffin cells, has recently been studied as a
potential steroidogenic agonist, but evidence for a direct effect on steroidogenesis in
humans is controversial and very limited. The aims of this thesis were to investigate
the direct action of VIP on adrenocortical steroid production, by using the human
H295R adrenocortical carcinoma cell-line, and to determine the second messenger
systems activated and the receptor types involved.
The steroid responses to All and forskolin were first characterised in the
H295R cell-line, including the effect of pretreatment with these agonists on the
steroid phenotype of the cells. Forskolin-pretreatment directed steroidogenesis
towards adrenal androgen production and away from 17-deoxysteroid production
compared with All-pretreated cells and control cells, demonstrating that the steroid
phenotype of the cells could be modified by different agonists which utilise different
second messenger systems.
VIP increased steroid secretion from H295R cells in a time-dependent
manner. The pattern of steroid secretion was altered depending on the pretreatment
conditions for the cell-line. VIP increased Cortisol, corticosterone and
androstenedione secretion from forskolin-pretreated cells but had no effect on
androstenedione production from control cells or All-pretreated cells. Although VIP
increased Cortisol and corticosterone from control and All-pretreated cells, forskolin
pretreatment enhanced the Cortisol and corticosterone responses to VIP.
XVIII
The effect of VIP on Cortisol production from forskolin-pretreated H295R cells was
studied further. VIP dose-dependently increased Cortisol secretion (threshold dose «
10"11 M, maximal dose « 3.3 x 10"8 M, pEC50 = 9.2 (±0.4) (n=4)). This response was
accompanied by a parallel, dose-dependent increase in cAMP accumulation
(threshold dose « 10 " M, maximal dose « 3.3 x 10"8 M, pEC50 = 8.6 (±0.5) (n=4)).
Changes in total phosphoinositide turnover and cGMP production were not detected
in response to VIP treatment ofH295R cells.
A p-adrenoceptor-mediated mechanism for VIP-induced Cortisol production
was excluded. Comparison of dose-response curves demonstrated a similar potency
of VIP and PACAP (a highly homologous peptide which shares some receptors with
VIP) for Cortisol secretion and cAMP production (pEC50s for Cortisol response to
VIP and PACAP were 9.4 (±0.4) and 9.8 (±0.1), respectively (n=3) and the pEC50s
for cAMP response to VIP and PACAP were 8.7 (±0.5) and 9.3 (±0.1), respectively
(n=3)), suggesting that these responses were mediated primarily by activation of
VPAC receptors, not PAC1 receptors.
The VPAC2 receptor superagonist, RO-25-1553, failed to stimulate Cortisol
or cAMP production from H295R cells at doses of 10"9 M and 10~8 M (P>0.05) whilst
the VPAC1 receptor antagonists, Cl-Phe6, Leu17-VIP and acetyl-tyr-GRF-amide, had
no effect on VIP-stimulated increases in Cortisol and cAMP production from H295R
cells (P>0.05). Therefore, the VPAC receptor subtype involved in VIP-mediated
Cortisol and cAMP responses was not clearly defined using these pharmacological
tools.
The technique of RT-PCR was used to detect the presence of VPAC1,
VPAC2 and PAC1 receptor transcripts in H295R cells. VPAC1 receptor mRNA was
detected in both untreated and forskolin-treated cells. VPAC2 receptor mRNA was
not detected. A very low level of PAC1 receptor mRNA was observed. In
conjunction with the pharmacological data obtained from comparison of VIP and
PACAP dose-response curves, the weight of evidence is that the Cortisol response to
VIP is mediated predominantly by VPAC receptors, not PAC1 receptors.
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Finally, the steroid responses of H295R cells to ANP, ATP, ACh, NA, 5HT
and VP were briefly examined. ANP consistently inhibited steroid secretion in this
cell-line.
In conclusion, VIP directly stimulates Cortisol secretion from the human
H295R adrenocortical cell-line by a mechanism involving activation of VPAC1
receptors coupled to the formation of cAMP. This supports the hypothesis that VIP
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A general introduction to the adrenal gland, adrenal steroidogenesis and its
regulation is presented in this chapter. In addition, the NCI-H295R (H295R) human
adrenocortical carcinoma cell-line and vasoactive intestinal peptide (VIP) are
introduced. More detailed introductions on sections of particular relevence to the
studies presented in subsequent chapters are included at the beginning of the relevent
chapter. For example, chapter 5.0 includes studies on the second messenger systems
activated by VIP in H295R cells and an introduction to the second messenger
systems studied in the chapter, as well as an introduction to the second messenger
systems activated by VIP in other tissues, is included at the beginning of chapter 5.0
rather than in chapter 1.0. Sections of the thesis have been cross-referenced
appropriately.
1.1 The adrenal gland
1.1.1 Gross anatomy of the adrenal gland
The adrenal glands comprise two ovoid organs situated on the superior pole
of each kidney. The shape and size of the adrenal gland varies between species from
almost spherical in the rat to more flattened and triangular in cattle. In the human,
the left adrenal gland is crescent shaped whereas the right adrenal, lying close to the
inferior vena cava, is more pyramidal. The paired human adrenals weigh
approximately 8 g and measure about 4-6 cm in length, 2-3 cm in width and 1 cm in
thickness. Each gland is surrounded by a thin layer of connective tissue and a thick
fibrous capsule.
The organs are made up of two morphologically and functionally distinct
types of glandular tissue; the inner catecholamine-producing medulla which arises
from neuroectoderm and the outer steroid-secreting cortex of mesodermal origin.
The medullary tissue comprises approximately 10 % of the weight of the human
adrenal and is found situated mainly in the head of the adrenal gland with the cortical
tissue in the tail. The body of the gland comprises both types of tissue.
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The adrenal cortex consists of three roughly concentric zones; the outermost
zona glomerulosa (zg), then the zona fasciculata (zf) and the inner zona reticularis
(zr), which is in contact with the adrenal medulla. These zones are morphologically
distinct and also functionally distinct in terms of which steroids are produced within
the zones (section 1.3.1). The zf and zr, however, are often referred to as one
functional zone (zff). In some species, and especially in the human, there is a degree
of convolution of the adrenal cortex, which results in close contact of both the zf and
the outer zg with the central medulla in specific regions of the gland.
1.1.2 Adrenal blood supply
The adrenals are supplied with blood from small arteries branching from the
aorta, the inferior phrenic artery and the renal artery. These arteries branch to form a
subcapsular arteriolar plexus which subsequently distributes into two types of
vessels; the thin-walled sinusoids which supply the cortex and the medullary arteries
that convey blood directly to the medulla. In the rat, the subcapsular arterioles have
muscular walls suggesting that they may be a site for the control of blood flow
through the gland. The arterial blood flows through capillary loops surrounding the
cells of the zg, then courses through radial capillaries extending through the zf, in a
centripetal formation parallel to the columns of cells within the zf, before entering a
further arterial plexus in the zr and finally draining into the central vein located
within the medulla.
The human adrenal vasculature has the added complexity of the existence of
arteriovenous loops, in which blood is carried through the zg and the zf then loops
back to the exterior of the gland in a site adjacent to its origin. In addition, the
central vein is surrounded by a cuff of inverted cortical tissue in which the three
zones are clearly recognisable.
The number of medullary arteries varies between species, with a relatively
large number in the dog and only 4-6 in the rat. These arteries pass through the
cortex without branching, forming a network of capillaries within the medulla which
then empty into the peripheral radicles of the central vein. The central vein empties
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into the renal vein from the left adrenal and directly into the inferior vena cava from
the right adrenal.
The vasculature of the adrenal is important in the functional zonation of the
cortex and in the regulation of steroidogenesis (sections 1.1.2 and 1.6.3).
1.2 The adrenal medulla
The adrenal medulla consists almost entirely of chromaffin cells. These are
irregularly shaped, polyhedral cells organised in cords or small clumps and
surrounded by nerves, connective tissue and blood vessels. A distinguishing feature
of the chromaffin cell is the inclusion of numerous chromaffin granules, containing
the catecholamines, noradrenaline and adrenaline. In humans, the predominant
catecholamine stored in the medullary chromaffin cells is adrenaline (85% of the
catecholamine store) and the medulla contains distinct noradrenaline-containing and
adrenaline-containing cells. In addition, a variety of non-catecholamine factors have
also been identified in chromaffin cells, including VIP (Phillips & Pryde, 1987).
The adrenal medulla is innervated by cholinergic, preganglionic sympathetic
neurons carried in the splanchnic nerve and stimulation of the splanchnic nerve
results in the release of catecholamines from chromaffin cells. In addition, other
factors, for example, VIP, appear to be released from chromaffin cells following
splanchnic nerve stimulation (Ehrhart-Bornstein et al, 1991a, Bloom et al, 1987).
The adrenal medulla also contains ganglion cells and post-ganglionic neurons. An
intra-adrenal nerve plexus with cell bodies in the medulla, and nerve fibres in the
cortex, has also been described (Holzwarth et al, 1987) (section 1.6.4.1). This intra-
adrenal nerve system contains several neural agents including noradrenaline,
neuropeptide Y (NPY) and VIP (Engeland et al, 1998, for review) (section 1.6.4.1).
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1.3 The adrenal cortex
1.3.1 Adrenocortical Zonation
The adrenal cortex is divided into three roughly concentric zones, the
outermost zg, the zf and the innermost zr. Initially these zones were distinguished
morphologically but a functional division has been shown to underlie these
morphological differences (see Figure 1.1 for a diagrammatic representation of
adrenocortical zonation). The zg lies just below the capsule of the gland and
constitutes approximately 15 % of the cortex in the human. The cells are small with
a low cytoplasm / nucleus ratio and large mitochondria with shelf-like cristae. They
are characteristically arranged in whorls, loops or baskets about 4-6 cells in diameter,
though the volume of the zg alters in response to the physiological status of the
animal.
The cells of the zf are larger than those of the zg, have a higher cytoplasm /
nucleus ratio, small ovoid mitochondria with tubulovesicular cristae and a lipid-rich
cytoplasm. They comprise approximately 75 % of the cortex and are arranged as a
series of centripetally orientated cords.
The network arrangement of cells of the human zr is sharply demarcated from
both the zf and the medulla and comprises cells of intermediate size and cytoplasm /
nucleus ratio. The cytoplasm is lipid-poor and contains numerous lipofuscin
granules. The degree of demarcation of the three zones varies between species; for
example, the zf and zr of the bovine adrenal cortex merge to form a single layer,
often referred to as the zff, whilst the bovine zg is clearly defined from the inner
zones. In contrast, the human zg is poorly demarcated and cells from the zf can be
observed directly under the capsule.
Additional zones may be observed in some species. These include 1) the X-
zone (Chester-Jones et al, 1957), found between the zr and medulla in mice. The X-
zone involutes at puberty to form a band of connective tissue; 2) the special zone,
found only in the inner cortex of adult female marsupials; 3) the zona intermedia (zi),
















Zonation of the mammalian adrenal cortex. Diagrammatic representation of the
arrangement of cells in a cross-section of the adrenal gland.
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between the zg and zf (Deane, 1962); 4) the fetal zone, found in the fetal adrenal of
primates, situated between the definitive cortex and the medulla. The fetal zone
constitutes the majority of the fetal adrenal mass but degenerates rapidly after birth
and has completely disappeared by one year.
Functional zonation of the adrenal is defined by the differences in enzyme
complements between zones and the resultant differences in steroids produced by
each zone. It closely approximates to the morphological zonation in that the zg is the
only site of aldosterone production whereas the zfr mainly produces Cortisol
(corticosterone in rats) and adrenal androgens are synthesised principally by cells of
the zr.
Several hypotheses exist to explain the formation and maintenance of the
adrenocortical zones, including the "zonal hypothesis", the "cell migration
hypothesis" and the "transformation field hypothesis".
1.3.1.1 The Zonal Hypothesis
The "zonal hypothesis" suggests that each zone is self-contained, responsible
for its own replenishment of cells following local cell death (Chester Jones, 1948). It
was based on the finding that all three zones contain proliferating cells. The zonal
theory proposes that each zone contains differentiated cells with its fixed
complement of steroidogenic enzymes.
1.3.1.2 The Cell Migration Hypothesis
The "cell migration hypothesis" proposes that a stem cell layer exists beneath
the capsule which contributes cells to the zg. These cells then migrate through each
of the zones, changing steroidogenic function in the process, and then dying within
the zr (Zajicek et al, 1986).
Variations on the cell migration hypothesis include the suggestion by Belloni
et al (1978) that the stem cell layer exists as an intermediate zone between the zg and
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zf, with cells migrating first into the zg then looping back towards and through the zf
and zr. Mitani et al (1994) identified an intermediate zone, 5-10 cells thick, between
the rat zg and zf. These cells were incapable of aldosterone and corticosterone
synthesis because they lacked P450aldo and P450cllp. Pulse-chase experiments
involving 5-bromo-2'-deoxyuridine labelling demonstrated that cells from this layer
migrate to the zff, suggesting that this may be the progenitor cell zone in the rat
adrenal cortex (Mitani et al, 1994).
1.3.1.3 The Transformation Field Hypothesis
This hypothesis suggests that the width of the zf alters at the expense of the
widths of the other two zones, in particular the zg. For example, ACTH treatment
results in an increase in zf width with a concomitant decrease in the width of the zg
(Bachmann, 1954).
1.3.1.4 The Steroid Gradient Hypothesis
The steroid gradient hypothesis proposed by Hornsby (reviewed by Hornsby
in The Adrenal Cortex, edited by Anderson & Winter, 1985), argues that the
centripetal vascular system creates a gradient of a particular substance across the
cortex (suggested by Flornsby to be corticosterone) which regulates the expression of
the steroidogenic enzymes. The enzymes proposed to be sensitive to this form of
regulation include aldosterone synthase, 11 P-hydroxylase and 21-hydroxylase. This
hypothesis attempts to explain the phenomenon of functional zonation and is
compatible with the cell migration theory of cell replenishment of the zones. The
hypothesis is dependent on the concept that the cells in each zone arise from the same
basic cell type, exhibiting temporary functional and morphological differences. This
concept is supported by the finding that cultured adrenocortical cells from each of the
zones quickly revert to the same steroidogenic phenotype (Hornsby & Crivello,
1983).
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It now appears that aspects of all the hypotheses described (1.1.3.1 - 1.1.3.4)
may be reconciled within the adrenal (discussed by Wolkersdorfer & Bornstein,
1998). Recent studies of apoptosis (programmed cell death) markers and
proliferation markers have indicated that cells in all three zones undergo apoptosis to
differing degrees (Wolkersdorfer et al, 1996). In addition, proliferation and DNA
repair occurs in zones of expected cell senescence, that is, the zr. Thus, it has been
hypothesised that tissue remodelling in the adrenal may be regulated at several
different levels throughout the gland and within each zone (Wolkersdorfer &
Bornstein, 1998).
1.4 Adrenocortical Steroids
The adrenal cortex produces three main types of steroids: mineralocorticoids
(for example, aldosterone), glucocorticoids (for example, Cortisol) and adrenal
androgens (for example, androstenedione and dehydoepiandrosterone (DHEA)). The
precursor to steroid production is cholesterol, a 27 carbon molecule consisting of
three cyclohexane rings (A, B and C) and one cyclopentane ring (D). The structure
of an unnatural compound, cholestane, which can be considered to represent the
backbone of the steroid structure, is illustrated in Figure 1.2.
1.4.1 Mineralocorticoids
The major mineralocorticoid produced by the adrenal cortex is aldosterone, a
21 carbon molecule with an 1 l[3-hydroxyl group which usually exists in a hemiacetal
form with the aldehyde group at CI8.
Formation of aldosterone is dependent on the presence of the enzyme
P450aldo (aldosterone synthase). This enzyme is only present in the zg. The
pathway leading to aldosterone production is illustrated in Figure 1.3. As can be
seen, corticosterone is produced by this pathway and is a precursor to aldosterone




The basic steroid structure. Cholestane, which has 27 carbon atoms in the positions shown,
is not found in nature, but may be considered chemically as the parent hydrocarbon for
cholesterol and related molecules.
Figure 1.3
Major pathways of adrenocortical steroidogenesis in mammals. Steroids in boxes (solid
line) are the steroids measured in these studies. Reactions confined to particular
adrenocortical zones are enclosed in dotted boxes.
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The major action of aldosterone is on the distal convoluted tubule of the
kidney where it regulates Na+ and K+ homeostasis by promoting Na+ reabsorption
and K+, H+ and NH4" excretion. Similar actions on Na+ / K+ exchange in other
secretory epithelia, such as the intestinal mucosa, have been demonstrated.
Aldosterone is released in response to hypovolemic stress. Thus, altered electrolyte
and fluid status is the most important physiological stimulus to aldosterone secretion
and can be induced experimentally by dietary sodium restriction or reduction of
extracellular fluid volume, for example, by controlled haemorrhage. Physiological
stimulation of aldosterone production within the adrenal is mediated primarily by All
and increased K+. ACTH can also increase aldosterone production (Ganguly &
Davis, 1994).
7.4.2 Glucocorticoids
Glucocorticoids are produced primarily by the zfr and the major
glucocorticoid in the human, bovine, sheep and guinea-pig is Cortisol. The pathway
for Cortisol synthesis is illustrated in Figure 1.3. Cortisol and corticosterone have
similar structures (see Figure 1.3), the only difference being an additional 17a-
hydroxyl group in Cortisol. The presence of the steroidogenic enzyme P450cl7
(17a-hydroxylase) is a requirement for Cortisol production and the lack of this
enzyme in most rodent adrenals means that corticosterone is the major glucocorticoid
secreted in these species.
Glucocorticoids have a diverse array of actions including effects on
carbohydrate and protein metabolism. In general, these actions are seen to be in
opposition to those of insulin in that glucocorticoids raise blood glucose levels by
stimulating increased hepatic gluconeogenesis and increased protein catabolism, to
release amino acids which are mobilised to the liver, for use in liver protein synthesis
and gluconeogenesis (Brooks, 1979).
Glucocorticoids also have an anti-inflammatory action in response to injury
or infection by inhibition of cytokine production (Bateman et al, 1989). Interactions
between the immune system and glucocorticoid secretion exist, with certain
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cytokines such as IL-1 and IL-6 stimulating glucocorticoid production and
glucocorticoids acting as immunosuppressants (Bateman et al, 1989).
Excessive amounts of renal Cortisol due to inhibition of 11 P-hydroxysteroid
dehydrogenase (lip-HSD), result in aldosterone-like actions on Na+ and water
retention due to an action on mineralocorticoid receptors (Edwards & Stewart, 1991;
Funder, 1996). Corticosterone is a less potent glucocorticoid than Cortisol in terms of
gluconeogenesis and anti-inflammatory action, but has a greater sodium-retaining
activity (Brooks, 1979).
The major physiological stimulus for glucocorticoid production at the site of
the adrenocortical cell is ACTH.
1.4.3 Adrenal androgens
The main adrenal androgens, androstenedione, DHEA and llp-
hydroxyandrostenedione, are secreted predominantly by the zr in humans and guinea-
pigs but by both the zf and zr in rats. The sulphated form of DHEA (DHEAS) is
produced in large quantites by the human adrenal.
This group of steroids are 19 carbon molecules consisting of the 4 carbon
rings (A, B, C and D) but no side chain (see Figure 1.3 for structures and
biosynthesis pathway). They are relatively weak androgens compared with
testosterone but can be secreted in large amounts after adrenarche. They are further
converted to the potent androgen, testosterone, or to oestrogens in other tissues.
Stimuli involved in androgen production are still unclearly defined. The main
debate is whether androgen production is stimulated predominantly by ACTH
(Anderson, 1980) or whether some other substance, often termed CASH (cortical
androgen stimulating hormone), regulates adrenal androgen production, either in
conjunction with or independently of ACTH. Indications that ACTH is not the only
major regulator of adrenal androgen secretion arise from a number ofphysiologic and
pathologic situations in which a divergence of adrenal androgen production and
ACTH secretion, either measured directly or as reflected by Cortisol concentrations,
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exists (McKenna & Cunningham, 1991; Parker, 1991 (review)). These include the
phenomenon of adrenarche, where adrenal androgen production increases, at about
age 5 years, reaching a peak around puberty, remaining steady until about age 40 / 50
years and thereafter declining. At the same time, ACTH and Cortisol levels remain
relativeley unaltered.
Candidates for CASH have included the POMC peptide, 'Joining Peptide'
(POMC-(79-96)) (Clarke et al, 1996), though this has been disputed (Penhoat et al,
1991; Robinson et al, 1991), (3-endorphin (Clarke et al, 1996) and prolactin (Higuchi
et al, 1984).
1.5 Adrenocortical Steroid Biosynthesis
The steroid pathways leading to synthesis of these main groups of adrenal
steroids are illustrated in Figure 1.3. Cholesterol is either taken up into
adrenocortical cells from the circulation or synthesised de novo from acetate and is
stored within the cell as cholesteryl ester droplets. Stimulation of steroidogenesis,
for example by ACTH, leads to the conversion of cholesterol esters to free
cholesterol and translocation to the mitochondria where conversion to the 21-
hydrocarbon, pregnenolone, takes place (sections 3.1.1.1 and 1.5.1.1).
Two major types of enzymes are involved in steroid biosynthesis: 1)
cytochrome P450s and 2) steroid dehydrogenases. The main enzymes involved in
human adrenal steroid biosynthesis and the genes encoding them are listed in Table
1.1). These enzymes are described in more detail in section 1.5.1.
1.5.1 Adrenocortical Steroidogenic Enzymes
The cytochrome P450 enzymes are found in most tissues and are located in
the mitochondria and endoplasmic reticulum. The active site of each enzyme
contains a heme group which binds the substrate. Steroidogenic P450s catalyse
either a single hydroxylation at a specific position on the steroid or a series of
consecutive hydroxylations which result in C-C bond cleavage or aromatisation of
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Characteristics of human adrenal cytochrome P450
genes
Enzyme Location Genes (n) Chromosome Protein (aa)
P450scc mitochondrial 1 15 482
P450cll mitochondrial 1 8 479
P450cl8/aldo mitochondrial 1 8 479
P450cl7 microsomal 1 10 508
P450c21 microsomal 1 (1) 6 494-495
Table 1.1
Genes encoding the major human steroidogenic enzymes of the adrenal cortex. Numbers in
brackets represent pseudogenes. For review see Hanukoglu (1992).
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the steroid ring (Hanukoglu et al, 1992). The process of hydroxylation involves
transfer of electrons from NADPH via a series of electron carriers, such as
adrenodoxin, to P450 oxidase, which monooxidises the P450 enzyme using 02. In
the mitochondria, electrons derived from NADPH are transferred to the iron-sulphur
protein, adrenodoxin, by the FAD-containing adrenodoxin reductase. The reduced
adrenodoxin dissociates from the adrenodoxin reductase and forms a complex with
cytochrome P450, to which the steroid substrate is bound. After reduction of P450,
the oxidised adrenodoxin returns to the adrenodoxin reductase. In the microsomes, a
single FMN and FAD containing reductase transfers electrons between NADPH and
cytochrome P450.
1.5.1.1 P450scc (cholesterol side-chain cleavage enzyme)
Transfer of cholesterol across the inner mitochondrial membrane may limit
steroid flux overall. However, P450scc is the rate-limiting enzyme of steroid
biosynthesis, catalysing the conversion of the 27-hydrocarbon cholesterol to the 21-
hydrocarbon pregnenolone via three successive monooxygenations (C20
hydroxylation, then C22 hydroxylation and finally cleavage of the C20-C22 bond).
This step occurs at the start of all three adrenocortical steroidogenic pathways.
The enzyme exists as a complex with adrenodoxin and adrenodoxin
reductase, which act as electron transport proteins transferring electrons from
NADPH to the terminal oxidase, P450scc (section 1.5.1). The enzyme has been
cloned in the human, bovine and rat species.
In the adrenal cortex, P450scc has been localised to the inner mitochondrial
membrane and is present in all three zones of the cortex (reviewed by Ishimura &
Fujita, 1997).
1.5.1.2 3J3HSD (3p-hydroxysteroid dehydrogenase)
Pregnenolone and 17a-hydroxypregnenolone (synthesised from pregnenolone
by 17a-hydroxylase (see 1.5.1.3) are converted to progesterone and 17a-
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hydroxyprogesterone, respectively, via the action of 3PHSD. This enzyme catalyses
a two step reaction: dehydrogenation of 3p-hydroxy-5-ene-steroid and isomerisation
of 3-oxo-5-ene-steroid.
At least two types of 3PHSD have been cloned in the human, though only the
type II enzyme has been detected in the adrenal cortex (reviewed in Labrie et al,
1994).
3PHSD has been localised in the same cells as P450scc, in all three zones of
the adrenal cortex and appears to be situated in the membrane of the smooth
endoplasmic reticulum (Ishimura & Fujita, 1997 for review).
1.5.1.3 P450c17 (17a-hydroxylase /17, 20 lyase)
This enzyme catalyses two separate reactions: 1) 17a-hydroxylation of 21-
hydrocarbon steroids and 2) cleavage of the C17-C20 bond of 21-hydrocarbon
steroids. The first reaction is involved in glucocorticoid and mineralocorticoid
synthesis and comprises the conversion of pregnenolone and progesterone to 17a-
hydroxypregnenolone and 17a-hydroxyprogesterone, respectively. The second
reaction is essential for the biosynthesis of androgens and results in formation of
DHEA from 17a-hydroxypregnenolone (and also formation of androstenedione from
17a-hydroxyprogesterone in the rat, but not the human) (see Figure 1.3) (Hanukoglu
et al, 1992 for review).
The regulation of the ratio of 17a-hydroxylase activity / 17, 20 lyase activity
is still unclear. It has been proposed that lyase activity is dependent on the rate of
flow of electrons to P450cl7. For example, an increased molar ratio of the transfer
protein P450 oxidoreductase to P450cl7 would result in an increased ratio of lyase
activity to 17a-hydroxylase activity of P450cl7. Alternatively, a cAMP-dependent
phosphorylation of serine and threonine residues on P450cl7 has been shown to be
important for lyase activity, possibly by increasing the affinity of P450cl7 for redox
partners (reviewed by Miller et al, 1997).
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The enzyme has been immunocytochemically localised to the smooth
endoplasmic reticulum of cells of the zf and zr, with strongest staining in the zf and
no staining in the zg (reviewed by Ishimura & Fujita, 1997). This is in accordance
with the absence of Cortisol production in the zg.
Only one gene for P450cl7 has been identified in the human whereas cattle
appear to have at least three CYP (P450cl7) genes (Miller et al, 1997 for review).
P450cl7 is absent from most rodent adrenals and, consequently, these species utilise
corticosterone as their major glucocorticoid.
1.5.1.4 P450c21 (21-hydroxylase)
This microsomal enzyme catalyses the formation of the precursors of Cortisol
and corticosterone, namely deoxycortisol and deoxycorticosterone, from 17a-
hydroxy progesterone and progesterone, respectively (Figure 1.3). It is expresssed in
all three zones of the cortex (Ishimura & Fujita, 1997). Since P450c21 is required for
both mineralocorticoid and glucocorticoid synthesis, a deficiency in the 21-
hydroxylation step channels steroid biosynthesis in the direction of androgen
production. For example, in the condition of congenital adrenal hyperplasia with 21-
hydoxylase deficiency, the cortex is broadened and consists mainly of zr-type cells.
Excessive production of 17a-hydroxylated substrates for 17, 20-lyase results in
heightened output of CI9 steroids, DHEA and androstenedione. Androstenedione
may be converted peripherally to testosterone, resulting in virilisation.
1.5.1.5 P45011J3 (11J3-hydroxylase)
P45011P is responsible for the formation of Cortisol from deoxycortisol and
corticosterone from deoxycorticosterone. Like P450scc, P45011P exists as a
complex with adrenodoxin and adrenodoxin reductase.
The enzyme has been localised to the inner mitochondrial membrane of cells
from all three adrenocortical zones in the bovine adrenal, though higher levels are
generally found in the zfr. The bovine enzyme exists as two similar isoforms, one
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present in the zg and the other in the zfr (White et al, 1992, for review). The zg
isoform catalyses aldosterone formation via 11 P-hydroxylation of
deoxycorticosterone, followed by 18-hydroxylation and 18-oxidation. The 18-
hydroxylation and 18-oxidation activities of the zfr isoform are suppressed,
preventing aldosterone formation in the zfr.
In the rat adrenal, however, P45011P appears to be localised exclusively in
the zfr (Ishimura & Fujita, 1997). Thus, the rat zg only synthesises relatively low
amounts of corticosterone through the action of P450aldo. A distinct enzyme,
encoded by a separate gene, with 11P-hydroxylation, 18-hydroxylation and 18-
oxidation activities exists in the rat and human zg, which is responsible for
aldosterone synthesis.
P45011P is also capable of hydroxylating androstenedione resulting in the
formation of 11 p-hydroxylated androgens.
1.5.1.6 P450aldo (aldosterone synthase)
Aldosterone synthase (also termed P450cmo, P450cl8 or P450aldo) catalyses
the 11 p-hydroxylation and 18-aldehyde conversion of deoxycorticosterone to
aldosterone (reviewed by White et al, 1992). The enzyme has some properties
similar to P4501 ip but is encoded by a separate gene (CYP11B2 gene for P450aldo
compared with CYP11B1 gene for P45011P). The human gene for aldosterone
synthase has been isolated (Mornet et al, 1989) and transcription of the gene is
regulated by All (White et al, 1992). It has been localised to the mitochondria of rat
and hamster zg cells (reviewed by Ishimura & Fujita, 1997).
1.6 Regulation of steroidogenesis
Steroid hormone output is regulated at several levels including:
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1) mass of the zone in which the steroid is synthesised; for example, an increase in zg
mass contributes to an increase in cortical aldosterone output relative to other end-
pathway steroids.
2) substrate availability, especially the rate at which cholesterol is transported to
P450scc, located on the inner mitochondrial membrane.
3) enzyme activity, determined by factors such as post-translational modification and
the availability of co-factors.
4) levels of steroidogenic enzymes', determined by rates of gene transcription,
stability of mRNA and translation rates. An increase in all adrenal steroidogenic
enzymes will lead to a general increase in steroid production, subject to
constraints imposed by rate-limiting steps, with no alteration in the secretion
ratios of one end-pathway steroid to another (the adrenal end-pathway steroids
being aldosterone, Cortisol (or corticosterone in the rat) and androstenedione (or
DHEA) in this context. An increase in the relative amount(s) of enzyme(s) will
increase the overall production of steroids on that enzyme pathway as well as the
ratio of the different end-pathway steroids.
Each of these parameters can be regulated together or separately by
steroidogenic agonists, for example, ACTH and AIL
1.6.1 The Hvpothalamic-Pituitarv-Adrenal (HPA) axis
Secretion of glucocorticoids from the adrenal cortex is stimulated, in part, by
adrenocorticotrophic hormone (ACTEl). This 39 amino acid peptide is synthesised in
the anterior pituitary from a precursor molecule, pro-opiomelanocortin (POMC),
from which other peptides are also derived such as (3-endorphin.
Stimulation ofACTH synthesis and secretion is primarily under the control of
corticotrophin releasing hormone (CRH), which is a 41 amino acid hypothalamic
peptide synthesised in the parvocellular portion of the paraventricular nucleus.
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Release of CRH from axon terminals at the median eminence occurs in response to
stress, such as pain, fear, hypoglycaemia, hypoxia and haemorrhage. The CRH
enters the hypophysial portal blood system and is transported to the anterior pituitary
where it stimulates receptors on pituitary corticotrophs to synthesise and secrete
ACTH (see Figure 1.4 for illustration of the HPA axis).
ACTH is transported humorally to the adrenal where it acts on ACTH
receptors to stimulate glucocorticoid production from the zf. A feedback inhibition
mechanism exerted by the glucocorticoids regulates the release ofACTH and CRH at
both the pituitary and hypothalamic levels.
Other factors such as arginine vasopressin (VP) and catecholamines can
indirectly regulate steroidogenesis through the HPA axis. The most important of
these is VP, which is synthesised in the hypothalamus and acts in the pituitary to
potentiate the action ofCRH.
Release of ACTH and glucocorticoids throughout the day follows a circadian
rhythm. The highest levels in human plasma are found just before waking and the
lowest levels in the late evening before sleeping. Glucocorticoids exert a feedback
inhibition on the circadian rhythm of the HPA axis.
1.6.2 The Renin-Angiotensin System (RAS)
The RAS is involved in the maintenance of volume homeostasis and
electrolyte balance and is activated in conditions such as haemorrhage and sodium
depletion. A decrease in sodium filtration in the kidney results in the release of
renin, a 38 kDa proteolytic enzyme, from the juxtaglomerular (JG) cells in the
afferent arteriole of the kidney (Peach, 1977). Release of renin is also stimulated by
decreased renal perfusion pressure and sympathetic stimulation of JG cells. This
enzyme is released into the circulation where it converts the plasma protein
angiotensinogen to the decapeptide angiotensin I (AI). The relatively inactive AI is
then cleaved by angiotensin converting enzyme (ACE), found primarily in the lungs,









Simplified illustration ofthe HPA axis. Stimulatory pathways are indicated by solid lines and
inhibitory pathways are indicate by dotted lines.
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1987). All exerts a negative feedback inhibition on renin release from JG cells (see
Figure 1.5 for diagramatic representation of the systemic RAS).
All exerts a variety of actions involved in the maintenance or restoration of
plasma volume, blood pressure and body sodium content, including vasoconstriction
and stimulation of aldosterone production from the adrenal cortex (Vallotton et al,
1987).
All has a short half-life in plasma (2-3 mins) and is rapidly broken down to
shorter fragments by aminopeptidases. Aminopeptidase A cleaves All to form the
heptapeptide AIII (des-Asp'-AII), which is physiologically active and is actually
more potent than All in the stimulation of aldosterone release (Peach, 1977).
1.6.3 Importance of the adrenal vasculature in the regulation of steroid
secretion
Increased blood flow through the adrenal has been associated with increased
steroidogenesis, a phenomenon attributed to several factors including: 1) increased
presentation rate of ACTH to adrenocortical cells, 2) release of endothelin-1 from
the endothelium in response to shear stress, which has been shown to directly
stimulate steroid secretion from adrenocortical cells (reviewed by Bassett & West,
1997).
The finding that changes in blood flow can modulate steroid secretion
irrespective of the presence of ACTH implies an indirect function for vasodilators in
the regulation of steroidogenesis. ACTH itself causes vasodilation by inducing the
release of the vasodilators, serotonin (5HT) and histamine, from mast cells located in
the capsular region near arterioles. Stimulation of the splanchnic nerve results in
increased blood flow and perfusion rate through the adrenal, probably resulting from
the release of vasoactive neuropeptides such as VIP. VIP has also been shown to
increase perfusion medium flow rate through the rat adrenal with a concomitant
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Simplified illustration of the pathway of the RAS leading to stimulation of aldosterone
secretion from the adrenal cortex.
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There is evidence that adrenal blood flow may also be regulated by
modulation of venous outflow from the gland (reviewed by Bassett & West, 1997).
The concept of vascular damming was first raised by Dobbie & Symington in 1966.
They postulated that blood could be trapped within the adrenal gland at the site of the
cortico-medullary junction, by a damming effect created by the transition from the
vessel-abundant vascular plexus in the zr to the relatively few vessels within the
medulla and the presence of longitudinal muscle bands within the thin-walled venous
radicles which empty into the central vein. It has been suggested that the entrapment
of blood within the adrenal may provide a site for storage of glucocorticoid which
can then be released quickly into the circulation in response to stress. Rapid release
of venous congestion is probably mediated by a vasodilator released locally within
the medulla. Intra-adrenal CRH has been suggested to be a likely candidate based on
the following: 1) CRH is a vasodilator, 2) CRH has been detected in the medulla, 3)
levels of CRH within the venous outflow increase following stimulation of the
splanchnic nerve 4) glucocorticoid secretion is increased in the presence of CRH if
the gland architecture is intact.
1.6.4 Intra-adrenal regulation of steroidogenesis
The previous section dealt with 'traditional' control mechanisms for
steroidogenesis. Accumulating evidence, however, exists for additional regulatory
mechanisms. These included observations that increased glucocorticoid secretion did
not always correlate with projected ACTH concentration or presentation rate in the
adrenal (see Charlton, 1990, for review). For example, an increase in glucocorticoid
secretion is detected in cases of raised intracranial pressure following acute brain
injury in man which is not accompanied by a corresponding rise in plasma ACTH
concentration (Feibal et al, 1983). Engeland et al (1981, 1985) demonstrated ACTH-
independent changes in adrenocortical sensitivity and increased Cortisol secretion in
response to small haemorrhage in awake dogs that appeared to be independent of
ACTH presentation rate. Also, corticosteroid secretion rhythms can be dissociated
from ACTH rhythms in rats (Dallman et al, 1978) and dogs (Engeland et al, 1981).
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Several putative neurotransmitters, such as VIP, have been detected in the
adrenal cortex and, together with the accumulating morphological evidence for
adrenocortical innervation (section 1.6.4.1), has indicated a neural control
mechanism in the adrenal cortex. In addition to a postulated direct neural regulation
(via nerve endings in the cortex in close contact with cortical cells), indirect
mechanisms involving neural regulation of a) adrenocortical blood flow, b) cell
growth or c) release of medullary peptides (with a putative paracrine action; section
1.6.4.2) may also affect adrenocortical cell function.
1.6.4.1 Adrenocortical Innervation
The adrenal medulla has a well documented supply of preganglionic
sympathetic, cholinergic, nerve fibres, arising from the splanchnic nerve and
terminating directly on the medullary chromaffin cells (Symington, 1969). These
nerves are involved in the secretion ofmedullary catecholamines.
In 1894 Dogiel described a rich nerve plexus within the adrenal cortex of
mammals, including humans. Despite this, the question of adrenocortical innervation
remained controversial until relatively recently. A series of studies by Dallman et al
(1976) found that nerves were responsible for the compensatory adrenal growth
following unilateral adrenalectomy, providing evidence for a direct effect of
innervation on the adrenal cortex. Splanchnic innervation also modulates adrenal
blood flow, indirectly influencing steroidogenesis (Engeland and Gann, 1989;
Edwards et al, 1986) (section 1.6.3).
Anatomical studies, involving the use of histological, electron microscopic
and catecholamine fluorescence techniques, demonstrated the presence of autonomic
axons within the adrenal cortex in the rat, pig (Unsicker, 1971), guinea-pig and
human (Garcia-Alvarez, 1970, Mikhail & Amin, 1969). Some of these fibres were in
close contact with cortical cells, implying a direct influence of nerves on
steroidogenesis.
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A neuronal system dependent on splanchnic nerve activity has been described
in the rat, with cell bodies arising in the adrenal medulla and fibres running between
the medulla and the cortex (Holzwarth et al, 1987). In addition, two postganglionic
sympathetic nerve plexuses (the afferent (sensory) and the efferent systems) are
present; both run alongside arteries, have their cell bodies outside the adrenal and
appear to be independent of splanchnic nerve stimulation (Holzwarth et al, 1987).
More recently, immunohistochemical staining of a neurone-specific marker,
ubiquitin hydrolase protein gene product 9.5 (PGP 9.5), demonstrated a number of
morphologically different nerves in the human adrenal cortex (McNicol et al, 1994).
Although large nerve trunks were seen traversing the cortex to the medulla, without
apparent synapsing in the cortex, networks of slender nerve bundles and individual
fibres were found in all adrenocortical zones. These fibres exhibited varicosities
indicative of neurotransmitter release. This supported the findings ofDorovini-Zis &
Zis (1991), who reported the presence of nerve terminals in close contact with zona
fasciculata endocrine cells in man. A variety of putative neurotransmitters have been
detected in association with adrenocortical nerves (reviewed by Vinson et al, 1994),
a few of which are briefly discussed below. Some of these neurotransmitters were
found co-localised within the same nerve fibres.
(a) Cholinergic innervation
The presence of acetylcholinesterase (AChE)-positive nerve fibres and cell
bodies within the ovine adrenal cortex was described by Robinson et al (1977).
These fibres, possibly derived from the splanchnic nerve, were distributed within the
cortical parenchymal tissue and formed a distinct neural plexus in the zr. In the
human adrenal, radial trunks of AChE-positive nerves traversed the zona fasciculata
from a subcapsular plexus, often linking with a second neural plexus in the zr
(Charlton et al, 1991; Gilchrist et al, 1993). Individual nerve fibres, branching from
these nerve trunks, synapsed within the cortical parenchyma and appeared to follow
the distribution of the capillaries in the cortex, consistent with a nerve supply to the
cortical cells and/or blood supply (Charlton et al, 1991). Indeed, acetylcholine
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modulated Cortisol secretion directly and also via changes in blood flow in calves
(Edwards & Jones, 1993a, 1993b). Acetylcholine has also been found to directly
stimulate steroidogenesis from isolated, perfused calf adrenals (Rosenfeld, 1955),
bovine zff cells (Hadjian et al, 1982), bovine zg cells (Kojima et al, 1986), frog
interrenal tissue (Benyamina et al, 1987) and rat adrenal glands (Porter et al, 1988).
A muscarinic receptor was postulated to be involved and the presence of this receptor
subtype within the bovine adrenal cortex reported (Hadjian et al, 1981). The
mechanism of action of ACh involved a stimulation of phosphatidylinositol turnover
(Hadjian et al, 1984; Kojima et al, 1986; Walker et al, 1990) and increased levels of
intracellular Ca2+ (Kojima et al, 1986).
(b) Catecholaminergic Innervation
This area has been reviewed in detail by Toth et al (1997). In brief summary,
catecholamine fluorescence studies and immunohistochemical detection of dopamine
P-hydroxylase (DBH; an enzyme involved in noradrenaline synthesis) have revealed
the presence of catecholaminergic neurones in the sheep (Robinson et al, 1977), rat
(Holzwarth et al , 1987) and human adrenal cortex (Charlton et al, 1992). The
nerves were principally noradrenergic (as indicated by the absence of
phenylethanolamine N-methyltransferase (PNMT; the enzyme which converts
noradrenaline to adrenaline) immunoreactivity (Holzwarth et al, 1987; Oomori et al,
1994)) and located mainly in the subcapsular and zona glomerulosa regions. The
distribution, in the human, was similar to the cholinergic innervation, with a second
plexus detected within the outer zr. The nerves did not appear to penetrate the inner
zr or the medulla (Charlton et al, 1992). Nerve fibres were detected in the muscular
walls of cortical blood vessels (Charlton et al, 1992), consistent with a modulatory
effect of postganglionic adrenergic nerves on adrenal blood flow (Carlsson et al,
1993). Branching fibres were also found in close contact with endocrine cells
(Charlton et al, 1992), supporting a direct steroidogenic action for catecholamines.
The catecholamine content ofmany adrenergic neurones found in the zg region was
unaffected by splanchnic nerve input and disappeared following chemical
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sympathectomy (Holzwarth et al, 1987), indicating an extra-adrenal origin of some
noradrenergic nerves in the adrenal.
Catecholamines have been shown to stimulate increased aldosterone secretion
from zg cell preparations of human adrenals (Neri et al, 1996). In addition,
catecholamines regulated steroidogenesis from other mammalian inner zone cells;
Lightly et al (1990) reported increased glucocorticoid secretion from bovine zfr cells
and Ehrhart-Bornstein et al (1994) demonstrated androstenedione secretion from
porcine zfr preparations. Adrenaline stimulated androstenedione release from
isolated, perfused pig adrenals which was antagonised by the P-adrenergic
antagonist, propranolol, but not by the a-adrenergic antagonist, phentolamine
(Ehrhart-Bornstein et al, 1994). Catecholamine-induced steroidogenesis was
accompanied by up-regulation of steroidogenic enzyme transcripts (Ehrhart-
Bornstein et al, 1991b).
(c) VIPergic Innervation
The presence of VIPergic innervation in the adrenal gland has been studied
most extensively in the rat (Hokfelt et al, 1981; Holzwarth et al, 1987; Oomori et al,
1994) but has also been shown to exist in the pig (Kong et al, 1989).
Immunohistochemical studies revealed the presence of a predominant VIPergic nerve
plexus in the capsule-zg region, often associated with blood vessels (Hokfelt et al,
1981; Holzwarth et al, 1987). However, some fibres were seen extending into the
deeper layers of the cortex (Holzwarth et al, 1984) and running between the medulla
and the cortex (Hokfelt et al, 1981) and appeared to innervate clusters of cortical
cells (Holzwarth et al, 1987).
Some VIPergic nerves probably constitute part of the intrinsic neural network
connecting the medulla and cortex, which is dependent on splanchnic nerve activity.
Some intra-adrenal ganglion cells were VIP-immunoreactive (Hokfelt et al, 1981;
Oomori et al, 1994). Splanchnic nerve ligation increased VIP-immunostaining in the
adrenal (Holzwarth et al, 1987) whilst stimulation of the splanchnic nerve resulted in
VIP release from the gland, detected in the adrenal vein of conscious calves (Bloom
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et al, 1987) and from isolated, perfused porcine and rat adrenals (Ehrhart-Bornstein
et al, 1991a; Wakade et al, 1991). In addition, Hokfelt (1981) reported that extrinsic
denervation of the adrenal gland did not affect the presence of VIP-immunoreactive
fibres and ganglion cells.
It is possible that VIPergic nerves may arise from both intra- and extra-
adrenal ganglia. Oomori et al (1994) reported that VIP-containing nerves and
ganglion cells in the medulla were non-catecholaminergic and immunonegative for
neuropeptide Y (NPY), different to those found in the superficial cortex (which were
often immunopositive for NPY, dopamine P-hydroxylase (DBH) and tyrosine
hydroxylase (TH)). The VIP-, NPY-, DBH- and TH-immunopositive fibres were
mainly distributed in the zg and often associated with blood vessels. Hinson &
Kapas (1996) reported that splanchnic nerve section affected VIP immunoreactivity
in the medulla and inner zones of the cortex but not in the capsule-zg. This supports
a dual origin for VIPergic nerves in the adrenal and suggests that VIP may regulate
outer and inner cortical function in different ways.
(d) Otherpeptidergic innervation
These include NPY, calcitonin gene-related peptide (CGRP) and
corticotrophin releasing factor (CRF).
NPY-immunoreactive nerve fibres have been detected in the adrenal cortex of
several mammalian species including horse, rat, mouse and cow (Varndell et al,
1984; Majane et al, 1985). In the rat, a network ofNPY-immunopositive nerves was
identified in the subcapsular-zg region, associated mainly with blood vessels
(Kuramoto et al, 1986). NPY was sometimes found co-localized with VIP in nerve
fibres in the rat outer adrenal cortex (Oomori et al, 1994). Receptors for NPY have
been detected using autoradiography in the bovine zg but not in other regions of the
gland (Torda et al, 1988). Direct modulation of steroidogenesis by NPY is
controversial. Although NPY-stimulated aldosterone secretion from adrenal slices
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was blocked by NPY receptor antagonists (Mazzocchi et al, 1996a), Hinson & Kapas
(1995) found no secretagogue effect of NPY on dispersed rat zg cells. Similar
conflicting data exists for dispersed rat inner cortical cells; Hinson et al (1994b)
noted a small increase in corticosterone secretion from in situ perfused rat adrenals
but not from dispersed rat zfr cells (Hinson et al, 1995). It has been postulated that
the steroidogenic action of NPY may be indirect, either through modulation of blood
flow (NPY-induced secretion of corticosterone from in situ rat perfused adrenals was
accompanied by a change in perfusion medium flow rate (Hinson et al, 1994a) or via
NPY-stimulated release of catecholamines (NPY elicits catecholamine release by
chromaffin cells and the P,-adrenoceptor antagonist, atenolol, inhibited NPY-
mediated aldosterone release by rat capsule-zg preparations (Bernet et al, 1994a,
1994b).
Varicose CGRP-containing nerves have been detected in the capsule-zg
region of the rat adrenal cortex, in close apposition to zg cortical cells (Kuramoto et
al, 1987). Most fibres, however, traversed the cortex to synapse within the medulla.
CGRP-positive fibres have also been found in the adrenal cortex of guinea-pigs
(Heym et al, 1995) and pigs (Kong et al, 1989). The steroidogenic effect of CGRP
appears conflicting. Although CGRP increased aldosterone and corticosterone
secretion from isolated perfused rat adrenals, accompanied by an increase in
perfusion medium flow rate (Hinson & Vinson, 1990), administration to rats
decreased plasma aldosterone levels (Mazzocchi et al, 1992) and inhibited All-
stimulated aldosterone secretion by rat zg cells (Mazzocchi et al, 1996b). Bloom et
al (1989) reported an increase in Cortisol secretion, from functionally
hypophysectomised calves, which could not be explained by increased blood flow
and ACTH presentation rate alone.
CRH-immunoreactive nerve fibres have been detected in the adrenal cortex of
sheep and rat zg (Rundle et al, 1988). Steroidogenic actions ofCRH may be indirect.
CRH failed to elicit a steroid response from dispersed zg cells (Neri et al, 1991) and
was shown to increase adrenal blood flow in calves (Jones & Edwards, 1992). Along
with effects on adrenal blood flow, CRH has been reported to increase adrenal
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sensitivity to ACTH in rats (van Oers et al, 1992). Administration of a CRH
antagonist to conscious calves, however, indicated that CRH does not mediate the
response to splanchnic nerve stimulation (Jones & Edwards, 1991).
1.6.4.2 Cortico-medullary Interactions
The adrenal medulla and the adrenal cortex have long been considered to be
two anatomically and functionally distinct endocrine tissues. Together with the
presence of a neural network linking the medulla to the cortex (section 1.6.4.1),
further evidence has recently been presented which supports both a morphological
and functional interaction between these two glands greater than hitherto suspected.
(a) Cortical actions on the medulla
Adrenocortical steroid hormones influence the functioning of the medulla
(reviewed by Axelrod and Reisine, 1984). Glucocorticoids regulate the synthesis of
adrenaline by modulating the activity of the medullary enzyme PNMT (an enzyme
involved in the conversion of noradrenaline to adrenaline, see Figure. 1.6) as well as
exerting a (lesser) control of the noradrenaline-forming enzyme, DBH. Presentation
of corticosteroids to medullary chromaffin cells is aided by the centripetal blood flow
from cortex to medulla in the adrenal. In addition, adrenocortical cells,
immunopositive for the steroidogenic enzyme 17 a-hydroxylase, have been found
scattered throughout the medulla of porcine, bovine and human adrenals (Bornstein
etal, 1991, 1994).
(b) Medullary action on the cortex
This area has been extensively reviewed by Nussdorfer (1996). The medulla
is innervated by preganglionic, cholinergic, sympathetic neurones carried in the












Illustration ofthe pathway for catecholamine synthesis in medullary chromaffin cells. Some
chromaffin cells do not contain PNMT and therefore cannot synthesise adrenaline. PNMT =
phenylethanolamme-jV-methyl transferase.
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chromaffin cell products, principally catecholamines. Over recent years, evidence
has emerged that the medulla may influence cortical function via a splanchnic nerve-
dependent mechanism (reviewed by Charlton, 1990; Edwards and Jones, 1993b).
Neurotransmitters released from splanchnic nerves may stimulate adrenocortical cells
1) directly, from free nerve endings within the cortex or 2) indirectly, by stimulating
chromaffin cells present within the medulla/adrenal cortex, causing the release of
chromaffin cell secretagogues. These, in turn, could modulate adrenocortical
function in a paracrine manner via specific receptors on the adrenocortical cells.
Although these chromaffin cell secretagogues may affect steroidogenesis directly,
they may act indirectly as well/instead, for example, by modulating adrenal blood
flow or activation of an intra-adrenal RAS. Also, sectioning of the splanchnic nerves
has been shown to decrease ACTH-induced glucocorticoid secretion from conscious,
functionally hypophysectomised calves (Edwards & Jones, 1987) and stimulation of
the splanchnic nerves to increase androstenedione secretion from isolated, perfused
pig adrenals (Ehrhart-Bornstein, 1994).
The predominant agents released from chromaffin cells following splanchnic
nerve activation are the catecholamines, adrenaline and noradrenaline. Both have
been shown to directly affect steroid secretion from outer and inner zone
adrenocortical cells, via adenylate cyclase-coupled p-adrenoceptors (see review by
Nussdorfer et al, 1996, and section 1.6.4.1b).
Other steroidogenic peptides have been detected in the adrenal medulla. It
has recently been demonstrated that human medullary chromaffin cells secrete VP
(Guillon et al, 1995) and that VP can stimulate both aldosterone and Cortisol
secretion from human adrenocortical cells (Guillon et al, 1995; Perraudin et al,
1993).
ANP mRNA has been detected in the adrenal medulla of humans (Lee et al,
1994) and rats (Morel et al, 1988). ANP inhibited both basal and All-stimulated
aldosterone release from mammalian zg cells (reviewed by Nawata et al, 1991).
Chromaffin granules release high concentrations of ATP (Rojas et al, 1986)
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which is known to stimulate Cortisol release from bovine inner zone adrenocortical
cells (Hoey et al, 1994).
Further indirect evidence for a paracrine regulation of the cortex by medullary
peptides/amines relates to the identification of chromaffin tissue within the adrenal
cortex. By using immunostaining techniques for the specific neuroendocrine
markers, synaptophysin and chromogranin A (as markers for chromaffin cells), rays
of chromaffin tissue, extending from the medulla, along with small clusters and
single chromaffin cells, have been observed in all zones of rat, porcine and human
(Bornstein et al, 1991, 1994) adrenal cortex. These chromaffin cells are in close
contact with adrenocortical cells, with no separating interstitium (Bornstein et al,
1991, 1994). Ultrastructural evidence showing exocytosis from a chromaffin cell in
direct apposition to an adrenocortical cell has been documented and lends further
support to a paracrine regulation of steroidogenesis by chromaffin cell products
(Bornstein et al, 1992).
1.6.5 The intra-adrenal RAS
All the components of the systemic RAS, namely, renin, angiotensinogen,
ACE, Al and All, have been identified in the rat adrenal cortex, indicating the
presence of an adrenal RAS (reviewed by Mulrow, 1998). The adrenal RAS has
been further localised primarily to the zg, with greater than 90 % of renin activity
found in zg cells (Doi et al, 1984). The majority of extractable Al and All was also
detected in zg cells (Nakamaru et al, 1985). Most studies on the intra-adrenal RAS
have been performed on the rat but the presence of renin in the human adrenal has
been observed (Naruse et al, 1983).
Although no definite physiological role for this local system has been
identified as yet, evidence exists to support a function in the regulation of aldosterone
(reviewed by Mulrow, 1998). In rats, adrenal renin activity and expression increased
following sodium depletion, accompanied by increased aldosterone production (Doi
et al, 1984). In addition, a high potassium diet caused an increase in adrenal renin
and aldosterone secretion whilst plasma renin activity decreased (Doi et al, 1984).
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Inhibition of the RAS, using ACE inhibitors, in superfused normal human
adrenal tissue and cultured bovine zg cells (therefore unexposed to stimulation by the
systemic RAS) showed a decrease in both All production and aldosterone secretion
(Fallo et al, 1991; Horiba et al, 1990).
The precise mechanism of action of locally produced All on steroidogenesis
is still unclear. Possibilities include an autocrine mechanism whereby All binds to
intracellular (perhaps nuclear) All receptors, or a paracrine action whereby All
released from one cell activates cell-surface receptors on adjacent cells (Mulrow,
1998).
1.6.6 The intra-adrenal CRH-ACTH system
CRH and ACTH immunoreactivity (Suda et al, 1986) have been detected in
the human adrenal medulla and CRH stimulated the release of ACTH from adrenal
fragments (Andreis et al, 1992), suggesting the presence of an intra-adrenal CRH-
ACTH system which may locally regulate adrenal function. CRH-containing cells
and nerves have also been detected in ovine adrenal (Rundle et al, 1988).
A direct action of CRH on adrenocortical function appears unlikely.
Adenylate cyclase-coupled CRH receptors have been detected in the monkey adrenal
medulla which, when activated, stimulate catecholamine secretion (Udelsman et al,
1985). In conjunction with a stimulatory action on intra-adrenal ACTH release
(Andreis et al, 1992), this suggests an indirect modulation of steroidogenesis by
CRH. Udelsman et al (1985) failed to detect the presence of CRH receptors on
adrenocortical cells. Locally secreted ACTH, however, probably acts in a direct
paracrine fashion to stimulate steroid secretion from adrenocortical cells. The
physiological significance of an intra-adrenal CRH-ACTH system is still unclear
though disturbance of the systemic CRH-ACTH system, for example, by
hypophysectomy, results in an increase in adrenal CRH and ACTH immunoreactivity
(Mazzocchi et al, 1994a).
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1.7 Vasoactive Intestinal Peptide (VIP)
VIP is a 28 amino acid peptide (see Figure 1.7) and is a member of a family
of peptides which includes pituitary adenylate cyclase activating polypeptide
(PACAP) and growth hormone releasing hormone (GHRH).
The human VIP gene has been isolated (Itoh et al, 1983; Okamoto et al,
1983). It contains seven exons (Gozes et al, 1986) and encodes at least two peptides;
exon 5 codes for VIP and exon 4 encodes peptide-histidine-methionine (PHM) in
humans (peptide-histidine-isoleucine (PHI) in the rat) (Nishizawa et al, 1985).
Another peptide, PHV (peptide-histidine-valine), can also be produced via a different
cleavage site between PHM and VIP and has been associated with smooth muscle
relaxation (Spokes et al, 1988).
The physiological importance of VIP is indicated by the high degree of
homology between VIP mRNA in humans and rats (80-90 %), with 90% homology
in the VIP-coding domain (Nishizawa et al, 1985). VIP was first isolated from
porcine gut (Said & Mutt, 1970), where it was found to have vasoactive and
secretory properties. Since then, VIP has been detected in the central and peripheral
nervous systems and in neuroendocrine cells, where it exhibits neurotransmitter and
hormonal actions. The actions attributed to VIP are varied; for example, VIP exerts
effects in the gastrointestinal system, including stimulation of gastric motility (Reid
et al, 1988), in the central nervous system and brain, including cerebral vasodilation
(Lee et al, 1984) and memory formation (Gozes et al, 1993) and in the reproductive
system, including oocyte maturation in the ovaries (Tornell et al, 1987), amongst
others. In particular, VIP acts as a secretagogue in a number of tissues, for example,
it stimulates secretion of prolactin from the anterior pituitary (Ehjalbert et al, 1980),
thyroid hormone (Ahren & Hedner, 1989) and catecholamines from the canine
adrenal medulla (Yamaguchi, 1993).
VIP has been localised, predominantly in neurons, in a wide number of
tissues. In the brain, it has been detected in high levels in the cerebral cortex (Said,
1986), hypothalamus (particularly the suprachiasmatic nucleus) (Baldino et al, 1988;
Said, 1986) and anterior pituitary (Morel et al, 1981) as well as other regions of the
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VIP H2N-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-CONH2 H2N-His-Ser-Asp-Gly-l -Phe-Thr-Asp-Ser-Tyr-Ser-Arg Tyrrg-Lys-Gln-Met-Ala Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-CONH2 PACAP27 PACAP38 H2N-His-Ser-Asp-Gly-l -Phe-Thr-Asp-Ser-Tyr-Ser-Arg Tyrrg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu Ala-Ala-Val-Leu-Gls-Lys Arg- Tyr-Lys-Gln-Arg-Val- s-Asn-Ly -CONH2 Figure1.7 AminoacidsequenceofVIPthrelatedpepitdes,PACA 27anP38. lines).TheVIPaminocids que ceidenticalhuma s,ratsndpigs.Thesequenceid ntitybetweenPACAP27a dVIindicated(soli
brain and central nervous system. VIP is often found co-localised with acetylcholine
in nerve endings (Hokfelt et al, 1980).
VIP has been detected in nerve terminals associated with the gastrointestinal
tract (Wattchow et al, 1988) and the tracheobronchial tree (Dey et al, 1988) and has
been detected in placenta and mast cells (Said, 1991, for review). Of particular
importance to this study was the detection of VIP and its transcript in the adrenal
medulla, within nerve terminals in the medulla and cortex and ganglion cells and
chromaffin tissue in the medulla (Hokfelt et al, 1981; Holzwarth et al, 1987; Oomori
et al, 1994). Evidence for a function of VIP in the regulation of adrenal
steroidogenesis is described in section 4.1.1.
1.8 The H295R human adrenocortical carcinoma cell-line
The NCI-H295 cell-line was initially characterised by Gazdar et al (1990) 7-
10 years after isolation of the cells from a primary adrenocortical carcinoma removed
from a female patient exhibiting signs of glucocorticoid, mineralocorticoid and
androgen excess. The cell-line was originally established as a population of cells
which grew in suspension, due to difficulties associated with fibroblast growth
(Gazdar et al, 1990). Unstimulated cells were reported to secrete more than 30
steroids, with the identification of approximately 20 of these (Gazdar et al, 1990).
More recently, a subpopulation of the original cells has been established
which is capable of growing as a monolayer culture (Rainey et al, 1993; 1994). This
population of cells, available from the ATCC and often referred to as H295R cells,
has recently been characterised (Rainey et al, 1994, review). The cells have
been found to express the major steroidogenic enzymes required for synthesis of
steroids from the mineralocorticoid, glucocorticoid and adrenal androgen pathways,
including P450scc, P450cl7, P450c21, P450cl8 and 3pHSD (Staels et al, 1993) and
have been shown to be capable of secreting the principal end-products of these
pathways; aldosterone, Cortisol and androstenedione (Bird et al, 1993; Rainey et al,
1993; 1994 (review)). Moreover, studies have shown that the H295R cell-line is
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steroidogenically responsive to a number of physiological agonists, including All
(Bird et al, 1993), K+ (Bird et al, 1995a) and, to a lesser extent, ACTH (Rainey et al,
1993). Certain key steroidogenic enzymes also appear to be regulated differently by
All and the protein kinase A activator, forskolin (Rainey et al, 1994). In particular,
forskolin increased expression of P450cl7 mRNA most potently, with lesser effects
on P450scc and 3(3HSD transcripts. In contrast, All increased 3PHSD mRNA to the
greatest extent, with lesser effects on P450scc and P450cl7 transcripts (Mason et al,
1995; Rainey et al, 1994).
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1.9 Alms of the thesis
1) To investigate the short-term and long-term effects of All and forskolin on the
secretion of Cortisol, corticosterone, aldosterone and androstenedione from the
H295R human adrenocortical carcinoma cell-line.
2) To investigate whether the steroid phenotype of the cell-line could be altered to a
relatively zg-like cell or a relatively zfr-like cell by pretreatment of H295R cells
with All or forskolin and measurement of the subsequent steroid responses to 4 h
All treatment.
3) To investigate a direct action ofVIP on steroid secretion from H295R cells and to
characterise this response in terms of second messenger systems activated and
receptor types involved, using specific receptor agonists and antagonists,
including VPAC receptor subtype-selective agonists and antagonists, and RT-PCR
analysis ofVPAC 1, VPAC2 and PAC1 receptor transcripts.
4) To undertake a preliminary investigation of the effects of a range of putative
paracrine and neuroendocrine agonists (ANP, ATP, 5-HT, VP, ACh, NA) on
steroid secretion from H295R cells.
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2.0 MATERIALS AND METHODS
2.1 MATERIALS
All chemicals were AnalaR grade and except where otherwise stated were
obtained from BDH Merck or Sigma Chemical Company.
2.1.1 Cell-line culture materials
American Type Culture Collection, Maryland, USA
NCI-H295R human adrenocortical carcinoma cell-line
Gibco BRL (Life Technologies) Ltd., Renfrew
Dulbecco's modified Eagle's medium / Ham's F12 nutrient mix (DMEM / F12),
Earle's Balanced Salt solution (EBSS), penicillin / streptomycin, trypsin (0.25%) /
EDTA (0.2%) solution, Ultroser serum replacement
Mackav & Lynn Ltd., Edinburgh
Corning tissue culture plasticware (75 cm2 flasks, 12-well plates)
Sigma Chemical Co. Ltd., Poole. Dorset
ITS (0.5 pg/ml insulin, 0.5 pg/ml transferrin, 0.5 ng/ml sodium selenite)
2.1.2 Agonists and antagonists
Boehrinser Mannheim UK, Lewes. E. Sussex
adenosine 5' triphosphate (ATP)
Ciba Laboratories. Horsham. W. Sussex
ACTH (1-24; synacthen)
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Martindale Pharmaceuticals. Romford, Essex
adrenaline
NIBSC, Potters Bar. Herts.
angiotensin II (asp'-val5; WHO standard 64/15), human atrial natriuretic factor (ANP
99-126; WHO standard 85/669)
Novabiochem. Switzerland
pituitary adenylate cyclase activating polypeptide 1-38 (PACAP 38)
Parke-Davis. Pontvvool, Gwent
arginine vasopressin (pitressin)
Pharmax Ltd.. Bexlev. Kent
isoprenaline (hydrochloride; as Saventrine)
Sanofi Winthrov Ltd., Guildford. Surrey
noradrenaline (tartrate; as levophed)
Sisma Chemical Co. Ltd., Poole, Dorset
acetylcholine chloride (ACh), human atrial natriuretic peptide (ANP), vasoactive
intestinal peptide (VIP; porcine, synthetic), [D-p-Cl-Phe6, Leu17]-VIP (human,
porcine, rat; synthetic)




Amersham International Pic. Little Chalfont, Bucks
Cortisol tracer (Cortisol -3-(0-carboxymethyl) oximino-(2-[l25I] iodohistamine)),
specific activity 2000 Ci / mmol.
Scottish Antibody Production Unit fSAPU), Carluke. Lanarkshire
antisera to Cortisol (batch no.: 7250X), non-immune sheep serum (batch no.: 7414Y),
donkey anti-sheep (goat) IgG (batch no.: 7426Y), donkey anti-rabbit IgG (batch no.:
7144X), normal rabbit serum (batch no.: 7374Y).
Sigma Chemical Co. Ltd., Poole, Dorset
aldosterone, androstenedione, corticosterone, charcoal, dextran, Cortisol, sodium
azide
Dr. B. C. Williams. Department ofMedicine. Western General Hospital, Edinburgh,
Scotland kindly supplied:
cAMP tracer (adenosine 3',5'-cyclic phosphoric acid 2'-0-succinyl-3 [125I]
iodotyrosine), cGMP tracer (guanosine 3',5'-cyclic phosphoric acid 2'-0-succinyl-3
[l25I] iodotyrosine), cAMP antibody, cGMP antibody, aldosterone tracer
(aldosterone-3(0-carboxymethyl)oximo-(2[I25I]iodohistamine), aldosterone
polyclonal antibody, corticosterone tracer (corticosterone-3(0-
carboxymethyl)oximo-(2['25I]iodohistamine), corticosterone polyclonal antibody,
cAMP stock standard, cGMP stock standard.
Dr. M. Wallace. Dept. Clinical Chemistry, Royal Infirmary, Glasgow. Scotland
kindly donated: androstenedione tracer (androstenedione-3-carboxymethyloxime
[l25I]iodohistamine), androstenedione antibody
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2.1.4 Molecular biology materials
Stratasene Ltd.. Cambridge
RT-PCR kit
Dr. E. Lutz, MRC Brain Metabolism Unit, Royal Edinburgh Hospital. Scotland
kindly donated: VPAC1 receptor primers, VPAC2 receptor primers, PACI receptor
primers, all VPAC1 receptor, VPAC2 receptor and PACI receptor positive control
material for PCR reactions, HPRT primers
2.1.5 Phosphoinositols assay and protein assay materials
Aldrich Chemical Co. Ltd., Gillinsham, Dorset
1,1,2-trichlorotrifluoroethane, tri-n-octylamine
Amersham International Pic. Little Chalfont, Bucks
myo-[3H]-inositol, specific activity 81 Ci / mmol.
BDHMerck Ltd., Lutterworth. Leicestershire
formic acid (ammonium salt), lithium chloride, perchloric acid, triethylamine,
ethylenediamine tetraacetic acid (EDTA, disodium salt)
Bio Rad Laboratories Ltd.. Hemel Hempstead, Herts.
AG1-X8 anion exchange resin
Canberra Packard. Pansbourne, Berks
scintillation vials, liquid scintillant (Ultima Gold)
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Siema Chemical Co. Ltd.. Poole. Dorset
ammonium formate, bovine serum albumin (BSA) (cell culture grade, fraction V),
laurylsulphate (sodium salt; SDS)
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2.2 METHODS
2.2.1 NCI-H295R Cell-Line Culture
NCI-H295R (H295R) cells were grown in 75 cm2 tissue culture flasks and
maintained in growth medium (DMEM / F12(l:l)(10ml per flask) containing 2%
Ultroser and 1% ITS solution) at 37°C under an atmosphere of 95% air/5% C02.
Exhausted medium was replaced with fresh medium every 2-3 days.
Cells were subcultured upon reaching confluence using trypsin (0.25%) /
EDTA (0.2%) solution, 5 ml / 75 cm2 flask for 60 sees. This was usually a period of
7-10 days, due to the low proliferation rate of these cells. At monthly intervals cells
were routinely subcultured into growth medium containing penicillin (50 IU/ml) and
streptomycin (50 pg/ml) and maintained in this medium prior to further passage.
This was to remove any low-level bacterial infections which may have been present.
Every three to four months, cells were also tested for the presence of any
mycoplasma infection. This was performed by fixing the cells in acetone and then
staining DNA (cell nuclei and mycoplasma, found in cytosol) using Hoechst 33258
fluorochrome, followed by visualisation using a UV spectrophotometer.
2.2.2 Treatment of cells with agonists and antagonists
2.2.2.7 Chronic treatment of H295R cells.
H295R cells were seeded into 12-well plates and maintained as described in
2.2.1 until confluent (7-10 days). Cells were then incubated with fresh growth
medium (as defined in 2.2.1) with or without All (10 nM) or forskolin (10 pM) for a
period of 96 h, this medium being replaced with fresh agonist-containing medium
every 24 h. Medium from each 24 h period was collected, stored at -20°C, and
subsequently analysed for Cortisol, corticosterone, androstenedione and aldosterone
content by radioimmunoassay (RIA) procedures. H295R cells were also treated in
the same manner with VIP (concentrations as stated in chapter 4.0) for up to 96 h and
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with a range of putative agonists (ANP, ATP, 5-HT, VP, ACh, NA; concentrations as
stated in chapter 7.0) for 24 h.
2.2.2.2 Short-term stimulation ofH295R cells following chronic treatment.
Following the chronic treatment phase with All or forskolin, as detailed in
2.2.2.1, cells were incubated with or without All (10 nM) for 4 h in order to
determine any possible effect of the different chronic pretreatment conditions on the
steroidogenic phenotype of the cells. Cells were also treated with a range of agonists
(VIP, ANP, ATP, 5-HT, VP, ACh, NA; concentrations as stated in chapters 4.0 and
7.0) and the steroidogenic responses of the cell-line characterised.
For these experiments, pretreatment agonists were removed by discarding the
medium and washing each well with 2 x 1 ml EBSS. Cells were then incubated in
fresh growth medium with agonist or without (basal) for 4 h at 37°C (doses and
alternative times as stated in sections 3.2, 4.2 and 7.2). At the end of the treatment
period, medium was aspirated from each well and stored at -20°C until assayed for
steroid content by RIA as described in section 2.2.4. The remaining monolayer of
cells was washed, solubilised and assayed for protein content as described in section
2.2.6. Steroid data was expressed as pmol steroid secreted per mg protein.
2.2.2.3 The effect of pretreatment of H295R cells with forskolin on the
subsequent VIP responses.
Cells were treated with growth medium containing forskolin (10 pM) for 72 h
(or as stated in time-courses). Medium and agonists were replaced every 24 h. After
this time, cells were washed with 2 x 1 ml EBSS and then incubated with growth
medium containing VIP for 4 h (concentrations as stated in chapter 4.0). Medium
was collected and stored at -20°C until assayed for steroid content by RIAs. Total
cellular protein from the remaining cell monolayer was determined (2.2.6).
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2.2.2.4 Effect of treatment with VIP, PACAP, RO-25-1553 and the p-
adrenoceptor agonists, adrenaline and isoprenaline, on steroid secretion and
cyclic nucleotide production by H295R cells
Following pretreatment of cells with forskolin (10 pM) for 72 h (2.2.2.3),
medium was discarded and cells were washed with 2 x 1 ml EBSS and then
incubated for 1 h in serum-free growth medium (DMEM / F12 (1:1) containing 1%
ITS) prior to the start of the experiment. Cells were then incubated in 1 ml / well
fresh serum-free growth medium containing VIP, PACAP, adrenaline or isoprenaline
for 4 h at 37°C (concentrations and alternative times as indicated in chapters 4.0 and
5.0). Medium was aspirated from the wells and stored at -20°C until assayed for
Cortisol or processed as described in 2.2.3.2 and subsequently assayed for cyclic
nucleotide content.
2.2.2.5 Effect of fi-adrenoceptor antagonists and VPAC receptor antagonists
on VIP-stimulated steroid secretion and cyclic nucleotide production by
H295R cells
Cells were pretreated with forskolin (10 pM) for 72 h, washed and incubated
in serum-free medium for 1 h prior to treatment with agonists or antagonists
(2.2.2.4). Cells were then incubated in serum-free medium alone (basal) or
containing antagonist (concentrations as stated in chapter 6.0) for 30 mins prior to the
addition of VIP (10"9 M or as stated in chapters) for 4 h at 37°C. Medium was
aspirated from each well and either stored directly at -20°C until assayed for Cortisol
or processed as described in 2.2.3.2 and subsequently assayed for cyclic nucleotide
content.
2.2.3 Measurement of cyclic nucleotide production
2.2.3.1 In cells
Forskolin-pretreated cells (2.2.2.4) were incubated in serum-free growth
medium with or without VIP (3.3 x 10"8 M) for 1, 2.5, 5, 10, 20, 60, 120, 240 min.
At each time-point, the medium was rapidly removed (and kept, 2.2.3.2) and 0.5 ml
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ice-cold 75% (v/v) ethanol added to each well for a period of 5 mins. Cells were
then scraped from the base of the well, using the rubber tip on the plunger from a 1
ml syringe, and removed to an Eppendorf tube. Each well was rinsed with 1 ml
ethanol (75% v/v) and this was added to the original 0.5 ml collected. The tubes
were centrifuged for 15 mins at 450g in a Heraeus Christ Labofuge B. The cyclic
nucleotide containing supernatants were decanted to glass tubes and the ethanol
evaporated off under a stream of air at 37°C for 1-2 h on a Techne-Dri block : DB3
fitted with a SC3 Jencons sample concentrator. This extraction method routinely
leads to 85-90 % recovery of cyclic nucleotide. Once evaporated to dryness, the
residues were reconstituted in 500 pi serum-free growth medium. Samples were
immediately acidified, by addition of 5 pi acetic acid (20% v/v) and acetylated by
addition of 15 pi of a freshly prepared 2 : 1 mixture of triethylamine / acetic
anhydride with immediate vortexing. Samples were stored at -20°C prior to
measurement of cAMP or cGMP by RIA (section 2.2.4).
2.2.3.2 In medium
Forskolin-pretreated cells (2.2.2.4) were incubated in serum-free growth
medium with or without VIP (3.3 x 10"8 M) for 1, 2.5, 5, 10, 20, 60, 120, 240 min
(for time-courses, or as detailed in sections 2.2.2.4 and 2.2.2.5). Medium from
stimulated cells was removed and divided into 2 aliquots: 350 pi was stored at -20°C
for analysis of Cortisol content by RIA and the remaining 650 pi was acidified using
6.5 pi acetic acid (20% v/v) for cyclic nucleotide measurement. This acidified
aliquot was then subdivided into a 250 pi portion (frozen at -20°C for measurement
of cyclic nucleotides using the 'non-acetylated' RIA method) and a 400 pi portion
(which was immediately acetylated using 12 pi of a 2 : 1 (v/v) mixture of
triethylamine / acetic anhydride and stored at -20°C prior to analysis using the
'acetylated' cyclic nucleotide RIA method).
In some experiments (chapter 5.0), the phosphodiesterase inhibitor IBMX (2-
isobutyl-l-methylxanthine, 0.5 mM) was included in the treatment media, to reduce
any possible degradation of cyclic nucleotides by phosphodiesterase which could
have been present in the cells.
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2.2.4 Radioimmunoassays
All radioimmunoassays (RIAs) were performed in polypropylene tubes using
a Clinicon Dilutrend automatic diluter. Duplicate tubes were set up for each standard
/ QC / unknown sample. Tubes containing working tracer solution alone were
included in each assay to allow measurement of the 'total counts' added to each tube.
Intra-assay drift and inter-assay precision were checked by incorporating quality
control (QC) samples in each assay and calculating the coefficients of variation
(CVs). The minimum detection limit (MDL) for each assay was calculated by
combining and plotting the precision profile data from at least n=10 assays (n=9
assays for cGMP RIA) and reading the concentration of assayed substance at which
the CV was >22% CV (McConway et al, 1989).
Following separation of the 'bound' and 'free' tracer fractions, the radioactive
pellets in the tubes were analysed in a gamma-counter (LKB 1621 Multigamma) for
the times stated and the radioactivity expressed as counts per minute (CPM).
Standard curves were fitted using the RIACALC (LKB / Pharmacia) software
package.
2.2.4.1 Standard Cortisol RIA
Cortisol secretion into the growth medium by H295R cells was measured
using a modification of the Cortisol RIA described by Gray et al (1983) which
employed a double antibody preprecipitate to separate bound and free tracer.
Cortisol standards (1-2000 nM) were prepared by dilution of a stock Cortisol
solution (10 mM in ethanol) in H295R growth medium and stored at -20°C.
Cortisol tracer (cortisol-3-(0-carboxymethyl) oximino-(2-[125I]iodohistamine;
obtained in methanol : water (9:1)) was diluted in assay buffer 1 (0.1 M citrate buffer
containing 0.2% (w/v) gelatin, 0.013% (w/v) sodium azide, pH 4.0) to obtain a
solution with approximately 104 counts / 700 pi (working tracer solution).
The double antibody preprecipitate was prepared from normal sheep serum
(530 pi), sheep anti-cortisol (polyclonal primary antibody from SAPU; 650 pi,
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reconstituted in assay buffer), 15 ml donkey anti-sheep /goat IgG (secondary
antibody) and 10 ml assay buffer. This solution was mixed, left to equilibrate
overnight at 4°C, then centrifuged at 230g for 15 mins. The soft pellet was
reconstituted in a total volume of 500 ml assay buffer to form the double antibody
preprecipitate working suspension.
700 pi working tracer was pipetted into each tube with 100 pi sample /
standard / QC. Preprecipitate antibody solution (250 pi) was then added and the
tubes vortexed and incubated for 2 h at 37°C. The tubes were centrifuged at 1800g
for 30 mins, the supernatants carefully decanted by inversion and the tubes gently
blotted on cellulose wadding before reversion. Pelleted antibody-bound counts were
measured on the gamma-counter for 120 seconds per tube.
The intra-assay drift was typically <10% and the inter-assay precision was <
10% for the range 50-2000 nM and <15% for the range 10-50 nM. The inter-assay
CVs for the QC samples 80 and 800 nM were 7% and 6% respectively. The MDL
for the assay was 6 nM. An example of a typical standard curve obtained (fitted to a
4-parameter logistic model) is shown in Figure 2.1.
2.2.4.2 More Sensitive Cortisol RlA
When necessary (measurements <50 nM), Cortisol secretion from H295R
cells was measured using a more sensitive "in-house" modification of the Cortisol
assay described in section 2.2.4.1. Polyclonal sheep anti-cortisol antibody, obtained
from SAPU, was initially used to bind Cortisol in the liquid phase. Following an
incubation phase, donkey anti-sheep / goat secondary antibody (which bound to the
first antibody) was used to separate the bound and free tracer.
Standards were prepared as described in section 2.2.4.1 (either in serum-
containing or serum-free growth medium to match the experimental conditions) but
in concentrations 0.31-80 nM, with QC samples of 4, 8 and 16 nM. Cortisol tracer
(as in 2.2.4.1) was diluted in 100 mM citrate-phosphate buffer, pH 4.0, containing
0.02% (w/v) gelatin and 0.0013% (w/v) sodium azide (assay buffer 2) to give a





















0 ~f 1—I I I I 1111 1—I rpTTT| 1—I I | I III] 1—I I | I 1111 1—I I | 1111|
0.1 1 10 100 1000 10000
[CORTISOL] (nM)
Figure 2.1
Representative standard curve for the 'standard' 125j radioimmunoassay of Cortisol.
Standard solutions of Cortisol (1-2000 nM, in H295R growth medium as used in each
experiment) were assayed in duplicate and the standard curve fitted to a four parameter
logistic equation. Tracer binding in the absence of Cortisol was typically 70-80% of the
total tracer added.
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Working Cortisol tracer (650 jj.1) and sample / standard / QC (50 pi) were
pipetted into tubes before addition of the primary antibody (sheep anti-cortisol; initial
dilution of 1:5000 in assay buffer 2). The tubes were vortexed and incubated for 4 h
at room temperature (20-25°C). 100 pi each of normal sheep serum (initial dilution
of 1:200 in assay buffer 2) and secondary antibody (donkey anti-sheep / goat IgG);
initial dilution of 1:15 in assay buffer 2) were then added, the tubes vortexed and
incubated overnight at 4°C. Following centrifugation at 1800g, for 30 mins, the
supernatant was carefully decanted (as described in section 2.2.4.1) and the tubes
counted in the gamma-counter for 120 seconds each.
Intra-assay variation was routinely <10% and inter-assay precision was <10%
for the range 10-80 nM. The inter-assay CVs for the QC samples 4, 8 and 16 nM
were 15%, 15% and 6% respectively. The MDL was 3 nM. An example of a typical
standard curve obtained (fitted to a 4-parameter logistic model) is shown in Figure
2.2.
2.2.4.3 Corticosterone RIA
Corticosterone secretion from H295R cells was measured by an "in-house"
RIA adapted from a method published by Al-Dujaili et al (1981). The method
employed the use of a polyclonal antibody to bind corticosterone and a dextran-
coated charcoal suspension to separate bound from free tracer.
Standards were prepared in experimental growth medium at concentrations
between 0.1-200 nM from a stock solution of 2 mM corticosterone in ethanol. QC
samples at concentrations of 1.5, 15 and 150 nM were routinely used in each assay.
Aliquots of standards and QCs were stored at -20°C.
A working solution of iodinated corticosterone tracer was prepared by
dilution in assay buffer 3 (0.1 M phosphate buffer, pH 7.4, containing 0.1% (w/v)
sodium azide and 0.1% (w/v) BSA) to give ~ 4000 cpm / 100 pi.
50 pi sample / standard / QC was added to each tube followed by 100 pi
tracer and then 100 pi of corticosterone antibody (initial dilution 1:8000 in assay
buffer 3, as determined by an antibody dilution curve), the tubes vortexed, covered in






















Representative standard curve for the more 'sensitive' radioimmunoassay method for
measurement of Cortisol. Standard solutions of Cortisol (1-80 nM, in H295R growth
medium as used in each experiment) were assayed in duplicate and the standard curve fitted
to a four parameter logistic equation. Tracer binding in the absence of Cortisol was typically
40-50% of total tracer added.
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cold charcoal suspension (0.6% (w/v) activated charcoal, 0.06% (w/v) dextran T70,
0.04% gelatin in 0.1 M phosphate buffer, pH 7.4) was added to each tube. Following
centrifugation at 1800g for 30 mins, 4°C, the supernatant, containing antibody-bound
tracer, was carefully decanted and the charcoal pellets, containing the remaining free
tracer unbound to antibody, were counted in a gamma-counter for 180 seconds.
Intra-assay drift was routinely found to be <10% and inter-assay CVs for QC
samples 1.5, 15 and 150 nM were 22%, 11% and 9% respectively. Overall, the inter-
assay precision was <15% for the range 2-50 nM. The MDL for the assay was 1.5
nM. A specimen standard curve (fitted to a 4-parameter logistic model) is illustrated
in Figure 2.3.
2.2.4.4 Aldosterone RIA
Aldosterone secretion from H295R cells was measured using an "in-house"
RIA adapted from Brochu et al (1989). The method was essentially similar to that
used for the corticosterone RIA, employing a charcoal suspension to separate free
from bound tracer.
Standards over the range 0.05-50 nM were prepared in experimental growth
medium, from a stock solution of 50 pM aldosterone in ethanol. QC samples were
used at 1, 10 and 20 nM. Intra-assay variation was typically <10%. The inter-assay
CVs for the QC samples 1,10 and 20 nM were 23%, 15% and 4% respectively. The
MDL could not be calculated as insufficient precision profile data was obtained.
Iodinated aldosterone ( aldosterone -3(0- carboxymethyl ) oximo -
(2[l25I]iodohistamine ) was diluted in assay buffer 3 (section 2.2.4(iii)) to give a
tracer solution at ~ 4000 cpm / 100 pi.
Tubes were set up as described for the corticosterone assay with 50 pi sample
/ standard / QC, 100 pi tracer and 100 pi antibody followed by overnight incubation
at 4°C. Bound tracer was separated from free tracer by addition of 500 pi charcoal
suspension followed by centrifugation (section 2.2.4.3). Figure 2.4 illustrates a
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Fisure 2.3
Representative standard curve for the radioimmunoassay for corticosterone. Standard
solutions of corticosterone (0.1-200 nM, in H295R growth medium as used in each
experiment) were assayed in duplicate and the standard curve fitted to a four parameter
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Figure 2.4
Representative standard curve for the 125j radioimmunoassay of aldosterone. Standard
solutions of aldosterone (0.05-52 nM, in H295R growth medium as used in each
experiment) were assayed in duplicate and the standard curve fitted to a four parameter




The RIA used to measure androstenedione secretion from H295R cells was an
adaptation of the method by Thomson et al (1989) and employed the use of a second
antibody precipitation to separate bound from free tracer.
Standards were prepared in experimental growth medium representing 0.5-35
nM. QC samples were used at 1.1 and 3.5 nM. Intra-assay drift was routinely found
to be <10% and inter-assay variation was <10% for the range 0.8-3.5 nM and <15%
for the range 0.5-6 nM. Inter-assay CVs for the QC samples 1.1 and 3.5 nM were
8% and 13% respectively. The MDL was 0.5 nM.
Radiolabeled androstenedione (androstenedione-3-carboxymethyloxime
[125I]iodohistamine) was diluted in assay buffer 4 (0.1 M phosphate buffer, pH 7.4,
containing 0.25% (w/v) BSA) to give a tracer solution at 104 cpm / 150 pi.
Into duplicate tubes was pipetted 50 pi sample / standard / QC, 150 pi tracer
solution and 200 pi androstenedione antibody (initial working dilution ~ 1:20,000,
determined by an antibody dilution curve, prepared in assay buffer 4). Tubes were
vortexed, covered with cling-film and incubated at room temperature (20-25°C) for 2
h.
Following the addition of 400 pi second antibody preprecipitate solution
(donkey anti-rabbit (1:40 dilution) and normal rabbit serum (1:250 dilution),
prepared in assay buffer 4), tubes were vortexed and incubated overnight at 4°C.
Tubes were centrifuged at 1800g for 45 mins, 4°C, and the supernatant decanted as
described in section 2.2.4.1. Pellets, containing antibody-bound tracer, were counted
on a gamma-counter for 120 seconds. Figure 2.5 shows a typical standard curve
obtained (fitted to a 4-parameter logistic model).
2.2.4.6 Cyclic nucleotide RIAs
The RIA methods used to measure cAMP and cGMP production by H295R
cells were based on the method of Brooker et al (1979). The antibodies used were
raised in rabbits against the succinylated form of the cyclic nucleotide and the



























Representative standard curve for the 125j radioimmunoassay for androstenedione.
Standard solutions of androstenedione (0.5-35 nM, in H295R growth medium as used in
each experiment) were assayed in duplicate and the standard curve fitted to a four parameter
logistic equation. Tracer binding in the absence of androstenedione was typically 55-65%
of total tracer added.
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pre-acetylation of standards and samples gave an increased assay sensitivity.
Depending on the sensitivity required in the RIA, cyclic nucleotides were measured
by either the 'non-acetylated cyclic nucleotide RIA' (the case for cAMP analysis) or
the 'acetylated cyclic nucleotide RIA' (the case for cGMP analysis).
(a) Non-acetylated cyclic AMP RIA
Standards were prepared from a stock solution of 32 pM of the sodium salt of
cAMP in acidified serum-free growth medium (20% (v/v) acetic acid 1: 99 serum-
free growth medium) over the range 1.25-320 nM. QC samples were used at 5, 20
and 80 nM. Intra-assay variation was <12% and inter-assay drift was <10% for the
range 15-200 nM and <15% for the range 5-320 nM. The MDL was 2 nM.
100 pi working tracer solution (containing ~6000 cpm/100 pi, diluted in 0.05
M acetate buffer, pH 5.0, 0.1% (w/v) gelatin) was combined with 50 pi sample /
standard / QC and 100 pi antibody working solution (initial titre determined by
performing an antibody dilution curve with each new batch of tracer, usually
~ 1:20,000) and incubated overnight at 4°C.
The separation of antibody-bound and -free tracer fractions (using a dextran-
coated charcoal suspension) and subsequent analysis of radioactive content of the
tubes was performed as described in section 2.2.4.3. An example of a typical
standard curve obtained (fitted to a 4-parameter logistic equation) is shown in Figure
2.6.
(b) Acetylated cyclic GMP RIA
Standards (over the range 0.125-32 nM), QCs (0.5, 5 and 10 nM) and samples
were pre-acetylated in glass tubes (as described in 2.2.3.2). Intra-assay drift was
routinely found to be <10% and inter-assay variation was <10% for the range 0.7-9
nM and <15% for the range 0.4-20 nM. Inter-assay CVs for the QC samples 0.5, 5
and 10 nM were 14 %, 8 % and 10 % respectively. The MDL was 0.25 nM (see
chapter 5.0).
100 pi sample / standard / QC was combined with 150 pi iodinated cGMP
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Representative standard curve for the radioimmunoassay for cAMP. Standard
solutions of the sodium salt of cAMP (1-320 nM, in acidified H295R growth medium, pH
5.0) were assayed in duplicate and the standard curve fitted to a four parameter logistic
equation. Tracer binding in the absence of cAMP was typically 70-80% of total tracer
added.
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0.1% (w/v) gelatin) and 100 |al antibody (initial titre determined from an antibody
dilution curve) and incubated overnight at 4°C.
A dextran-coated charcoal suspension was used to separate bound and free
tracer fractions (as described in 2.2.4.3). Figure 2.7 shows a typical standard curve
obtained (fitted to a 4-parameter logistic model).
2.2.5 Measurement of total PHI phosphoinositol
Stimulation of phosphatidylinositol turnover was measured in H295R cells.
The method used is described by Bird et a! (1992).
H295R cells were seeded into 12-well plates and grown to near-confluence.
Cells were then pretreated with growth medium with or without forskolin (10 pM)
for 24 h (1 ml / well), then in serum-free growth medium with the addition of
[3H]inositol (10 pCi / ml) and forskolin (10 pM) for a further 48 h (0.5 ml / well).
Before subsequent acute treatment with agonists, labelled medium was removed and
the cells incubated at 37°C, for 15 mins, with 0.5 ml DMEM / F12 supplemented
with 0.2 % (w/v) BSA to wash away extracellular inositol. This medium was then
removed and replaced with 0.45 ml DMEM / F12 containing 0.2% BSA, 10 mM
unlabelled inositol (to chase unincorporated labelled inositol out of the cells) and 10
mM LiCl (to inhibit phosphoinositol phosphatases). After 15 mins, additions of 50
pi DMEM / F12, 0.2% BSA were added with or without agonists and the cells
incubated at 37°C for 30 mins. At the end of this time, 250 pi ice-cold perchloric
acid (15% v/v) was added to each well to denature proteins and lyse the cells.
The cells were then scraped from the base of the wells, using the rubber tip
from the plunger of a 1 ml syringe, and the contents of the well removed, with a 0.5
ml water wash, to a 1.5 ml Eppendorf tube. The samples were centrifuged at 3300g
in a microfuge (Scotlab microcentaur) for 3 mins and the supernatants (containing
free inositol and phosphoinositols) transferred to glass tubes. A mixture of 1:1 (v/v)
trichlorotrifluoroethane / tri-n-octylamine was freshly prepared and 1.5 ml added to
each tube, and the samples vortexed until the contents appeared milky. Following
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Representative standard curve for the 125j radioimmunoassay for cGMP. Standard
solutions of the sodium salt of cGMP (0.1-32 nM, in acidified H295R growth medium, pH
5.0) were acetylated (as described in section 2.2.3.2), assayed in duplicate and the standard
curve fitted to a four parameter logistic equation. Tracer binding in the absence of
acetylated-cGMP was typically 60-70% of total tracer added.
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upper aqueous phase (0.9 ml) was removed to a fresh Eppendorf tube and stored at -
20°C prior to assay.
Columns for phosphoinositols extraction were prepared by loading 0.5 ml of
a 1:1 AGI-X8 anion exchange resin / distilled water suspension into polypropylene
columns with a 1 cm diameter scintered glass base. The gel bed was washed through
with 4 ml distilled water prior to sample loading.
Samples (0.9 ml) were thawed, 100 pi EDTA (10 mM) added to each and
then loaded onto the columns. The columns were washed with 2 x 4 ml distilled
water to remove unbound inositol. The total phosphoinositols were then eluted with
2 x 2 ml ammonium formate (1 M) / formic acid (0.1 M) buffer into scintillation
vials (2 vials per sample). 3 ml scintillant (HydroLuma) was added to each vial and
shaken well to mix the phases. The radioactivity of the samples (in disintegrations
per minute, DPM) was determined by counting for 10 minutes in a Canberra-Packard
CA1900 liquid scintillation counter.
2.2.6 Protein assay
The cellular protein content of each well was determined by the dye-binding
technique of Bradford (1976) adapted for use on a Cobas Fara (Roche Diagnostics,
Welwyn Garden City, UK) centrifugal analyser.
Working Coomassie Brilliant Blue G-250 was prepared as described by
Bradford (1976) although it was filtered, before use, through Whatman grade 1 filter
paper.
Wells were washed with 2 x 1 ml EBSS and the cells solubilised in 0.5 ml
NaOH (0.3 M) / SDS (0.1% w/v) and removed to a polypropylene tube. Wells were
rinsed with 0.5 ml distilled water and this wash added to the tube. Samples were
diluted 1:10 with distilled water prior to analysis. Assay standards covering a range
of concentrations ofBSA (0-100 pg/ml) were used to construct a standard curve.
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2.2.7 Molecular Biology methods
In order to demonstrate the presence of VIP receptor mRNA, H295R cells
were grown to near-confluence in 75 cm2 flasks. Cells were treated for 72 h in
growth medium with or without forskolin (10 pM) (medium and agonists replaced
every 24 h) prior to extraction of total RNA.
2.2.7.1 Isolation of total RNA from H295R cells
In order to ensure all items used in the extraction of RNA from cells were
RNAse free, sterile, disposable plasticware was used wherever possible. Glassware
was washed and baked overnight at 160°C and non-sterile plasticware washed in
DEPC-treated water for 2 h at 37°C, rinsed and autoclaved. Wherever possible,
solutions (prepared in RNAse-free glassware with autoclaved water) were treated
with 0.1% DEPC for at least 12 h and then autoclaved. Gloves were worn
throughout the procedure.
The method used was an adaptation of the RNAzol method described by
Chomczynski & Sacchi (1987). Briefly, cells were rinsed with EBSS (warmed to
37°C) to remove traces of growth medium, then lysed with 2 ml RNAzol per 75 cm2
flask. Using a cell-scraper, cells were detached from the bottom of the flask and the
viscous mixture pipetted up and down several times to ensure solubilisation of the
RNA, then transferred to 2 x 1.5 ml Eppendorf tubes (1 ml per tube) and placed on
ice. Following the addition of 100 pi of chloroform, tubes were vortexed for 15
seconds, left on ice for 5 mins, then centrifuged in a microfuge at 13000 rpm, 4°C,
for 15 mins. The upper aqueous phase was carefully removed to a fresh Eppendorf
tube, avoiding the protein interphase layer. The RNA was precipitated by the
addition of 1 volume of isopropanol, mixed by inversion and incubated at 4°C for 30
mins. RNA was then pelleted by centrifugation (13000 rpm, 4°C, 15 mins) and the
supernatant discarded. The pellet was washed with 180 pi 70% (v/v) ethanol,
vortexed briefly and re-centrifuged. After removal of supernatant, the pellet was air-
dried for 10-15 mins prior to resuspension in 50 pi DEPC-treated water. Samples
were stored at -70°C.
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The concentration and purity of RNA in each sample was determined by
measuring the A260 (1 x A260 unit = 40 pg RNA) and the A260 / A280 ratio, respectively,
in a UV spectrophotometer.
2.2.7.2 Detection of VIP and PACAP receptor mRNAs in H295R cells by
reverse transcription-polymerase chain reaction (RT-PCR)
These methods were initially performed with the assistance of Dr. Eve Lutz,
MRC Brain Metabolism Unit, Royal Edinburgh Hospital, who also kindly provided
the VPAC1 receptor, VPAC2 receptor, PAC1 receptor and HPRT primers and
positive control material.
(a) Reverse transcription (RT) oftotal RNA to obtain cDNA
The method used was that described in the Stratagene RT-PCR kit manual.
5-10 pg total RNA (diluted in DEPC-treated water to a volume of 38 pi) was reverse
transcribed in a 50 pi reaction volume. Following the initial addition of 3 pi random
primers (100 ng/pl) to the RNA solution, the mixture was heated to 65°C for 5 mins,
then cooled slowly to room temperature, to denature the secondary structure of the
RNA and to allow the primers to anneal. The following reagents were then added:
5 pi of 1 Ox first strand buffer
1 pi ofRNAse Block Ribonuclease Inhibitor (40 U/pl)
2 pi of lOOmMdNTPs
1 pi ofMMLV-RT (reverse transcriptase; 50 U/pl).
The tubes were vortexed and incubated at 37°C for 1 h followed by 5 mins at 90°C to
denature the MMLV-RT.
(b) Polymerase Chain Reaction (PCR)
The polymerase chain reaction was used to amplify specific sequences for
the VPAC 1 receptor, VPAC2 receptor and PAC 1 receptor. Primer sets used for each











HPRT primers were included as a control:
5 '-(GCTSCACTGCMCIAGIAACTWCATCCAC)-3 '(forward)
5' -AARCAGTAIAGIAYIGCIACMAYIARCCCTGGAA)3' (reverse)
(where S=G or C, M=A or C, W=A or T, R=A or G, Y=C or T and I=inosme)
Primers were designed using the primer design program available from the UK
Human Genome Mapping Project Resource Centre Computing Facilities (web page:
http://www.hgmp.mrc.ac.uk/). All the primers used were intron-spanning.
Positive control material used for each receptor was:
VPAC1 receptor: Agt 10 lung cDNA (human);
VPAC2 receptor: human placental cDNA;
PACI receptor: A,gt 10 brain cDNA (human).
Negative control tubes containing each set of primers but no DNA (5 pi
DEPC-treated water instead) were included.
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cDNA (5 jo.1) from the reverse transcription reaction was amplified in a 100 pi
reaction volume containing:
10 pi of 10 X DNA polymerase buffer
0.8 pi of lOOmMdNTPs
1 pi of 15 pM primer set
82.7 pi DEPC-treated water
0.5 pi Taq DNA polymerase (5 U/pl) (added after initial heat
denaturation : simplified 'hot start' conditions)
The 'standard' reaction buffer used was 10 mM Tris HC1, 50 mM KC1, 1.5
mM MgCl2, pH 8.8, though a buffer containing 10 mM Tris HC1, 25 mM KC1, 3.5
mM MgCl2, pH 8.3, was used once during optimisation of the VPAC1 receptor PCR
procedure.
25 pi light mineral oil was layered on top of each reaction tube and reaction
carried out in a Perkin Elmer thermal cycler. The reaction conditions used were:
91 °C for 5 mins (initial heat denaturation step), then a run of 35 cycles of:
91°C for 1 min (denaturation)
65°C for lmin (annealing)
72°C for 3 mins (extension)
followed by a final elongation step at 72°C for 10 mins. For optimisation of the
procedure the following were varied: cycle number (30, 35 and 40), annealing
temperature (65°C and 72°C).
(c) Analysis ofPCR products by agarose gel electrophoresis
10 pi of PCR product (from below the oil layer) was combined with 2 pi gel
loading buffer and loaded onto an ethidium bromide-containing 0.8% (w/v) agarose
gel and electrophoresed alongside 123 bp DNA molecular weight markers. The PCR
product was visualised under ultraviolet trans-illumination.
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2.2.8 Statistical analyses of data
Statistical analyses of data were perfomed using the Student's t-test with
Bonferroni correction and data were considered significantly different from basal
data (or as stated) at a P-value of less than 0.05. P-values are quoted as *P<0.05,
**P<0.02, ***P<0.01 and P>0.05 (non-significant).
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3.0 Steroid responses of H295R cells to All and forskolin
and alteration of the steroid phenotype of the cell-line
3.1 Introduction
3.1.1 Mechanism of steroidogenic action ofACTH in the adrenal
ACTH can regulate steroid production indirectly, for example, by increasing
blood flow rate through the adrenal (section 1.6.3) and directly, by stimulating
ACTH receptors on adrenocortical cells (Schimmer et al, 1968). ACTH stimulation
of adrenocortical steroidogenesis is considered to be mainly mediated via the second
messenger adenosine 3' 5' cyclic monophosphate (cAMP) (Schimmer et al, 1995, for
review). An increase in intracellular cAMP production can be artificially created
using the adenylate cyclase activator, forskolin (section 5.1.1).
Extracellular calcium is also important in transducing the ACTH signal since
ACTH-induced aldosterone secretion is inhibited in human adrenal glomerulosa cells
in calcium-free conditions (Gallo-Payet et al, 1996) and the calcium chelator, EGTA,
inhibited ACTH-induced steroid synthesis in bovine zff cells (Kimoto et al, 1996)
and ACTH-induced protein kinase activity in adrenal cells (Watanabe et al, 1997).
The actions of ACTH on steroid production can be described in terms of an
'acute' effect (taking place within a few minutes to hours) and a 'chronic' effect
(taking place over hours-days).
3.7.1.1 Acute action ofACTH
This effect generally involves an increase in cholesterol supply to the inner
mitochondrial enzyme P450scc, which catalyses the first step in all adrenal steroid
biosynthesis. The increase in substrate availability results in increased enzyme
activity and increased steroidogenesis.
Following receptor activation, ACTH causes an increase in cholesteryl ester
conversion to free cholesterol, by increasing the activity of the enzyme cholesteryl
ester hydrolase via cAMP-dependent protein kinase phosphorylation (Beckett &
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Boyd, 1977). In addition, ACTH increases the rate of transport of cholesterol across
the inner mitochondrial membrane and binding to P450scc. This process involves
two steps: transport of cholesterol to the outer mitochondrial membrane and
translocation from the outer membrane to the inner mitochondrial membrane. The
first step is thought to involve components of the cytoskeleton. ACTH may facilitate
changes in the cytoskeletal structure that result in lipid droplets and mitochondria
achieving contact by activating protein kinases, including cAMP-dependent-protein
kinase A (PKA) and protein kinase C (PKC) (reviewed by Hall & Almahbobi, 1997).
The second, cycloheximide-sensitive, step involves a labile protein and results in
transfer of cholesterol from the outer mitochondrial membrane to the inner
mitochondrial membrane. The identity of this protein is still debated but candidates
include StAR (Steroidogenic Acute Regulatory) protein, SCP2 (Sterol Carrier Protein
2), SAP (Steroidogenesis Activator Polypeptide) or PBR / DBI (Peripheral
Benzodiazepine Receptor and its intracellular ligand, Diazepam Binding Inhibitor)
(Stocco & Clark, 1996 for review).
3.7.1.2 Chronic action ofACTH
The chronic phase is characterised by effects of ACTH on steroidogenic
enzyme expression in the adrenal cortex. The importance of ACTH in maintaining
steroid enzyme levels in adrenocortical cells was first established from studies with
hypophysectomised animals. Hypophysectomy resulted in a dramatic decrease in
P450 enzyme levels in the rat adrenal cortex which could be restored upon
administration of ACTH (Purvis et al, 1973). It has subsequently been shown that
ACTH increases steroidogenic enzyme mRNA synthesis and translation via a cAMP-
dependent mechanism (Simpson & Waterman, 1988). The gene for each
steroidogenic enzyme appears to have its own regulatory system for cAMP-
responsive transcription (Waterman & Bischoff, 1997). ACTH and cAMP have been
shown to increase the expression of several adrenal steroidogenic enzymes including
P450scc, P450cl7, P45011P and P450c21 (Simpson & Waterman, 1988).
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Typically, an increase in enzyme transcripts is not seen until approximately 6
h after ACTH treatment of the cells, with increase in enzyme activities a further 6-12
h later (Hanukoglu et al, 1990). The circadian nature of ACTH stimulation of the
adrenal cortex in non-stress conditions probably results in a maintenance of levels of
steroidogenic enzymes rather than causing fluctuations in enzyme levels.
3.1.2 Mechanism of steroidogenic action ofAll in the adrenal
All is the major stimulus to aldosterone secretion from the adrenal cortex. It
binds and activates specific All receptors on zg cells, leading to activation of
phospholipase C (PLC) and subsequent formation of inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG) (section 5.1.3) and an increase in intracellular
calcium concentration. A rapid rise in intracellular calcium has been correlated with
an increased production of aldosterone (reviewed by Ganguly & Davis, 1994). The
increase in intracellular calcium concentration is biphasic; a rapid transient rise is
followed by a sustained increase. The initial rise in cytosolic calcium has been
attributed primarily to IP3-mediated release from intracellular calcium with the
secondary, lower but sustained, increase dependent upon influx across the plasma
membrane, probably through voltage-gated calcium channels (see Ganguly & Davis,
1994). DAG is required for the activation of protein kinase C (PKC), by increasing
the affinity of the enzyme for phospholipids at physiological calcium concentrations
(Nishizuka et al, 1984). Activation of PKC in the steroidogenic action of All is
important, as demonstrated by the use of phorbol esters, for example, phorbol
myristate acetate (PMA), which activate PKC. However, it has been suggested that
calcium-calmodulin may actually be more important than PKC in the stimulation of
steroid secretion (Ganguly & Davis, 1994).
All also stimulates formation of 12-HETE (12-hydroxyeicosatetraenoic acid),
a product of the lipoxygenase pathway of arachidonic acid metabolism, in human zg
cells and this has been linked to aldosterone synthesis (Natarajan et al, 1988a). It has
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been suggested that the arachidonic acid required for this pathway is derived from
DAG (Natarajan et al, 1988b).
All stimulates PLC activity and concomittant steroid production from bovine
and human zfr cells but not from rat zff cells. This is in keeping with the lack of
detectable All receptors on rat zfr cells. All can also alter expression of certain
steroidogenic enzymes in cultured human adrenal cells, in particular, it increases
expression of P450aldo (Aguilera et al, 1980; Kramer et al, 1980).
The aims of this chapter were to examine the steroid responses of H295R
cells to chronic (up to 96 h) and short-term (4 h) treatment with All, the principal
physiological mineralocorticoid agonist, and forskolin, a direct activator of adenylate
cyclase. Forskolin was used instead of ACTH, the principal regulator of
glucocorticoid secretion in vivo, because of reported relatively poor responses of
these cells to ACTH (perhaps due to low ACTH receptor density) compared with
activators ofprotein kinase A (Rainey et al, 1993).
Of particular interest in these studies was the effect of chronic pretreatment
with either All or forskolin on 1) the overall steroidogenic responsiveness of the cells
to subsequent (4 h) agonist stimulation and 2) the alteration of steroidogenic
phenotype. The ability to alter the steroidogenic phenotype of the cell-line would
allow the effects of VIP (and other agonists) on zona glomerulosa-like and zona
fasciculata/reticularis-like cells to be determined.
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3.2 Results
3.2.1 Steroid responses of cells to chronic treatment with All or
forskolin
The time-dependent chronic actions of All and forskolin on Cortisol,
corticosterone and androstenedione secretions were studied.
Both All and forskolin were found to cause concentration-dependent
increases in Cortisol secretion (see Figure 3.1). A concentration of 1 nM All caused
a statistically significant increase (P<0.01) in 2 out of 3 experiments and a
concentration of 10 nM All caused a statistically significant (P<0.01) increase in 3
out of 3 experiments, triplicate incubations performed in each experiment. Forskolin
caused significant stimulation of Cortisol secretion at all three concentrations
(P<0.01) (triplicate incubations performed in a single experiment). Concentrations of
10 nM All and 10 pM forskolin were used in later experiments.
The chronic effects of All or forskolin treatment were investigated by
stimulating cells with these agonists for 24, 48, 72 or 96 h. Media and agonists were
replaced every 24 h so that only the medium from the last 24 h of each treatment
period was collected for steroid assays. Figure 3.2 shows the different Cortisol,
corticosterone and androstenedione secretion profiles obtained. Response Ratios
(RR, response to stimulus / basal secretion) for individual experiments are presented
in Table 3.1. Chronic treatment of the cells with All resulted in a time-dependent
increase in Cortisol and corticosterone secretion. Maximum Cortisol output and RR
were observed after 72 h All treatment (mean RR after 72 h = 5.9 (±1.7)-fold, n=5
individual experiments). Maximum corticosterone output and RR were observed
after 48-72 h All treatment (RRs = 6.8-fold and 11-fold in n=2 individual
experiments, triplicate incubations performed in each), thereafter declining.
Androstenedione secretion did not significantly alter over the course of the chronic
incubation (P>0.05, calculated from triplicate incubations in each of 2 separate









































basal 1 5 25
[forskolin] (pM)
Dose-dependent Cortisol secretion from H295R cells in response to a) All or b) forskolin.
Cells were treated for 24 h with fresh growth medium alone (basal, open bar) or medium
containing All (0.1, 1 or 10 nM, hatched bars) or forskolin (1, 5 or 10 pM, cross-hatched
bars). At the end of this time, medium was removed and assayed for Cortisol content by
RIA. Cells were solubilised and assayed for total protein content. Results are expressed as
mean (± s.d). of data from triplicate incubations and are representative of those obtained in
n=3 experiments for All, n=l experiment for forskolin. Significant stimulation of Cortisol
secretion, compared with basal Cortisol secretion, is indicated at ***P<0.01. Doses of 10
nM All and 10 pM forskolin were chosen as treatment doses for subsequent experiments.
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Fisure 3.2
Secretion of a) Cortisol, b) corticosterone and c) androstenedione from H295R cells in
response to chronic treatment with All or forskolin. Cells were treated with fresh growth
medium alone (basal, solid bars) or containing All (10 nM, hatched bars) or forskolin (10
p.M, open bars) for 24, 48, 72 or 96 h. Medium and agonists were replaced every 24 h.
Medium from each 24 h period of treatment was collected and measured for Cortisol,
corticosterone and androstenedione content by RIAs. Results shown are mean (±s.d.) of
triplicate measurements from one of 5 similar experiments for Cortisol data and one of 2
experiments for corticosterone and androstenedione data. *P<0.05, ***P<0.01 compared
with basal secretion.
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All24h All48h All72h All96h
3.082 23.728.33 5.533 664.822 515.44 5.944 496.114 88.57 5.924 796.513 177.8
3.730 4.392 5.919 5.653
2.597 1.290 1.671 1.776
forskolin24h forskolin48h forskolin72h forskolin96h
2.97323 892.8 31 6.594 89.935.6011.86 10.447.975.925 1018. 6 12.98.7524 345 423.91
4.077 7.773 11.638 15.880
2.432 2.992 5.628 8.120
Table3.1 Cortisol,cor ico teroneandndrostenedionese r ti si re ponstchr ict atmentw thAllrfo sk l n.Cw et ea dithgr w h mediumalone(b sal)ormediucontainingAll10nMforsko i( p )r24,487296h.M iumandago istsw rereplac dv ry24 Mediumfromeach24hperiodftr at entwascollectednme suredCortisol,cortic st roneand enedionecont tbyRIA .ults presentedinth sabl sasRespo seatio(ress imulus/b alecr tion)foachs paratexperimentperfo ed(n=5f C rtisol,=2 corticosteroneandndr tenedione)(seextpagf corticosteroneanndrost dioned a
CORTICOSTERONEresponsetochr icAll/ forskolintreatme t Responseatiorelativtb sal Exposuretimef cellstoagoni tExpt.12
Mean (n-2)
range
All24h All48h All72h All96h
3.902 48 6.819 6 3.1410.95 2.044 33
3.190 8.210 7.045 3.185
0.710 1.400 3.905 1.145
forskolin24h forskolin48h forskolin72h forskolin96h
6.754 67 4.958 77 5.5818.14 5.0915.4
5.710 6.860 11.860 10.290
1.040 1.910 6.280 5.200
Table3.1continued:sepr viousagf rlege d.















































Chronic treatment of the cells with forskolin also led to a time-dependent
increase in steroid responses. Total Cortisol output and RR were still increasing after
96 h exposure to forskolin (mean RR = 15.9 (±8.1)-fold, n=5 individual
experiments). Corticosterone output and RR were maximal after 72 h forskolin
treatment (RRs = 6-fold and 18.1-fold in 2 separate experiments, triplicate
incubations performed in each). In contrast to chronic All treatment, forskolin
caused a time-dependent increase in androstenedione secretion and RR, reaching
maximums after 72 h and 96 h treatment (RRs = 4.6-fold and 8.4-fold, respectively,
from 2 individual experiments, triplicate incubations performed in each) {Figure 3.2
and Table 3.1).
The ratios of secretion rate of one steroid relative to the secretion rate of
another steroid (for example, the ratio of corticosterone secretion / Cortisol secretion,
calculated from the RR for each) are presented in Table 3.2.
Both basal levels of aldosterone and levels following treatment of cells with
All or forskolin were generally non-detectable. The lower detection limit for the
aldosterone radioimmunoassay used could not be calculated accurately as not enough
data was generated to determine precision profiles for each assay. However,
aldosterone secretion was measured in 2 separate experiments, in response to All in
one experiment and in response to forskolin in the other {Table 3.3).
3.2.2 Steroid responses of cells to acute treatment with angiotensin II
or forskolin.
3.2.2.1 Time-course of short-term treatment with All or forskolin
Cells were treated with growth medium alone (basal) or medium containing
All (10 nM) or forskolin (10 pM) for 2, 4 or 8 h. Figure 3.3a) shows the combined
RRs for short-term All or forskolin treatment from n=3 individual experiments. The
Cortisol RR was greater at 4 h than at 2 h for both All (P<0.01 in 2 out of 3
experiments, calculated from triplicate incubations within each experiment) and
forskolin (P<0.02 in 2 out of 3 experiments, calculated from triplicate incubations
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Chronic forskolin treatment (hours)
24 h 48 h 72 h 96 h
corticosterone / Cortisol 1 2.3 0.8 0.5 0.4
2 2.0 1.8 2.3 1.2
Cortisol / androstenedione 1 2.0 6.0 6.9 2.8
2 T.O 1.4 1.2 1.6






Steroid responses to chronic treatment with All (10 nM) or forskolin (10 pM) for 24, 48, 72
or 96 h. Medium and agonists were replaced every 24 h. Medium from the last 24 h of the
treatment period was collected and assayed for Cortisol, corticosterone and androstenedione
content by RIAs. Steroid data was normalised with respect to basal secretion (Response
Ratio, RR). These RRs were then expressed themselves as a ratio of secretion of one steroid
relative to secretion of a different steroid, for example, corticosterone secretion with respect
to Cortisol secretion, to give an indication of shift in steroidogenesis from one pathway to
another. These ratios are presented in the table above.
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ALDOSTERONE response to chronic All /
forskolin treatment
Mean (+/- s.d.)
(pmol /mg protein / 24 h)
Exposure time of
cells to agonist Expt. 1 Expt.2
Basal 24 h ND 1.85 (0.16)
All 24 h ND 4.94 (0.50)
forskolin 24 h 6.37 (1.35) -
Basal 48 h ND 1.50 (0.45)
All 48 h 7.16 (1.23) 5.79 (3.13)
forskolin 48 h ND -
Basal 72 h ND 0.91 (0.09)
All 72 h ND 9.06 (2.99)
forskolin 72 h 3.49 (1.85) -
Basal 96 h ND 0.97 (0.13)
All 96 h ND 13.75 (0.34)
forskolin 96 h 3.00 (1.49) -
Table 3.3
Aldosterone responses to chronic treatment with All (10 nM) or forskolin (10 pM) for 24,
48, 72 or 96 h. Medium and agonists were replaced every 24 h. Medium from each 24 h
period of treatment was collected and assayed for aldosterone content. Results presented in
the table above are mean (±s.d.) from triplicate incubations within each experiment.
ND=non-detectable by the RIA used. Cells were not treated with forskolin in Expt.2 .



























Time-course to determine the Cortisol response to short-term treatment ofH295R cells with
All or forskolin. Cells were treated with growth medium alone (basal) or medium
containing All (10 nM) or forskolin (10 p.M) for 2, 4 or 8 h. After this time, medium was
assayed for Cortisol content by RIA and data corrected for total cellular protein content.
Figure 3.5a) shows stimulation of Cortisol secretion by All (hatched bars) or forskolin (open
bars), expressed as a Response Ratio (response to stimulus / basal secretion). Results are
mean (±s.d.) of combined data from n=3 experiments, triplicate incubations performed in
each. Figure 3.5b) shows a representative experiment (from the set of n=3) demonstrating
that the medium concentration of Cortisol continues to increase at 8 h, with respect to 4 h,
even though the Response Ratio does not. Results are mean (±s.d.) of triplicate
measurements. (Basal O, All A, forskolin ). *P<0.05, **P<0.02, ***P<0.01 compared
with basal secretion.
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after 4 h agonist exposure (Figure 3.3b)), the RRs were less at 8 h than after 4 h for
both All and forskolin treatments (Figure 3.3a)).
3.2.2.2 Steroid responses of cells to 4 h treatment with All or forskolin
Cells were treated with growth medium alone (basal) or medium containing
All (10 nM) or forskolin (10 p.M) for 4 h (selected on the basis of the time-courses
performed, see section 3.2.2.1 above) at 37°C. Figure 3.4 shows the combined
Cortisol, corticosterone and androstenedione responses (expressed as mean Response
Ratios ± s.d.) obtained from n=4 individual experiments for Cortisol and
corticosterone and n=3 individual experiments for androstenedione. Data from the
individual experiments are presented in Table 3.4, expressed as pmol / mg cellular
protein / 4 h. Forskolin significantly stimulated Cortisol secretion (2.1 (±0.6)-fold
increase over basal for n=4 separate experiments. P<0.05 in 4/4 experiments, P<0.01
for 3 of these 4, calculated from triplicate incubations within each experiment) and
corticosterone secretion (2.4 (±0.6)-fold increase over basal for n=4 experiments.
PO.Ol in 3/4 experiments, calculated from triplicate incubations within each
experiment). Forskolin only stimulated androstenedione secretion over basal levels
in 1/3 experiments (P<0.05, calculated from triplicate incubations within the
experiment) (Table 3.4).
The steroid response to 4 h All treatment was variable: All stimulated
Cortisol and corticosterone secretion in 2/4 experiments (P<0.01 for 2/4 expts for
both Cortisol and corticosterone responses, calculated from triplicate incubations
within each experiment), failing to stimulate either steroid in the other 2 experiments
(P>0.05) (Table 3.4). For the 2 experiments where All treatment elicited a steroid
response, the RRs were 2.3-fold and 2.3-fold for Cortisol and 2.6-fold and 2.8-fold
for corticosterone. 4 h All treatment did not alter androstenedione secretion above
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Figure3.4 Effectsofshort-term(4h)treatmentwithAllrfo skolinC rtisol,cortic st ronendandrostenedi nes r iorH295Rce .C lw treatedfor4hwithgrowthmediumal ne(b sal,d ttelin )containingAll10M)o skolipM).M d uco ntsfth3 steroidsweredeterminedbyRIAs,corr ctfot talellularp otein.e ulpres nt dham an(±s. .)fbinr mn=4exper ments forCortisolandcorticosteronen=3expe imentsndrostenedione,res dRes n eiosrelativtb sas e .
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Cortisol, corticosterone and androstenedione secretions in response to 4 h treatment with
growth medium alone (basal), All (10 nM) or forskolin (10 juM). Cortisol, corticosterone
and androstenedione contents of 4 h media were measured by RIAs and corrected per mg
cellular protein. Results presented are mean (±s.d.) for triplicate incubations for each of
n=4 experiments for Cortisol and corticosterone and n=3 experiments for androstenedione.
Statistically significant changes in secretion compared with basal secretion are indicated by
*P<0.05 and ***P<0.01.
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3.2.3 Effects of 96 h pretreatment with All or forskolin on subsequent
steroid responses to 4 h agonist treatment
3.2.3.1 Effect of different pretreatment times on subsequent agonist-induced
steroid response.
A preliminary experiment was performed to determine the optimum time-
period for pretreating the cells with All or forskolin, prior to 4 h agonist treatment.
Cells were pretreated with All (10 nM) or forskolin (10 pM) for 24, 48, 72 or 96 h.
Medium and agonists were replaced every 24 h. Following the defined pretreatment
period, cells were washed and treated for a further 4 h with fresh growth medium
alone (basal) or medium containing All (10 nM) or forskolin (10 pM). Figure 3.5
shows Cortisol, corticosterone and androstenedione responses to 4 h treatment with
the above agonists following different periods of pretreatment with All or forskolin
("control" cells were maintained in exactly the same way as pretreated cells, except
there was no pretreatment agonist added to the medium).
The Cortisol and corticosterone responses of the cells to 4 h All or 4 h
forskolin were increased following pretreatment with either All or forskolin,
reaching a plateau after 72-96 h pretreatment with either All or forskolin.
Androstenedione secretion in response to 4 h All or 4 h forskolin was unaltered,
relative to basal levels, from All preteated H295R cells. Forskolin pretreatment, in
contrast, increased the subsequent androstenedione responses to 4 h All and 4 h
forskolin, with the 4 h forskolin response reaching a plateau after 48 h pretreatment
and the 4 h All response still increasing after 72-96 h pretreatment (Figure 3.5). A
96 h pretreatment time was chosen for further experiments.
3.2.3.2 Alteration of the steroidogenic phenotype of H295R cells following
pretreatment with angiotensin II or forskolin
96 h treatment with All (10 nM) caused no change in 4 h basal
androstenedione production (P>0.05 in 4/4 individual experiments, calculated from
triplicate incubations within each experiment) but significantly increased basal
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96hr preincubation conditions
Figure 3.6
Different profiles of a) Cortisol, b) corticosterone and c) androstenedione responses to 4 h
All treatment following 96 h pretreatment under different conditions. Cells were
preincubated for 96 h with growth medium alone (control) or medium containing All (10
nM) or forskolin (10 pM). After washing, cells were subsequently treated for 4 h with or
without All (10 nM). These graphs show 4 h basal (open bars, □) and 4 h All stimulated
(solid bars, ■) secretions of the 3 steroids following the different preincubation conditions.
Results are expressed as mean (±s.d.) for triplicate incubations from a representative
experiment of a set of n=4 experiments. *P<0.05, ***P<0.01 compared with basal
secretion.
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Ratio of RRs (mean +/- s.d.)
96 h All preincubation 96 h fskn preincubation Statistics
corticosterone/androstenedione 1.6 (+/- 0.07) 1.1 (+/- 0.24) P<0.05
cortisol/androstenedione 1.3 (+/- 0.08) 1.1 (+/-0.45) NS
cortisol/corticosterone 0.8 (+/- 0.06) 1.1 (+/-0.57) NS
Table 3.5
Steroid responses to 4 h treatment with All (10 nM) following 96 h preincubation of the
cells with growth medium alone (control) or containing All (10 nM) or forskolin (fskn, 10
pM). Medium from the 4 h treatment period was collected and assayed for Cortisol,
corticosterone and androstenedione content. Data obtained by RIA for each steroid were
normalised with respect to basal secretion (Response Ratio). These ratios were then
expressed themselves as a ratio of secretion of one steroid with respect to secretion of a
different steroid, for example, corticosterone secretion with respect to androstenedione
secretion (corticosterone / androstenedione), to give an indication of shift in steroidogenesis
from one pathway to another induced by the different pretreatment conditions. These ratios
are presented in the table above. Statistically different ratios between the different
pretreatment conditions are taken at P<0.05. Values of P>0.05 were considered non¬
significant (NS).
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Cortisol secretion (P<0.05 in 4/4 experiments, calculated from triplicate incubations
within each experiment) and basal corticosterone secretion (P<0.05 in 3/4
experiments, calculated from triplicate incubations within each experiment). In
contrast, 96 h forskolin pretreatment significantly decreased 4 h basal production of
all three steroids (P<0.05 in 3/4 experiments, calculated from triplicate incubations
within each experiment).
4 h treatment of H295R cells with All (10 nM) following 96 h preincubation
with All resulted in a RR of 1.3 (±0.2)-fold for Cortisol, 1.7 (±0.4)-fold for
corticosterone and 0.9 (±0.1)-fold for androstenedione (n=4 experiments for all three
steroids). This compared with RRs of 1.5 (±0.2)-fold, 1.6 (±0.5)-fold and 1.7 (±0.6)-
fold for Cortisol, corticosterone and androstenedione respectively after 96 h
preincubation with forskolin (n=4 experiments for all three steroids) {Figure 3.6). If
the RRs for corticosterone and androstenedione are expressed as a ratio of increased
corticosterone secretion to androstenedione secretion and these ratios are taken as an
indication of shift in steroid production away from adrenal androgens and towards
17-deoxysteroid secretion or vice versa, then following All preincubation the ratio
was 1.6 (±0.07) whereas following forskolin preincubation the ratio was 1.1 (0.24)
(n=4). Statistical comparison of these ratios was significant with P<0.02 {Table 3.5).
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3.3 Discussion
Most previous studies which have investigated the steroid responses to
agonists from H295R cells have either looked at one steroid in particular or, where
several steroids have been measured, have only examined secretion following a fixed
period of incubation with each agonist, usually 48 h (Bird et al, 1995b, 1996a,
1996b; Mason et al, 1995; Rainey et al, 1993). In this chapter, the time-dependent
changes in chronic secretion of Cortisol, corticosterone, androstenedione (and
aldosterone) to All or forskolin were examined, along with the short-term responses
to these agonists. Aldosterone, Cortisol and androstenedione were measured because
they are end-pathway steroids produced in the adrenal {Figure 1.3). However, due to
the difficulties experienced with the detection of aldosterone secretion, corticosterone
production was measured instead. The ability to alter the steroidogenic phenotype of
the cell-line was investigated.
The profiles for Cortisol, corticosterone and androstenedione secretion
following increasing lengths of chronic treatment with All or the protein kinase A
activator, forskolin, were investigated {Figure 3.2). Forskolin was used to mimic the
ACTH-induced activation of protein kinase A, since H295R cells show poor
response to ACTH (Rainey et al, 1993), which could relate to the low levels of
ACTH receptor mRNA found in these cells (Mountjoy et al, 1994). Preliminary
experiments using ACTH were also performed in this study, which confirmed that
ACTH was a poor agonist for Cortisol, corticosterone and androstenedione secretion
from control cells and, although the steroid responses to ACTH increased following
pretreatment of the H295R cells with All or forskolin, the steroid responses were still
poor compared to those elicited by forskolin under the same conditions {data not
shown).
The steroid secretion profiles obtained for chronic treatment were different
for All and forskolin. By examining the ratios of corticosterone secretion to Cortisol
secretion (that is, corticosterone / Cortisol) and corticosterone / androstenedione
{Table 3.2), it is clear that 48 h exposure of the cells to AII predominantly stimulates
corticosterone secretion in these cells. In contrast, by 96 h exposure to All there was
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a relative decrease in the ratios of corticosterone / Cortisol and corticosterone /
androstenedione, indicating a shift away from corticosterone production. This could
be the result of a relative increase in Cortisol secretion, a relative decrease in
corticosterone secretion or both. The fact that androstenedione secretion did not
increase at 96 h suggests that corticosterone production must have decreased to some
extent. Indeed, the RR for corticosterone production to All fell (35 % in 1
experiment and 60 % in the other experiment) after 96 h treatment, whereas the
Cortisol RR remained constant. Thus, All appears to predominantly stimulate the
mineralocorticoid pathway up to 48 h treatment, but further exposure leads to a
decrease in this effect. All markedly increases 3pHSD mRNA and activity in
H295R cells whilst having a lesser effect on P450cl7 mRNA expression and activity
(Rainey et al, 1994; Bird et al, 1996b). These effects were observed after 20 / 24 h
treatment with All (Rainey et al, 1994; Bird et al, 1996b), which would be in
keeping with the steroid responses seen after 48 h in this study. The pattern of
3PHSD and P450cl7 mRNA expression in cultured human zfr cells in response to
All shows maximal increase in 3PHSD expression at 24 h, gradually decreasing at
48, 72 and 96 h, though still remaining elevated with respect to 12 h-treated cells. In
the same study, P450cl7 mRNA levels remained constant up to 96 h (Lebrethon et
al, 1994). Thus, a decrease in 3PHSD mRNA at 96 h, coupled with an unaltered
level ofP450cl7 mRNA, would result in a decrease in the ratio of 3PHSD / P450cl7
transcripts at 96h with respect to 48 h. If the assumption is made that the altered
transcript ratio is reflected in a corresponding change in enzyme synthesis (and
activity) (Hum & Miller, 1993; Parker & Schimmer, 1993), the outcome would be a
decrease in corticosterone secretion relative to Cortisol and androstenedione
secretion. A similar effect in H295R cells could explain the change in steroid
responses to All seen with increasing length of treatment.
A further possibility is that the cells may have become desensitised to AIL
Sensitivity of cells to All can decrease in a number ofways; the surface All receptor
numbers can decrease by internalisation (Ouali et al, 1997) or the phophoinositide
response may diminish following prolonged exposure to All (Enyedi & Spat, 1987).
However, since the Cortisol response did not decline at 96 h (compared with the
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corticosterone response), this explanation appears less plausible. Indeed, whilst
chronic All treatment has been shown to cause an initial decrease in AT,-receptor
mRNA from H295R cells, little effect on All-binding or subsequent
phosphoinositidase C response was observed (Bird et al, 1995a).
With increasing length of chronic forskolin treatment, the ratios of
corticosterone / Cortisol and corticosterone / androstenedione progressively decreased
from 24 h to 96 h, consistent with a shift away from corticosterone production
towards Cortisol and androstenedione production. Rainey et al (1994) demonstrated
that 48 h treatment with activators of the protein kinase A pathway (forskolin and
dbcAMP) greatly increase the expression and activity of P450cl7, accompanied by
an increase in Cortisol and androstenedione secretion. It can be seen in Figure 3.2
that Cortisol and androstenedione productions are still increasing after 72-96 h
forskolin treatment. This would suggest that the inhibitory mechanisms regulating
the chronic All response after 72-96 h are different from those controlling chronic
forskolin action. The steroid secretory response over the period 72-96 h exposure to
forskolin was greater than that seen over the same period in response to AIL This
again demonstrates the different regulatory mechanisms involved in the control of
chronic All or forskolin response.
The stimulation of corticosterone by forskolin probably reflects an overall
increase in steroidogenesis by the cells, since forskolin has been shown to increase
expression of several steroidogenic enzymes to varying degrees, including P450scc,
3pHSD, P450cl7 and P450c21 (Rainey et al, 1993; Bird et al, 1995b; Staels et al,
1993).
An unexpected finding was that basal aldosterone levels were rarely detected
and neither All nor forskolin consistently gave a detectable increase in aldosterone
secretion. Bird et al (1993, 1996b) characterised an aldosterone response from
H295R cells to both All and forskolin. Moreover, both All and forskolin increase
aldosterone synthase mRNA levels, the greater effect being produced by All (Bird et
al, 1993; Holland et al, 1993). However, basal levels of P450aldo mRNA and basal
secretion of aldosterone in these cells were reportedly low (Holland et al, 1993). In
the studies reported here, basal aldosterone was detected in only 1 experiment and
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stimulated aldosterone in only 2 experiments (in response to All in one and to
forskolin in the other) (see Table 3.3). The loss of a measurable aldosterone
response, either basal or stimulated, suggests an extremely low level of aldosterone
synthase activity. Since the corticosterone response was readily measurable, this
would further support this explanation. Slight differences in culture conditions,
compared with other studies in these cells could affect P450aldo expression or
activity, and may explain the differences in ability to measure aldosterone. Another
possibility is that the cells have mutated and lost their ability to express this enzyme,
though this is less likely given the long period of establishment of the cell-line
(approximately 7 years) (Gazdar et al, 1990) and the maintenance of an extensive
steroidogenic enzyme complement after this time (Staels et al, 1993). Moreover,
aldosterone secretion was measurable on 2 separate occasions.
The short-term (4 h) steroid responses to All and forskolin were also
examined in this cell-line. A 4 h incubation was chosen for these short-term
treatment studies because the RR was higher than at 8 h and the total steroid output
was higher than at 2 h, aiding measurement of the steroids by RIA {Figure 5.5).
Forskolin stimulated an increase in Cortisol and corticosterone secretions but
failed to significantly increase androstenedione secretion above basal. This contrasts
with the chronic action of forskolin, which increased androstenedione secretion in a
time-dependent manner {Figure 3.4).
The Cortisol and corticosterone responses to All were inconsistent from one
experiment to another. In 2/4 experiments, All stimulated a significant increase in
Cortisol and corticosterone (P<0.01 for both steroids) {Table 3.4) but failed to do so
in the other 2 experiments (P>0.05). As with chronic treatment, All had no effect on
androstenedione secretion {Figure 3.4).
The responsiveness (in terms of RR) of these cells to 4 h treatment differed
from that observed with chronic (24-96 h) treatment. The importance of ACTH in
the maintenance of steroidogenic capacity of cells was first demonstrated in rat
adrenal cortex, where it was discovered that hypophysectomy led to a rapid fall in
both microsomal and mitochondrial cytochromes P450 (Kimura et al, 1969; Pfeiffer
et al, 1972; Purvis et al, 1973). ACTH administration restored enzyme levels.
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Cultured adrenal cells from several species quickly lose their ability to synthesise
steroids. For example, human adrenal zfr cells in culture exhibit a rapid and
progressive decline in levels of P450scc, P45017a and 3pHSD mRNAs and proteins,
which were restored, to varying degrees, upon treatment with ACTH or All
(Lebrethon et al, 1994). If recently isolated and cultured cells can rapidly lose their
steroidogenic capacity, it is not inconceivable that the basal steroidogenic enzyme
levels of the long-standing H295R cell-line may be very low. This would explain the
poorer responsiveness of the cells to short-term stimulation.
It was therefore decided to 'prime' the cells before investigating the steroid
responses to 4 h stimulation. The reasons for this were two-fold: 1) to increase the
steroidogenic capacity of the cells prior to acute treatment and 2) to investigate
whether it was possible to alter the steroidogenic phenotype of the cell-line,
depending on the choice of pretreatment agonist. Based on known effects on steroid
enzyme expression, it was expected that pretreatment of the cells with All would
confer a glomerulosa-like phenotype on the cells whereas pretreatment with forskolin
(to mimic ACTH-induced protein kinase A activation) would confer a more
fasciculata-reticularis phenotype on the cells.
Previous studies on the chronic effects of All or forskolin on these cells
suggested that steroidogenic responsiveness was maximal with 72 h or 96 h treatment
(Figure 3.2). The pretreatment time-course (Figure 3.5) demonstrates that the
responsiveness to acute agonist treatment is also highest after 72 h or 96 h
pretreatment with All or forskolin. A pretreatment time-length was chosen that was
close to optimal for all 3 steroids being measured. For All and forskolin
pretreatments, there was little difference between 72 h or 96 h pretreatment on the
subsequent All-induced Cortisol, corticosterone or androstenedione responses. Since
the All-induced androstenedione response was possibly marginally better following
96 h pretreatment, this time period was chosen for further experiments.
Both All and forskolin pretreatment increased the responsiveness (RR) of the
cells to a subsequent 4 h All exposure (Figure 3.6). Indeed, All had little effect on
steroid secretion from "control" cells, but significantly stimulated steroid secretion
after "All pretreatment" or "forskolin pretreatment".
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The profiles of steroids secreted differed depending on the pretreatment
agonist. A 96 h pretreatment with All resulted in an increase in All-stimulated
Cortisol and corticosterone (P<0.05 and P<0.01, respectively, n=4), whereas
significant increases in androstenedione and corticosterone secretions were seen after
forskolin pretreatment (P<0.01 for both steroids, n=4) (Figure 3.6). If the ratio of
increased corticosterone secretion to androstenedione secretion is calculated and used
as a measure of the shift in steroid production away from adrenal androgens and
towards 17-deoxysteroid secretion or vice versa (Table 3.4), it is clear that H295R
cells produce more androstenedione in relation to corticosterone following forskolin
preincubation as compared to All preincubation. Thus, chronic forskolin treatment
alters steroid production towards the adrenal androgen pathway and away from 17-
deoxysteroid production, favouring a more zfr-like phenotype. This observation is
consistent with what is already known in relation to the effects of forskolin and All
on expression of steroid pathway enzymes. Thus, the ratio of 3[3HSD / P450cl7
mRNA most probably increases following All treatment (favouring the
mineralocorticoid pathway) and decreases following forskolin treatment (favouring
the glucocorticoid / androgen pathways).
Interestingly, basal Cortisol and cortiscosterone secretions were lower
following 96 h forskolin pretreatment, compared with "control" cells. In contrast,
All pretreatment increased basal secretion of Cortisol and corticosterone. Basal
androstenedione secretion was unaffected by either pretreatment agonist. The reason
for these changes in basal steroid secretion is unclear. As mentioned before, chronic
forskolin treatment raises levels of P450cl7 mRNA and activity, resulting in a
decrease of the 3pHSD / P450cl7 ratio, and a shift in steroidogenesis towards
adrenal androgens. If the lyase activity of P450cl7 was induced to a greater degree
than the hydroxylase activity, pregnenolone would be converted mainly to DHEA.
Consequently, pregnenolone and 17-OH-pregnenolone pools may become smaller.
The decrease in starting substrate for the mineralocorticoid and glucocorticoid
pathways could result in a decrease in basal corticosterone and basal Cortisol
secretion. Basal androstenedione levels would be unaffected if the DHEA pool was
already large, such that an increase in 17,20-lyase activity and DHEA formation did
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not actually increase the size of this pool to any significant degree. The initial
characterisation of these cells by Gazdar et al (1990) suggests that DHEA levels in
these cells are high. Mechanisms controlling the differential regulation of 17a-
hydroxylase activity and 17,20-lyase activity ofP450cl7 are still unclear. It has been
suggested that the amount of available P450 oxidoreductase may determine the ratio
of one activity to another (Yanagibashi & Hall, 1986). Whilst this fnay explain the
differences in 17a-hydroxylase and 17,20-lyase activities between the testes and the
adrenal (the molar ratio of P450 oxidoreductase to P450cl7 is 3-fold higher in the
testes than the adrenal), it does not easily explain changes in 17a-hydroxylase and
17,20-lyase activities within the adrenal gland itself. Miller et al (1997) recently
supported these findings and added that post-translational phosphorylation of the
P450cl7 protein appears to increase the efficiency of electron transfer between
P450cl7 and P450 oxidoreductase. Post-translational phosphorylation of P450cl7
seems to be cAMP-dependent (Miller et al, 1997). Another possibility for the intra-
adrenal regulation of 17a-hydroxylase and 17,20-lyase activities stems from the
findings of Couch et al (1986), who noted that various adrenal steroids appeared to
inhibit the 17a-hydroxylase reaction to a greater extent than the 17,20-lyase reaction.
Chronic All pretreatment, on the other hand, increases expression of 3PHSD,
resulting in a relative increase in the 3[3HSD / P450cl7 ratio, compared with
"control" cells. This would result in conversion of pregnenolone primarily to
progesterone and 17a-OH-pregnenolone to 17a-OH-progesterone, with relatively
little conversion to DHEA. Again, the change in the size of the DHEA pool may be
negligible, so that an increase in basal androstenedione is not seen. Channeling of
steroidogenesis down the mineralocorticoid and glucocorticoid pathways could
explain the increase in basal corticosterone and Cortisol seen following chronic All
pretreatment. Subsequent acute All treatment would increase steroidogenesis
primarily by increasing cholesterol transfer to P450scc (involving All-stimulated
upregulation of StAR expression (Clark et al, 1995)), rather than further altering the
enzyme ratios. Thus the ratios of enzymes induced by the pretreatment conditions
would determine the pattern of steroids seen in response to acute exposure to AIL
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Current theories suggest that cells in the three zones of the adrenal cortex
arise from a common undifferentiated, progenitor cell because transposition of cells
from all zones of the adrenal cortex to in vitro culture results in a loss of their zone-
specific properties (Homsby & Crivello, 1983) (section 1.3.1). Migration of a cell
from its origin in an outer stem cell layer through all three zones of the cortex has
been demonstrated by the appearance of a pattern of radial stripes of a 21-
hydroxylase promoter / p-galactosidase reporter transgene throughout the cortex of
transgenic mice (Morley et al, 1996). Precisely what determines and regulates the
differentiated phenotype of this cell is still unclear. The ability of the H295R cell-
line's steroid phenotype to be shifted from predominantly one pathway to another
means that this cell-line could be a useful model for studying mechanisms regulating
zonation and the differential expression of the steroid pathways. Moreover, these
cells could potentially be used to estimate the effects of different putative
steroidogenic agonists on zg-like function or zfr-like function.
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4.0 Steroid responses of H295R cells to short-term and
chronic treatment with VIP
4.1 Introduction
There is now strong evidence for innervation of the adrenal cortex, raising the
question of a neuroendocrine regulation of steroidogenesis (section 1.6.4.1). In
addition, the intermingling of adrenocortical and medullary chromaffin tissues
(section 1.6.4.2) begs the question as to whether chromaffin cell secretagogues may
also modulate adrenocortical steroid secretion in a paracrine fashion.
So far, most studies into the paracrine and neuroendocrine control of
steroidogenesis have been limited to species other than the human. Because many of
these potential agonists have established indirect effects on steroidogenesis, for
example, via actions on the HPA axis, it has sometimes been difficult to distinguish
between indirect and direct actions in vivo. The presence of a paracrine /
neuroendocrine mechanism of regulation can investigated with the aid of in vitro
studies. However, the difficulty in obtaining fresh normal, human adrenal glands
post-mortem or at operation has hindered investigations on cultured human
adrenocortical cells.
VIP has been shown to influence adrenal function in several ways, including
effects on growth (Rebuffat et al, 1994) and adrenal blood flow (Bloom et al, 1987).
In addition, a function for VIP in the circadian rhythm has been suggested (Cugini et
al, 1991). In this chapter, the H295R human adrenocortical tumour cell-line was used
to investigate a direct action ofVIP on adrenocortical steroidogenesis.
4.1.1 Regulation of adrenal steroidogenesis by VIP
VIP has been shown to stimulate steroid secretion from adrenocortical cells.
Precisely how VIP mediates this effect is still unclear. Plenty of evidence exists for
an indirect modulation of steroidogenesis by VIP. In addition to increasing perfusion
flow rate through isolated, perfused rat adrenals (Hinson et al, 1994a), VIP also
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decreased vascular resistance in conscious, functionally hypophysectomised calves
(Bloom et al, 1987). Thus, VIP may increase blood flow through the adrenal in vivo,
thereby leading to an increase in steroid secretion (section 1.6.3). Within the adrenal
gland, stimulation of the splanchnic nerves results in vasodilation of adrenal blood
vessels and VIP has been postulated to be a neurotransmitter released following
splanchnic nerve activation (Bloom et al, 1988).
VIP has also been shown to stimulate the release of catecholamines from
medullary chromaffin tissue in rats and dogs (Wakade et al, 1991; Yamaguchi,
1993). The steroidogenic effect of VIP has been attributed by many authors to an
indirect action requiring VIP-stimulated catecholamine release from medullary
chromaffin cells (also found within the adrenal cortex (section 1.6.4.2)) and
subsequent stimulation of steroidogenesis by the action of catecholamines on
adrenocortical cells. Evidence for this indirect action includes the observation that
VIP-stimulated aldosterone and corticosterone secretion from rat adrenals was
attenuated by P-adrenoceptor antagonists (Bernet et al, 1994a; Hinson et al, 1992;
Mazzocchi et al, 1993a). Recently, Bornstein et al (1996) reported steroid secretion
in response to VIP from dispersed human adrenal cells, which was attenuated by a p-
adrenoceptor antagonist. It was postulated that the steroidogenic effect of VIP was
mediated by catecholamine release from interspersed chromaffin cells detected
within the culture.
These observations still leave open the question as to whether VIP can
stimulate adrenocortical cells directly. Stimulation of steroid secretion in response to
VIP was noted from perfused rat and porcine adrenal glands (Hinson et al, 1992,
1994b; Ehrhart-Bornstein et al, 1991a) and from an intact rat capsule-zg preparation,
where the subcapsular neural network remained relatively intact (Hinson et al, 1992;
Holzwarth et al, 1987; Bernet et al, 1994a), but not from dispersed rat adrenocortical
cells (Hinson et al, 1992; Enyedi et al, 1983). VIP infusion into conscious calves
resulted in increased Cortisol production but only in the presence of ACTH infusion
(Bloom et al, 1987). Mazzocchi et al (1994b) advanced the hypothesis that VIP
directly stimulated aldosterone and corticosterone secretion from dispersed rat
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capsular and inner adrenocortical cells, respectively, by acting on a subset of ACTH
receptors.
Further evidence for a direct action of VIP includes the autoradiographic
detection of VIP binding sites in rat adrenal cortex (Cunningham & Holzwarth,
1989). These were found throughout the cortex, but were more concentrated in the
subcapsular / zg zone. Stimulation of the splanchnic nerves resulted in a release of
VIP in the gland, detectable in the adrenal vein of conscious calves (Bloom et al,
1987), and also following splanchnic nerve stimulation of isolated, perfused porcine
adrenals with an intact nerve supply (Ehrhart-Bornstein et al, 1991a). Thus, VIP
released within the adrenal may reach concentrations high enough to affect
adrenocortical cells in a paracrine manner, by acting on a specific VIP receptor.
The aim of this series of experiments was to investigate the effects of VIP on
Cortisol, corticosterone and androstenedione production by H295R cells. The effects
of chronic (24 - 96 h) and short-term (4 h) treatment with VIP on steroid secretion
were investigated. Cells were treated with All and forskolin as positive controls
since the steroid responses of H295R cells to these agonists were characterised in
chapter 3.0.
As reported in Chapter 3.0, the steroidogenic capacity of H295R cells can be
increased by pretreatment with either angiotensin II or forskolin. Moreover,
depending on the pretreatment agonist used, the steroidogenic phenotype of the cells
can be altered. Chronic pretreatment of cells with All resulted in a potentially zona
glomerulosa-like (zg-like) phenotype of the cells, whereas forskolin pretreatment
induced a more fasciculata / reticularis-like (zfr-like) steroidogenic phenotype (see
Chapter 3.0). The short-term (4 h) steroid responses to VIP following chronic (96 h)
pretreatment of the cells with either All or forskolin were investigated, and compared
with "control" cells (no agonist added to medium during pretreatment period), based
on the hypotheses: 1) the increase in steroidogenic capacity induced by pretreatment
might increase the magnitude of the steroid responses to VIP and 2) VIP may act
preferentially on a particular zone of the adrenal cortex. By pretreating the cells with
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All or forskolin, the actions of these agonists on zg-like and zff-like steroid
phenotypes could be examined.
The effect of 96 h pretreatment of H295R cells with VIP itself on the
subsequent 4 h VIP-induced Cortisol response was also investigated.
Finally, a pretreatment time-course was performed to determine the optimum




4.2.1 Steroid responses from H295R cells following 24 h treatment with
VIP
Table 4.1 shows the Cortisol, corticosterone and androstenedione responses to
24 h treatment with VIP. Cells were also treated with All (10~8 M) and forskolin (10"
5 M), as positive controls and for comparison ofmagnitudes of responses.
VIP (10"7 M) significantly stimulated Cortisol secretion (2.4 (± 2.4) -fold, n=3
individual experiments, P<0.01, calculated from triplicate incubations within each
experiment) and corticosterone secretion (2.4 -fold, P<0.01, calculated from triplicate
incubations in 1 experiment) but failed to stimulate androstenedione secretion above
basal levels (P>0.05, calculated from triplicate incubations in 1 experiment). Within
each experiment, the Cortisol response to VIP was less than that seen to either All or
forskolin (see Table 4.1).
The steroid responses to increasing incubation times with VIP were
investigated. Figure 4.1 shows the time-course for Cortisol, corticosterone and
androstenedione secretion in response to 24, 48, 72 and 96 h VIP treatment. The
Response Ratios (RR, response to stimulus / basal secretion) for the individual
experiments are shown in Table 4.2. Although cells were exposed to VIP for the
times indicated, medium and agonists were replaced every 24 h and only medium
from the last 24 h of each treatment period was collected and assayed for steroid
content.
VIP (l(f7 M) significantly stimulated Cortisol and corticosterone secretion
after 24, 48 72 and 96 h treatment (P<0.01) (see Figure 4.1 and Table 4.2). The
Cortisol response to VIP increased with time, causing 2.5 (±1.4)-fold, 3.1 (+1.4)-fold,
4.5 (±2.6)-fold and 6.3 (±4.3)-fold increases, relative to basal secretion, after 24, 48,
72 and 96 h treatment, respectively (n=3) (see Figure 4.1). The data for each
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Figure 4.1
Time-dependent changes in a) Cortisol, b) corticosterone and c) androstenedione secretions
in response to chronic treatment with VIP. Cells were treated with growth medium alone
(basal, open bars) or medium containing VIP (10~7 M, solid bars) for 24, 48, 72 or 96 h.
Medium and agonists were replaced every 24 h. Medium from the last 24 h of each
treatment period was collected and assayed for steroid content by separate RIAs. Steroid
data was corrected for total cellular protein. Results shown are mean (±s.d.) of
measurements, performed in triplicate, from one experiment (from a set of n=3 separate
experiments for Cortisol and n=lexperiment for corticosterone and androstenedione).
Statistically significant changes in steroid secretion with respect to basal secretion are noted
by ***P<0.01, calculated from triplicate incubations within each experiment.
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Time-dependent CORTISOL Response
Response Ratio relative to basal
Expt. 1 Expt. 2 Expt. 3 Mean s.d.
24 h VIP 1.7 4.1 1.6 2.47 1.42
48 h VIP 2.3 4.7 2.4 3.13 1.36
72 h VIP 3.0 7.5 2.9 4.47 2.63
96 h VIP 3.6 11.2 4.1 6.30 4.25
Time-dependent CORTICOSTERONE Response
Response Ratio relative to basal
Expt. 1 Mean s.d.
24 h VIP 2.4 2.40 -
48 h VIP 1.9 1.90 -
72 h VIP 2.6 2.60 -
96 h VIP 3.2 3.20 -
Time-dependent ANDROSTENEDIONE Response
Response Ratio relative to basal
Expt. 1 Mean s.d.
24 h VIP 1.1 1.10 -
48 h VIP 1.1 1.10 -
72 h VIP 1.1 1.10 -
96 h VIP 1.3 1.30 -
Table 4.2
Tune-dependent changes in Cortisol, corticosterone and androstenedione secretion in
response to chronic treatment with VIP. Cells were treated with growth medium alone
(basal) or containing VIP (10~7 M) for 24, 48, 72 or 96 h. Medium and agonists were
replaced every 24 h. Medium from the last 24 h of the treatment period was collected and
assayed for steroid content by separate RIAs. Steroid data was corrected for cellular
protein. Results here are expressed as Response Ratios (response to stimulus / basal
secretion) for individual experiments, triplicate incubations performed in each.
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VIP also induced a significant rise in corticosterone secretion (relative to
basal secretion) (PO.Ol, for triplicate incubations in 1 experiment), resulting in 2.4-
fold, 1.9-fold, 2.6-fold and 3.2-fold increases in corticosterone secretion after 24, 48,
72 and 96 h treatment, respectively (see Figure 4.1).
An increase in androstenedione secretion above basal levels was not detected
after 24, 48, 72 or 96 h VIP (1CT7 M) treatment (P>0.05, for triplicate incubations in 1
experiment) (see Figure 4.1 and Table 4.2).
4.2.2 Cortisol response from H295R cells to 4 h treatment with VIP
Figure 4.2 shows the Cortisol responses to short term (4 h) treatment with
VIP. Cells were treated with All (10"8 M) and forskolin (10~5 M) as positive controls
and for comparison of responses.
A 4 h treatment with VIP (10 7 M) resulted in a 1.8 (±0.4) -fold increase in
Cortisol secretion (n=4 individual experiments, PO.05 calculated from triplicate
incubations within each experiment). This compared with a 2.1 (±0.3) -fold increase
following forskolin (10~5 M) treatment (n=4 individual experiments) and a 1.4 (±0.4)
-fold increase following All (10"s M) treatment (n=4 individual experiments).
4.2.3 Effect of pretreatment of H295R cells with All or forskolin on the
subsequent 4 h steroid responses to VIP
The Cortisol, corticosterone and androstenedione responses to VIP (10"'° M to
10"7 M) following 96 h pretreatment of cells with All or forskolin are shown in
Figure 4.2. "Control" cells were treated in the same way as All- or forskolin-
pretreated cells, except that no agonist was added during the pretreatment period.
VIP (10"10 M to 10"7 M) evoked a concentration-dependent and significant
increase in Cortisol secretion from "control" cells (PO.Ol for each concentration,
calculated from triplicate incubations in 1 experiment). Concentrations of 10"8 M and
10"7 M VIP also caused a significant stimulation of corticosterone secretion(P<0.05
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and P<0.01, respectively, calculated from triplicate incubations). Androstenedione
levels were unaffected by any dose ofVIP in "control" cells (P>0.05, calculated from
triplicate incubations) (see Figure 4.3).
VIP also stimulated Cortisol and corticosterone secretion in a concentration-
dependent manner from All-pretreated H295R cells (see Figure 4.3). Chronic
pretreatment of H295R cells with All (10 nM) resulted in a marked increase in the
corticosterone response to VIP. The threshold concentration for a significant
(P<0.01) stimulation of corticosterone secretion decreased to < 1CT9 M VIP,
compared with < 10"8 M in "control" cells (see Figure 4.3) and 10"8 M VIP elicited a
2.7-fold increase in corticosterone from All-pretreated cells compared with a 1.7-fold
increase in "control" cells. VIP still failed to stimulate androstenedione secretion
over basal (P>0.05, calculated from triplicate incubations in a single experiment) (see
Figure 4.3).
Chronic forskolin (10 pM) pretreatment greatly enhanced the subsequent
Cortisol and corticosterone concentration-responses to VIP in terms of both RR and
total steroid output; for example, 10"8 M VIP caused secretion of 52 (±3) pmol / mg
protein / 4 h Cortisol from "control" cells, which equated to a 2.3-fold increase over
basal secretion, compared with Cortisol secretion of 240 (±42) pmol / mg protein / 4 h
from forskolin-pretreated cells, with a RR of 6.9-fold. VIP (1CT10 M to 10~7 M)
caused a stimulation of androstenedione secretion following chronic forskolin
pretreatment (P<0.01 for all concentrations except 10"7 M, where P<0.05, calculated
from triplicate incubations in a single experiment) (see Figure 4.3). The threshold
concentration ofVIP required to stimulate androstenedione secretion was < 10"10 M.
4.2.4 Effect of pretreatment of H295R cells with VIP on subsequent 4 h
Cortisol response to VIP
Having determined the effects of All and forskolin pretreatment on
subsequent VIP action, it was decided to investigate the effect of 96 h VIP
pretreatment on the 4 h VIP response. The Cortisol responses to 4 h VIP (10~9 M to







































Cortisol secretion in response to short-term (4 h ) treatment with VIP. Cells were treated
with medium alone (basal, dotted line) or containing VIP (10~7 M), All (10~8 M) or
forskolin (10~5 M, fskn) for 4 h (cells were treated with forskolin and All as a positive
control and for comparison of responses). After 4 h, medium was removed and assayed for
Cortisol content by RIA. The results from n=4 separate experiments been combined and are
presented as mean Response Ratios (response to stimulus / basal secretion) (±s.d.).
Statistically significant changes in secretion compared with basal secretion within individual
experiments are noted by **P<0.02 and *P<0.05, in 4/4 experiments for fskn and VIP.
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Effect of 96 h VIP preincubation of cells on the subsequent 4 h Cortisol response to VIP.
Cells were pretreated with growth medium alone ("control" cells) or containing VIP (10"7
M) for 96 h. Medium and agonists were replaced every 24 h. After 96 h pretreatment, cells
were washed thoroughly and incubated with either growth medium alone (solid bar labelled
'basal') or containing VIP (10~9, 10~8 or 10~7 M, A) or forskolin (10~5 M, bar labelled
'fskn') for 4 h. After this time, medium was removed and assayed for Cortisol by RIA.
Steroid data was corrected for total cellular protein. Combined data (mean (±range, i.e.
min-max, —)) from n=2 separate experiments, triplicate incubations performed in each, are
shown. Statistically significant changes in steroid secretion, with respect to basal secretion,
calculated from triplicate incubations within each experiment are noted by *P<0.05 and
***p<0 oi. For data from each individual experiment see Table 4.3.
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VIP (10~9 M to 10"7 M) significantly increased Cortisol secretion from "control" cells
(PO.Ol for 10"9 M and 108 M VIP and P<0.05 for 10"7 M VIP, calculated from
triplicate incubations within each experiment, from n=2 separate experiments).
However, the response was enhanced by prior 96 h treatment of the cells with VIP
(10"7 M), a dose of 10"8 M VIP resulting in 5.3-fold and 6.3-fold stimulations of
Cortisol over basal (n=2 experiments, triplicate incubations performed in each)
compared with a 1.6-fold and 2.0-fold increases, respectively, from "control" cells
(n=2). The Cortisol response to forskolin (10~5 M) was also greatly enhanced
compared with "control" cells (30.5-fold and 10.9-fold compared with 2.4-fold and
2.1-fold for "VIP-pretreated" and "control" cells respectively (n=2, triplicate
incubations performed in each).
4.2.5 Optimising the pretreatment time with forskolin prior to 4 h VIP
treatment
Figures 4.3 and 4.4 show that pretreating H295R cells with forskolin
increased the subsequent Cortisol response to VIP to a greater degree than
preincubation with All and to a similar degree as preincubation with VIP. It was
decided to pretreat the cells with forskolin in all further VIP experiments. A time-
course was performed to optimise the pretreatment time with forskolin (10 pM).
Although pretreatment of the cells was performed in serum-containing growth
medium, serum-free growth medium was used for the subsequent 4 h VIP treatment
in this experiment and all subsequent experiments with VIP.
Figure 4.5 shows the effect of 24, 48, 72 or 96 h forskolin pretreatment on the
4 h Cortisol response to VIP (10"8 M). Total Cortisol output was maximal after 72 h
pretreatment in one experiment and 96 h in a second experiment, when 4 h treatment
with VIP (10"8 M) resulted in a Cortisol secretions of 52 (±3.9) and 43 (±5.4) pmol /
mg protein / 4 h respectively (n=2 separate experiments, triplicate incubations
performed in each) (see Figure 4.5). A time-dependent increase in Cortisol
responsiveness (in terms of n-fold increase (RR)) to VIP was observed following
forskolin pretreatment (see Table 4.4). The responsiveness of the cells was similar
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96 h CONTROL pretreatment
Mean (+/- s.d.)
Cortisol response to 4 h VIP
(pmol /mg protein / 4 h)
basal 10-9 M VIP 10 8 M VIP 10 ~7 M VIP
Expt. 1 18 (1.4) 32 (3.4) 29 (3.1) 26 (4.4)
Expt. 2 22(1.8) 43 (2.0) 44 (1.0) 37 (5.7)
mean 20 37.5 36.5 31.5
range 2 5.5 7.5 5.5
96 h VIP pretreatment
Mean (+/- s.d.)
Cortisol response to 4 h VIP
(pmol /mg protein / 4 h)
basal 10 9 M VIP 10-8 M VIP 10'7 M VIP
Expt. 1 7 (0.5) 25 (1.6) 37 (4.9) 67 (12.3)
Expt. 2 11 (1.9) 38 (0.4) 69 (2.7) 80 (14.8)
mean 9 31.5 53 73.5
range 2 6.5 16 6.5
Table 4.3
Effect of 96 h VIP pretreatment of H295R cells on Cortisol response to subsequent 4 h
treatment with VIP, compared with 'control'cells. Cells were pretreated with growth
medium alone ('control') or containing VIP (10~7 M) for 96 h. Medium and agonists were
replaced every 24 h. Following the pretreatment period, cells were washed thoroughly and
treated with serum-free medium alone (basal) or containing VIP (10~9 M, 10~8 M, 10"? M)
for 4 h. Medium was then collected and assayed for Cortisol content by RIA. Steroid data
was corrected for cellular protein. Results here are expressed as mean (±s.d.) Cortisol
secretion (pmol / mg protein / 4 h), calculated from triplicate incubations within each
experiment of n=2 separate experiments.
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Figure 4.5
Time-courses to determine the optimum length of time to pretreat cells with forskolin in
order to enhance the Cortisol response to subsequent 4 h treatment with VIP. Cells were
pretreated with forskolin (10 pM) for 24, 48, 72 or 96 h. After the defined pretreatment
period, cells were washed thoroughly and then incubated with serum-free growth medium
alone (basal, open bars) or containing VIP (10~8 M, hatched bars) for 4 h. After this time,
medium was collected and assayed for Cortisol content by RIA. Data was corrected for
cellular protein. Results presented are mean (±s.d) of data, calculated from triplicate
incubations, from 2 separate experiments.
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CORTISOL response to VIP (RR)
Forskolin pretreatment time (hours)
24 48 72 96
Expt. 1 2.07 2.64 3.15 2.30
Expt.2 2.00 2.66 3.62 6.05
Mean 2.04 2.65 3.39 4.18
Table 4.4
Effect of increasing length ofpretreatment time with forskolin on the subsequent Cortisol
response to VIP. Cells were pretreated with growth medium alone ("control") or containing
forskolin (10 pM) for 24, 48, 72 or 96 h. After pretreatment, cells were washed thoroughly
and then treated with serum-free growth medium containing VIP (10~8 M) for 4 h. After
this time, medium was collected and assayed for Cortisol content by RIA. Steroid data was
corrected for total cellular protein. Results in this table are expressed as Response Ratios
(response to stimulus / basal secretion, RR) from n=2 separate experiments, triplicate
incubations performed in each.
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after 72 h and 96 h pretreatment, when 10"8 M VIP elicited 3.4 (range ± 0.2)-fold and
4.2 (range ±1.9)-fold increases in Cortisol secretion over basal, respectively (n=2,
triplicate incubation performed in each). A pretreatment time of 72 h was chosen for
subsequent experiments.
The increase in cell responsiveness to VIP following 72 h forskolin
pretreatment was confirmed (see Table 4.5). A dose of 10"8 M VIP resulted in a 3.6
(±0.6)-fold stimulation of Cortisol secretion over basal from forskolin-pretreated cells
(n=4). This compared with a 2.0 (±0.3)-fold increase over basal from "control" cells
(n=4).
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72 h CONTROL pretreatment
Cortisol Response Ratio to 4 h VIP
10-8 M VIP 3.3 x10'8 M VIP 10-7 M VIP
Expt. 1 2.18 2.17 1.67
Expt.2 2.03 2.54 1.70
Expt. 3 1.64 2.05 1.48
Expt 4 2.25 2.62 2.47
Mean 2.03 2.35 1.83
s.d. 0.27 0.28 0.44
72 h FORSKOLIN pretreatment
Cortisol Response Ratio to 4 h VIP
10-8 M VIP 3.3 xW8 MVIP W7 M VIP
Expt. 1 2.97 2.85 4.01
Expt.2 3.57 4.09 3.42
Expt. 3 4.31 4.94 4.38
Expt.4 3.44 3.75 3.71
Mean 3.57 3.91 3.88
s.d. 0.56 0.86 0.41
Table 4.5
Effect of 72 h pretreatment of H295R cells with forskolin on the subsequent 4 h Cortisol
response to VIP. Cells were pretreated with forskolin (10 pM) for 72 h, the medium and
agonist replaced every 24 h. "Control" cells were treated in exactly the same way except
that no forskolin was added to the incubation medium. After pretreatment, the cells were
washed thoroughly and then treated with serum-free growth medium alone (basal) or
containing VIP (10~8 M, 3.3 x 10*8 M or 10~7 M) for 4 h. After this time, medium was
collected and assayed for Cortisol content by RIA. Steroid data was corrected for total
cellular protein. The results are expressed as Response Ratios (response to stimulus / basal
response) calculated from triplicate incubations from n=4 separate experiments.
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4.3 Discussion
VIP directly stimulated steroid production from H295R cells in a dose-
dependent and time-dependent manner. The steroid responses of the cells to All (10'
8 M) and forskolin (10 5 M) were similar to those presented in chapter 3.0, except that
the 24 h All-induced corticosterone response did not reach significance (P>0.05) in
this set of experiments.
Similar to All and forskolin, 24 h VIP treatment caused an increase in Cortisol
and corticosterone secretion but not androstenedione production (see Table 4.1). The
Cortisol response to VIP was of a lesser magnitude than that elicited by either All or
forskolin. This is unlikely to be due to a desensitisation of the steroid responses to
VIP because the Cortisol response continued to increase up to 96 h VIP exposure (see
Figure 4.1). Thus, VIP exerts a clear steroidogenic effect in H295R cells, though is a
less potent chronic (24 h) agonist than All or forskolin.
Chronic (24 - 96 h) VIP treatment progressively enhanced the Cortisol
responsiveness of the cells (in that the RR increased with time), similar to that seen
in response to forskolin (Chapter 3.0 and Figure 4.1), though VIP was a less potent
chronic agonist than forskolin over the 96 h treatment period (Table 4.2 and Table
3.1). This observation raises the possibility that chronic VIP treatment increases the
expression of key steroidogenic enzymes. Indeed, VIP has been shown to upregulate
expression of P450scc and P450cl7 mRNAs in hen granulosa cells (Johnson et al,
1994) and P450scc synthesis in cultured rat ovarian granulosa cells (Trzeciak et al,
1986).
Unlike Cortisol, the chronic corticosterone responsiveness of H295R cells to
VIP did not increase between 24 - 96 h treatment (see Figure 4.1). This differed
from the chronic corticosterone response to All or forskolin, where the sensitivity of
the cells increased with time following All or forskolin treatment (as described in
Chapter 3.0).
These steroidogenic effects of VIP meant that the ratios of Cortisol /
corticosterone and Cortisol / androstenedione increased with time. Corticosterone /
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androstenedione remained relatively constant with increasing time of VIP treatment.
Since VIP can alter the expression of P450scc and P450cl7 in ovarian tissue
(Johnson et al, 1994; Trzeciak et al, 1986), it is possible that chronic VIP treatment
can modulate the steroid phenotype of this cell-line in a similar way to All or
forskolin (see chapter 3.0).
Short-term (4 h) treatment with VIP led to a concentration-dependent increase
in Cortisol and corticosterone secretion (see Figure 4.3). As with chronic VIP
treatment, androstenedione secretion was unaffected by short-term VIP treatment.
The 4 h corticosterone response to VIP was greatly enhanced following prior
96 h treatment with All, as evidenced by the decrease in threshold concentration of
VIP from 10"8 M in "control" cells to 10*9 M in "AJI-pretreated" cells (see Figure
4.3). The responsiveness of the cells for Cortisol secretion actually decreased slightly
after All-pretreatment. This pattern of response would be consistent with a shift in
steroidogenic phenotype to a zg-like cell by chronic All pretreatment (as discussed in
Chapter 3.0). Androstenedione secretion remained unaffected by VIP, in keeping
with this argument.
Following forskolin pretreatment, 4 h VIP caused a concentration-dependent
increase in the secretions of all 3 steroids (see Figure 4.3). VIP was found to
stimulate androstenedione secretion from H295R cells only after chronic forskolin
pretreatment, consistent with the activation of the androgen pathway being highly
dependent on cAMP in this cell-line. This contrasts with the lack of effect of VIP on
androstenedione following pretreatment of the cells with All (a "non-cAMP"
agonist). VIP-mediated androstenedione secretion has been demonstrated from
isolated perfused porcine adrenals (Bornstein et al, 1993) and from cultured human
adrenal cells (Bornstein et al, 1996), though indirect mechanisms of action were
attributed to VIP. This study suggests that, if VIP binding-sites are present on zfr
cells, VIP may also regulate androstenedione production directly.
The sensitivity of the cells to VIP markedly increased following forskolin
pretreatment, with an increase in Response Ratios for all 3 steroids and a decrease in
the threshold concentration for corticosterone secretion, from 10"8 M in "control"
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cells to 10"'° M (or less) in "forskolin-pretreated" cells (see Figure 4.3). Possible
explanations include an upregulation of VIP receptors at the cell-surface or
alternatively an upregulation of steroidogenic enzyme expression. Evidence for the
latter explanation is that forskolin pretreatment also enhanced the steroid responses to
a subsequent 4 h re-challenge with forskolin. Indeed, forskolin has been shown to
markedly increase the expression of a number of key steroidogenic enzymes in this
cell-line (as discussed in Chapter 3.0). Although an accompanying increase in cell-
surface VIP receptors cannot be excluded, it seems possible that the increased
sensitivity of the cells to VIP reflects an overall increase in responsiveness of the
cells to steroidogenic agonists resulting from increased enzyme expression induced
by forskolin pretreatment.
A 96 h pretreatment of H295R cells with VIP itself also increased the
subsequent Cortisol response to acute VIP treatment, compared with "control" cells
(see Figure 4.4). The 4 h response to forskolin was also enhanced by chronic VIP
pretreatment, consistent with VIP modulating steroidogenic enzyme expression.
On the basis of these results, H295R cells were pretreated with forskolin prior
to short-term VIP treatment in subsequent experiments. Studies were first
undertaken to determine the optimum length of time to pretreat the cells with
forskolin (see Figure 4.5). A pretreatment time of 72 h was chosen on the basis of
steroid output (pmol / mg protein / 4 h), steroidogenic capacity (RR) and overall
convenience of experimental time-length (see Figure 4.5 and Table 4.4). The
increased responsiveness (RR to 4 h VIP treatment) of the cells following 72 h
forskolin pretreatment, compared with "control" cells, was then confirmed in a series
of experiments (see Table 4.5).
In summary, extensive evidence exists that VIP modulates steroid secretion
from the adrenal. Whether VIP exerts this effect (in part) directly on adrenocortical
cells has been unclear until now. In this study, VIP directly stimulated Cortisol,
corticosterone and androstenedione production from H295R cells. Moreover, VIP
appeared to be a potent stimulator of steroidogenesis in these cells. Bomstein et al
(1996) obtained comparable results with human adrenal cells in culture which
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secreted Cortisol and androstenedione, as well as DHEA, testosterone and
aldosterone, in response to VIP. Although these authors attributed the response to an
indirect effect involving catecholamine release, the studies presented in this chapter
clearly show that VIP has a direct action on steroidogenesis by adrenocortical cells,
an effect that may have been masked in primary cultures of adrenocortical cells,
which are likely to contain contaminating chromaffin cells.
Interestingly, a direct, receptor-mediated steroidogenic action for VIP on the
zg of rat adrenals has recently been reported (Hinson et al. 1996; Hinson & Kapas,
1997). These receptors may be regulated by sodium status in vivo because a low
sodium diet in rats resulted in increased aldosterone response to VIP, compared with
a control sodium diet (Hinson & Kapas, 1995), and also increased VIP receptor
binding and augmented adrenal content of VIP (Hinson et al, 1996). The possible
physiological importance of a direct action of VIP on adrenocortical steroidogenesis
is further discussed in chapter 8.0.
As developed further in this thesis, the H295R cell-line is of use in further
characterising this direct VIP action, for example, in terms of second messenger
systems activated and receptor subtypes involved.
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5.0 Characterisation of the Cortisol and second messenger
responses from H295R cells to VIP
5.1 Introduction
A number of intracellular signalling mechanisms and second messengers have
been implicated in the regulation of adrenal steroidogenesis, including: 1) the
adenylate cyclase-cAMP system, 2) phospholipase C (PLC)-mediated inositol
trisphosphate and diacylglycerol (DAG) formation, 3) the guanylate cyclase-cGMP
system, 4) phospholipase A2-induced release of arachidonic acid and formation of
eicosanoids, 5) phospholipase D-induced cleavage of phospholipids generating
phosphatidic acid and DAG, 6) calcium fluxes.
In this chapter, three of these second messengers were investigated following
treatment of H295R cells with VIP. These were: 1) cAMP production, 2) cGMP
production and 3) phosphoinositide turnover. These second messengers were
selected on the basis that they have been shown to be stimulated by VIP in other
tissues (section 5.1.4). The formation of each of these three second messengers will
be reviewed in the following sections.
5.1.1 Adenylate cvclase-cAMP system
The earliest signalling mechanism identified in adrenocortical cells was the
adenylate cyclase-cAMP system (Sutherland & Rail, 1958). Adenylate cyclase (AC)
is a hormone-sensitive enzyme which catalyses the conversion of adenosine-5'-
trisphosphate (ATP) to the intracellular second messenger molecule, cyclic-3',5'-
monophosphate (cAMP) (Figure 5.1). To date, at least nine isoforms of AC have
been identified; the regulatory properties of each may vary. In particular, it now
appears that Ca2+ / protein kinase C (PKC) is important in the regulation of several of
these isoforms (reviewed by Antoni, 1997), leading to cross-talk between receptors
which activate these different systems, for example, ACTH receptors (which are
predominantly associated with increased cAMP production) and All receptors (which
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cAMP-dependent protein kinase
Structure ofthe hormonally regulated adenylate cyclase. Agonists, for example, ACTH,
interact with stimulatory receptors (Rs) which activate the enzyme catalytic unit (C) via a
pertussis-toxin insensitive G protein (Gs). The enzyme can also be inhibited by agonists
which interact with receptors linked to inhibitory G proteins (Gj). cAMP, formed from
ATP, stimulates cAMP-dependent protein kinases, eventually leading to activation of
steroidogenesis through the phosphorylation of specific enzymes (P450scc).
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have been linked to increased intracellular Ca2+ and PKC activation). So far, the
AC3 isoform has been detected in bovine zg cells (Burnay et al, 1998).
cAMP further transmits the intracellular signal by activating the cAMP-
dependent protein kinase, protein kinase A, leading to subsequent phosphorylation
events. PKA is a tetrameric enzyme, which exists in multiple isoforms, and consists
of two catalytic subunits (C), which specifically phosphorylate serine and threonine
residues, and two regulatory subunits (R) (Doskeland et al, 1993). The importance of
cAMP-dependent protein kinase in adrenal steroidogenesis was demonstrated by
Wong et al (1986) using mutant cells which lacked cAMP-dependent protein kinase
activity. Transformation of the cells with DNA from an ACTH- and cAMP-
responsive adrenocortical cell-line resulted in the recovery of a steroid response to
ACTH and 8-bromo-cAMP (Wong et al, 1986).
Changes in AC activity occur after hormone-binding and activation of an AC-
coupled receptor, for example, the ACTH receptor. This results in the activation of a
guanine nucleotide-binding regulatory protein (G-protein), which couples the
hormone-sensitive receptor to AC.. The structure and function of G-proteins in the
activation of AC was reviewed by Gilman (1995). In summary, each G-protein
consists of three subunits, designated a, p and y. The p and y subunits are highly
homologous between each specific G-protein, whereas the a-subunits show more
structural diversity. Indeed, the nomenclature for each specific G-protein is
designated by the a-subunit of the molecule. With respect to AC, members of two
subfamilies of G-protein are directly regulatory: 1) the Gs group, members of which
stimulate AC activity and 2) the G, group, members ofwhich inhibit AC activity.
Activation of the G-protein involves displacement of GDP by GTP from the
a-subunit of the G-protein molecule, followed by dissociation of the a-subunit from
the P and y subunits, which remain associated as a py complex. The a and Py
subunits are capable of altering AC activity by binding to the enzyme. The a-
subunits of the Gs family generally stimulate AC activity whereas the a-subunits of
certain members of the G, family inhibit AC activity. The effect of the Py complex
depends on the type of AC involved; for example, Py enhances activity of AC2,
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whilst inhibiting the activity of AC1 (Tang & Gilman, 1991). The process ends
when the intrinsic GTPase activity of the a-subunit hydrolyses the bound GTP to
GDP. The GDP-a-subunit re-associates with the Py-subunits and basal levels of AC
activity are then restored.
Whilst the Gs and G( subfamilies of G-proteins exert a direct action on
adenylate cyclase activity, other G-proteins can influence cAMP production. For
example, All receptor-mediated stimulation of Gq in adrenal zg cells (Smrcka et al,
1991) ultimately results in PKC activation, which modulates adrenal cell AC activity
such that a further increase in cAMP production occurs (Baukal et al, 1994). Thus,
All and ACTH can synergistically increase cAMP levels in adrenocortical zg cells.
Intracellular cAMP is degraded by phosphodiesterases; the activities of these
enzymes in different tissues are important in the modulation of cAMP signalling
(Conti et al, 1995).
5.1.2 Guanylate cvclase-cGMP system
Guanylate cyclase (GC) is a ubiquitous enzyme which converts guanosine-5'-
triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP), an
intracellular second messenger. GC has been shown to exist in a cytosolic (soluble)
form and a membrane-associated (particulate) form.
The structure and mechanism of activation of soluble guanylate cyclase
(sGC) is reviewed by Hobbs (1997). The enzyme exists as haem-containing
heterodimers containing an a and p subunit. Several isoforms of sGC have been
cloned, comprising different combinations of a-subunit isoforms and P-subunit
isoforms (so far discovered; al, a2, (a3) and pi, P2, (P3)). Although both a and p
subunits contain catalytic sites at their C-termini, dimerisation of the a and P
subunits is obligatory for catalytic activity of the enzyme (Hobbs, 1997, for review).
sGC is most potently activated by nitric oxide (NO), formed from NO
synthase (NOS) action on L-arginine (Mayer & Andrew, 1998, for review). Three
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isoforms of NOS have currently been identified (nNOS; found in brain and central
nervous system, eNOS: found in endothelial cells and iNOS; inducible form of
NOS).
The N-terminal haem-moiety of sGC is responsible for conferring NO-
sensitivity to the enzyme. Oxidation of the haem group results in loss of enzyme
activity whilst binding of NO to the haem group of sGC results in formation of a
pentacoordinate nitrosyl-haem complex and activation of the enzyme (Hobbs, 1997,
for review).
The particulate form of GC (pGC) is a transmembrane protein, associated
with organelle membranes as well as cell-surface membranes. As with sGC, several
isoforms are thought to exist (GC-A-F) (Wedel & Garbers, 1997). An important
activator of pGC, with respect to the adrenal, is ANP (Anand-Srivastava & Trachte,
1993, for review). ANP binds to the NH2-terminal, extracellular, peptide binding
domain of the enzyme, resulting in activation of the intracellular catalytic domain
without the involvement of G-proteins. The intracellular domain contains a protein
kinase-like region, as well as a catalytic region, which is necessary for ANP control
ofpGC activity (Anand-Srivastava & Trachte, 1993).
cGMP further transmits the intracellular signal by actions on cGMP-
dependent protein kinases (Lohmann et al, 1997), cGMP-dependent
phosphodiesterases (Beavo, 1995) and cyclic nucleotide-gated ion channels (Biel et
al, 1998).
5.1.3 Phosphoinositide (PI) metabolism
Phosphoinositides constitute approximately 2 - 8% of cell membrane
phospholipids. Hormone-stimulated turnover of phosphoinositides was first
described by Hokin & Hokin (1953), following the observation of increased 32P
incorporation into phospholipids of pancreatic exocrine cells in response to
cholinergic stimulation. Michell (1975) later suggested that this agonist-mediated
rise in phospholipid turnover was linked to increases in intracellular Ca2+, leading to
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the ultimate recognition of inositol 1,4,5-trisphosphate (Ins(l,4,5)P3) (released from
phospholipase C (PLC) action on phosphoinositide 4,5-bisphosphate) as an important
intracellular second messenger and regulator of cytosolic Ca2+ concentrations (Streb
et al, 1983; Berridge & Irvine, 1984). A second effect of PLC action on
phosphoinositide substrate is release of the product DAG, an activator ofPKC.
The major pathways of phosphoinositide metabolism are shown in Figure
5.2. The two important metabolites of this pathway (which serve as second
messengers), Ins(l,4,5)P3 and 1,2-diacylglycerol (DAG), are formed by PLC-
mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). PLC
activity is increased following agonist binding to specific receptors, for example, the
All receptor in adrenocortical zg cells. Evidence suggests that this effect is mediated
via a G-protein, Gq (Smrcka et al, 1991). Whilst Ins(l,4,5)P3 is responsible for Ca2+
mobilisation, DAG activates the Ca2+-dependent protein kinase C (PKC) (Berridge &
Irvine, 1989, review).
Rapid inactivation of Ins(l,4,5)P3 to free inositol occurs via 1) sequential
dephosphorylation by phosphatases, forming Ins(l,4)P2, then Ins(4)P, then free
inositol or 2) conversion to Ins(l,3,4,5)P4 by Ca2+/calmodulin-dependent cytosolic 3-
phosphokinase. The latter pathway may be predominant as 3-phosphokinase has a
greater affinity for Ins(l,4,5)P3 than the 5-phosphatase which degrades it to
Ins(l,4)P2.
Ins(l,3,4,5)P4 may also promote Ca2+ influx / mobilisation (Ely et al, 1990)
prior to conversion to the relatively inactive Ins(l,3,4)P3, subsequent
dephosphorylation to inositol monophosphates and final degradation by a non¬
specific, lithium-sensitive, monophosphatase to yield free inositol. Inclusion of
lithium in experimental media allows the accumulation of inositol phosphates for
assay. Other tetrakisphosphates (Ins(l,3,4,6)P4 and Ins(3,4,5,6)P4) as well as InsP5
and InsP6 may be formed in adrenocortical cells (Balla et al, 1989a).
DAG is phosphorylated by DAG-kinase to form phosphatidic acid (PtdOH),
which is then converted to phosphatidylinositol (Ptdlns) via cytidine-
129
^ _












(InsP,) (InsPJ (InsPjJ (InsPJ (lnsP5/lnsPj
Fizure 5.2
An outline of the major metabolic pathways which are activated as a consequence of
phospholipase C action-on Ptdlns(4, SjPj to produce the second messengers, Ins(l, 4, 5)P-$
and DAG. The final steps in the recycling of Ins(l, 4, 5)P3 to free inositol (Ins) can be
inhibited by lithium, leading to accumulation ofphosphoinositols.
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diphosphodiacylglycerol (CDP-DAG) combination with free inositol. The
phosphoinositides PtdIns(4)P and PtdIns(4,5)P2 are formed from Ptdlns by sequential
phosphorylation of the inositol ring by specific kinases.
5.1.3.1 lns(1,4,5)P3 and DAG in adrenocortical cells
The hydrolysis of phosphoinositides in bovine and rat zg cells (Kojima et al,
1985; Farese et al, 1984) as well as bovine zfr cells (Bird et al, 1989) in response to
All has been demonstrated and this effect has been linked to steroid secretion (see
section 3.1.2 for mechanism ofAll action in adrenocortical cells). However, in ovine
zfr cells, All failed to stimulate steroidogenesis whilst still causing an increase in
phosphoinositide turnover (Viard et al, 1990). Ins(l,4,5)P3 was produced in a
biphasic manner in cultured bovine zg cells (Balla et al, 1989b), and the secondary
increase was associated with an increase in Ins(l,3,4,5)P4. Distinct receptors for
Ins(l,4,5)P3 and Ins(l,3,4,5)P4 have also been detected on bovine adrenal
microsomes (Guillemette et al, 1987; Enyedi & Williams, 1988). An All-induced
biphasic increase in DAG formation has also been described (Hunyady et al, 1990).
DAG activates PKC, an enzyme first identified by Nishizuka (1984) which
also requires phospholipid and Ca2+ for its activation. PKC activity has been detected
in bovine and rat adrenocortical cell preparations (Coyne et al, 1986; Widmaier &
Hall, 1985). In addition, PKC has been shown to phosphorylate the first enzyme of
steroidogenesis, P450scc (Vilgrain et al, 1984).
Agonist-stimulated phosphoinositide turnover and regulation of
steroidogenesis has been reviewed by Bird et al (1990b). Kojima et al (1985)
demonstrated that sustained All-induced steroidogenesis from superfused bovine zg
cells could only be fully reproduced by co-administration of the Ca2+ ionophore,
A23187, and the phorbol ester, 12-0-tetradecanoylphorbol-13-acetate (TPA; an
activator of PKC), suggesting that both Ca2+ influx and PKC activation are required
for prolonged stimulation of steroidogenesis by PLC agonists.
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5.1.4 Second messenger systems activated by VIP
The best characterised and most commonly observed intracellular response
following VIP administration is activation of AC and increased cAMP production.
Couvineau et al (1990) demonstrated VIP receptor coupling to Gs in rat liver and VIP
has been shown to increase cAMP levels in cerebral cortex (Magistretti &
Schorderet, 1984), thyroid (Siperstein et al, 1988), liver, pituitary (Rostene, 1984),
gastric smooth muscle cells (Jin et al, 1993), mouse N1E-115 neuroblastoma cells,
PC 12 cells (Wessels-Reiker et al, 1991) and in a human colon carcinoma cell-line
(LoVo) (Yu et al, 1992) amongst others.
Whilst in many tissues VIP appeared to stimulate cAMP production alone, in
some cell types (for example, guinea pig / rabbit gastric smooth muscle cells and rat
pinealocytes), it also caused an increase in cGMP levels (Jin et al, 1993; Murthy et
al, 1993, 1995; Schaad et al, 1995). Studies by Murthy et al (1993) on dispersed
rabbit gastric muscle cells indicated that this action involved VIP-specific G-protein-
coupled receptors, distinct from those which activate AC, which stimulated Ca2+
influx (through a methoxyverapamil-sensitive Ca2+ channel), leading to activation of
a constitutive NOS, NO generation, GC activation, cGMP synthesis and cGMP-
dependent protein kinase activation. In rat pinealocytes, VIP also stimulated cGMP
production via NO and activation of sGC (Spessert, 1993), followed by an increase in
intracellular Ca2+, apparently via a cGMP-gated, /-cA-diltiazem-sensitive, rod-type
cation channel (Schaad et al, 1995).
Increased phosphoinositide turnover has been demonstrated following VIP
treatment of rat superior cervical ganglia (Audigier et al, 1986). In addition, VIP
increased Ins(l,4,5)P3 in the adrenal medulla (Malhotra, 1988) and activated PKC in
nuclei isolated from rat hippocampus (Weill, 1989).
VIP has been shown to depolarise retinal horizontal neurons via a cAMP-
independent mechanism (Lasater et al, 1983). In cultured rat zf cells, VIP modulated
T-type Ca2+ channels via a PKA-independent mechanism (Barbara & Takeda, 1995).
VIP also modulated membrane potentials of spinal cord dorsal root terminals and
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motoneurons (Phillis et al, 1978) and submucosal plexus neurons (Mihara et al,
1985).
In this chapter, the Cortisol response to VIP from H295R cells was further
characterised and accompanying activation of the AC-cAMP, GC-cGMP and PI
second messenger systems was investigated. Cells were pretreated with forskolin (10
pM) for 72 h, to enhance the subsequent Cortisol response, as discussed in chapter
4.0. Following the pretreatment period, all subsequent treatments with VIP were
performed in serum-free medium.
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5.2 Results
5.2.1 Concentration-dependent Cortisol secretion from the H295R cell-
line in response to VIP
In order to determine the characteristics of the VIP-induced Cortisol response
from the H295R cell-line, the cells were treated with a range of concentrations of
VIP from 10 " M to 10"7 M VIP for 4 h. Figure 5.3 shows the resulting
concentration-dependent Cortisol secretion from the H295R cells, reaching a
maximum 3.9 (±0.9)-fold increase by 3.3 x 10"8 M (n=4 individual experiments), the
threshold effect occurring at 10"11 M (n=4 individual experiments). The pEC50 value
(negative logarithm to the base 10 of the concentration (Molar) producing a half-
maximal response) obtained was 9.22 (±0.43) (n=4 individual experiments). The
maximal Cortisol effect ofVIP was equivalent to that produced by 10 pM forskolin.
5.2.2 Secondmessenger pathways activated by VIP in H295R cells
5.2.2.1 cAMP production following treatment ofH295R cells with VIP
(a) Time-course ofcAMPproduction in response to VIP
Since a concentration of 3.3 x 10~8 M VIP induced a maximal Cortisol
response in H295R cells, this concentration was used to determine a time-course for
VIP-induced cAMP accumulation in the overlying medium (see Figures 5.4a and
5.4b). Levels of cAMP in the medium remained steady in control cells (treated with
serum-free growth medium alone, indicated as 'basal' in Figures 5.4a and 5.4b),
whereas VIP treatment resulted in a significant and time-dependent increase in the
amount of cAMP in the overlying medium. Accumulation of cAMP in the medium
increased slowly up to 10 minutes exposure to VIP {Figure 5.4a), thereafter rising
more steeply with longer VIP treatment {Figure 5.4b). Levels of cAMP measured
were still increasing after 4 h VIP treatment. Because cells were stimulated for 4 h
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Figure 5.3
Concentration-dependent increase in Cortisol secretion in response to 4 h treatment with
VIP. Forskolin-pretreated cells were washed and then treated with VIP (10~11 M to 10~7 M,
•) or forskolin (10~5 M, solid bar labelled fskn) for 4 h. After this time, medium was
removed and assayed for Cortisol content by RIA. Cortisol data was corrected for total
cellular protein content. Data from 4 separate experiments, triplicate incubations performed
in each, were combined and expressed as mean (±s.d.) Response Ratios (response to
stimulus / basal secretion).
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Figure 5.4a
Time-dependent accumulation of cAMP in medium following treatment with VIP (1-10
mins). Cells were treated with serum-free growth medium alone (basal, □) or containing
VIP (3.3 x 10"8 M, •) for 1, 2.5, 5, 10, 20, 60, 120 or 240 mins. After the defined treatment
period, medium was collected and processed (as decribed in Methods) for analysis of cAMP
content by RIA. Results presented are mean (±s.d.) for triplicate incubations from 2
separate experiments. Figure 5.4a shows the time-points from 1 to 10 mins. Figure 5.4b
(next page) shows the entire time-course from 1 to 240 mins. A statistically significant
difference between basal cAMP concentration and VIP-stimulated cAMP levels at any
particular time-point is indicated by *P<0.05 and ***P<0.01.
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Figure 5.4b
Time-dependent accumulation of cAMP in medium following treatment with VIP (1-240
mins). Cells were treated with serum-free growth medium alone (basal, □) or containing
VIP (3.3 x 10-8 m, •) for 1, 2.5, 5, 10, 20, 60, 120 or 240 mins. After the defined treatment
period, medium was collected and processed (as decribed in Methods) for analysis of cAMP
content by RIA. Results presented are mean (±s.d.) for triplicate incubations from 2
separate experiments. Figure 5.4a (previous page) shows the time-points from 1 to 10 mins.
Figure 5.4b shows the cAMP accumulation for each time-point over the time-course from 1
to 240 mins. A statistically significant difference between basal cAMP concentration and
VIP-stimulated cAMP levels at any particular time-point is indicated by *P<0.05 and
***P<0.01.
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with VIP for the Cortisol studies, a time-point of 4 h was chosen for measurment of
cAMP accumulation in response to different concentrations ofVIP.
(b) cAMP concentration-response curves to VIP
Figure 5.5(A) shows the concentration-dependent increase in cAMP
accumulation following VIP treatment, reaching a maximum of 16 (±ll)-fold
increase with 3.3 x 10~8 M (from n=4 individual experiments with n-fold increases of
10.0, 10.8, 32.6 and 11.0), with a threshold change occurring at 10"u M (n=4
individual experiments). The maximum cAMP response was similar to that induced
by 10 pM forskolin. Figure 5.5(B) shows the Cortisol concentration-response curve
for comparison.
The mean pEC50 (±s.d.) obtained for cAMP accumulation in the media was
8.6 (±0.45) (n=4 experiments). Table 5.1 shows the individual pEC50 values
obtained for Cortisol and cAMP production from 4 separate experiments in response
to VIP. The mean pEC50 values for Cortisol and cAMP production were not
statistically different (P>0.05).
5.2.2.2 Measurement of cGMP production following treatment of H295R cells
with VIP
(a) Time course and concentration-response investigations
Time-courses, using a concentration of 3.3 x 10"8 M VIP, and concentration-
response curves to VIP (4 h treatment) were performed. In some experiments, there
appeared to be an increase in cGMP over basal levels (see Table 5.2). However, the
levels of cGMP detected in most of these experiments were very low and two
concerns presented themselves, which were investigated: 1) was the apparent
increase in cGMP actually a result of cross-reactivity of the cGMP antibody with the
high levels of cAMP produced in response to VIP? and 2) were the extremely low





Concentration-dependent increase in cAMP secretion into the medium in response to 4 h
treatment with VIP (A). Cortisol secretion from identically-treated H295R cells is shown in
(B) for comparison. Forskolin-pretreated cells were washed thoroughly, then treated with
VIP (10" to 10"7 M, •) or forskolin (10"5 M, solid bar) for 4 h. Aliquots of medium
were assayed directly for Cortisol content by RIA or processed (as described in Methods) for
cAMP measurement by RIA. Data (corrected for total cellular protein) was combined and is
expressed as mean (±s.d.) Response Ratios (response to stimulus / basal secretion, RR) from
4 separate experiments for both Cortisol and cAMP results.
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Expt. 1 9.533 (0.10) 9.193 (0.10)
Expt.2 8.921 (0.12) 8.294 (0.33)
Expt. 3 j 9.640 (0.19) 8.591 (0.21)
Expt. 4 8.796 (0.14) 8.194 (0.21)
Mean
pEC50 (+/-s.d.)
9.223 (0.43) 8.568 (0.45)
Table 5.1
Comparison ofpEC50 values for Cortisol secretion and cAMP production from H295R cells
treated with a range of doses of VIP (lOrll M - 10-7 M) for 4 /? Treatment of cells,
processing of medium and analysis of medium content of Cortisol and cAMP by specific
RIAs was carried out as described in Methods. Data expressed are mean (± s.d.) pEC50
from triplicate incubations performed in each of n=4 experiments. The mean (± s.d.) pEC50
values from the combined data are also expressed.
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cGMP response to VIP
(pmol / mg protein / 4 h)
Expt. 1 Expt. 2 Expt. 3 mean s.d.
basal 0.08 0.23 0.24 0.18 0.09
VIP 10-11 M 0.17 0.25 0.24 0.22 0.04
VIP 10-10 M 0.24 0.30 0.37 0.30 0.07
VIP 10-9 M 0.30 0.41 0.42 0.38 0.07
VIP 10-8 M 0.39 0.41 0.41 0.40 0.01
VIP 3.3 x 10-8 M 0.39 0.43 0.50 0.44 0.06
VIP 10-7 M 0.39 0.54 0.41 0.45 0.08
Table 5.2
Measurment of cGMP levels in overlying medium ofH295R cells following 4 h treatment
with VIP. Forskolin-pretreated cells were washed thoroughly and then treated with serum-
free medium alone (basal) or containing VIP (10~11 M - 10~7 M) for 4 h. After this time,
medium was collected and processed (as described in Methods) and assayed for cGMP
content by RIA. Data from n=3 separate experiments, triplicate incubations performed in
each, were corrected for total cellular protein and are presented in Table 5.2 with the mean
(±s.d.) of combined data.
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(b) Calculation ofcross-reactivity ofcAMP with cGMP antibody
The cross-reactivity of the cGMP antibody with cAMP was determined by
analysing the binding of acetylated cAMP standards (lpM to ImM) to the cGMP
antibody in comparison to acetylated cGMP standards. The logit B/BO was plotted
against the cyclic nucleotide concentration on a logarithmic scale. This produced a
linear function. Cross-reactivity was estimated at logit B/BO = 0. Figure 5.6 shows
this plot. The cross-reactivity, determined from 3 separate experiments was 0.01
(±0.003) %. Based on this level of cross-reactivity, the cAMP produced in response
to VIP is unlikely to account for the cGMP detected.
(c) Calculation ofminimum detection limit (MDL) ofcGMP RIA
The MDL for the assay was calculated by combining and plotting the
precision profile data from n=9 assays. Figure 5.7 shows the graph of the precision
profile from which the MDL was calculated by reading the concentration of cGMP at
which there is a 22% CV (McConway et al, 1989). The MDL was calculated to be
>0.25 nM. Most of the cGMP levels measured from the various experiments
performed were below this limit. Inclusion of the phosphodiesterase inhibitor,
IBMX, in the experimental media did not alter the cyclic nucleotide concentrations in
these cells.
5.2.2.3 Measurement ofphosphoinositide turnover in response to VIP
VIP (3.3 x 10"8 M) failed to increase phosphoinositide turnover in H295R
cells (n=3 experiments, P>0.05, calculated from triplicate incubations within each
experiment), whereas the positive control treatment, All (10"8 M), caused a 2.4
(±0.25)-fold increase in phosphoinositide turnover from "control" pretreated cells
(n=3 experiments, P<0.02 for 2/3 experiments, calculated from triplicate incubations
within each experiment) and a 1.5 (±0.15)-fold increase in forskolin-pretreated cells
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[cyclic nucleotide] (nM)
■ cGMP * cAMP
Figure 5.6
Calculation ofcAMP cross-reactivity with the cGMP antibody. cAMP standards ▲ (1 pM-
1 mM) were prepared in the same way as the usual cGMP standards ■ (0.03 nM-32 nM)
used for the RIA standard curve. The assay was performed as normal, with the cAMP
standards measured as samples. B/BO was calculated for each standard (cGMP and cAMP)
and the logit function plotted against the cyclic nucleotide concentration on a logarithmic
scale. The cross-reactivity of cAMP with the cGMP antibody was calculated at the 0 logit



















Calculation of the minimum detection limit for the cGMP RIA employed. Precision profile
data from n=9 separate assays were combined and the dose-error curve plotted, as shown
above. The minimum detection limit was taken as the concentration of cGMP with a CV
(coefficient of variation) equal to 22% (McConway et al, 1989).
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(a)
[3H]-phosphoinositol accumulation in response to VIP-
control cells (dpm)
expt 1 expt 2 expt 3
basal 1671 (799) 2481 (821) 3843 (229)
VIP 10-11 M 1239 (123) 2373 (589) 4297 (318)
VIP 10-10 M 1050 (255) 3022 (97) 3201 (194)
VIP 10-9 M 1448 (368) 3166 (40) 3828 (195)
VIP 10-8 M 1126 (92) 3349 (385) 3831 (36)
VIP 3.3 x 10-8 M 1630 (108) 3544 (282) 3677 (77)
All 10-8 M 3580 (111) "5710 (432) "*10109 (613)
(b)
[3H]-phosphoinositol accumulation in response to VIP-
forskolin pretreated cells (dpm)
expt 1 expt 2 expt 3
basal 2905 (559) 5570 (508) 5793 (314)
VIP 10-11 M 2922 (430) 5373 (216) 6522 (219)
VIP 10-10 M 3165 (474) 5535 (581) 7653 (1649)
VIP 10-9 M 2959 (567) 5141 (174) 7115 (860)
VIP 10-8 M 3221 (203) 5655 (240) 6485 (329)
VIP 3.3 x 10-8 M 3228 (74) 6592 (500) 6502 (982)
All 10-8 M 4518 (281) 7400 (1045) ***9413 (445)
Table 5.3
Effect of VIP and All on phosphoinositide breakdown in (a) control pretreated and (b)
forskolin pretreated H295R cells. Cells were pretreated for 72 h with either growth medium
alone (a) or forskolin (10 pM) (b). During the last 48 h of this pretreatment period cells
were incubated with [^Hj-inositol to label membrane inositol phospholipids. Cells were
stimulated in DMEM / F12 without agonists (basal) or with various doses ofVIP (10"^ M -
3.3 x 10~8 M) or All (10"8 M) for 30 mins. Phosphoinositide breakdown was assayed as
described in Methods. Data presented here are from n=3 experiments, with triplicate
incubations performed in each., and are expressed as mean disintegrations per minute (dpm)
*
(±s.d.). Statistically significant changes in dpm measured with respect to basal are
represented by **P<0.02 and ***P<0.01.
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(n=3 experiments, P<0.01 in 1/3 experiments, calculated from triplicate incubations
within each experiment) (see Table 5.3)
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5.3 Discussion
The aim of this chapter was to determine the second messenger responses
elicited by VIP in H295R cells.
In other tissues, VIP stimulation has been linked to the activation of a number
of second messenger systems, including cAMP production, cGMP production,
increased phosphoinositide turnover and changes in intracellular Ca2+ levels (section
5.1.4). In the adrenal gland, stimulation of steroidogenesis by the physiological
regulators, ACTH and All has been predominantly associated with increased cAMP
formation and phosphoinositide turnover and calcium influx, respectively (sections
3.1.1 and 3.1.2).
VIP increased Cortisol secretion from H295R cells in a concentration-
dependent manner. Maximal stimulation occurred at a concentration of 3.3 x 10"8 M
VIP, which was similar to that observed for glucocorticoid secretion from dispersed
rat adrenocortical cells (Mazzocchi et al, 1994b; maximal stimulation of Cortisol
secretion observed with a concentration of 10"8 M), perfused porcine adrenal glands
(Ehrhart-Bornstein et al, 1991a; maximal stimulation with 10"8 M VIP) and cultured
human adrenal cells (Bornstein et al, 1996; maximal stimulation with 10"7 M). The
maximal Cortisol response to VIP from H295R cells was equivalent to that produced
by 10 p,M forskolin, indicating that VIP is a potent stimulator of Cortisol production
in these cells.
The cAMP concentration-response curve paralleled the Cortisol
concentration-reponse curve in that maximal cAMP production occurred at the same
concentration of VIP as maximal Cortisol secretion (3.3 x 10 s M). The threshold
concentration ofVIP was also the same for Cortisol and cAMP and the pEC50 values
for Cortisol and cAMP production were not significantly different (9.22 ± 0.43
compared with 8.7 ± 0.45, respectively, P>0.05). In addition, 3.3 x 10"8 M VIP was
equipotent with 10 pM forskolin for Cortisol secretion and similar in potency to
forskolin-stimulated cAMP production. Bodart et al (1997) recently investigated the
effect of VIP on human adrenocortical tumour cells, with respect to aldosterone
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secretion, and demonstrated a potent effect on cAMP production with a similar EC50
(0.38 ± 0.021 nM) to that obtained in this study.
The stimulation of cGMP production in adrenocortical cells has been
associated with an inhibitory effect on steroidogenesis since ANP inhibits
aldosterone production and also causes an increase in cGMP (Ganguly, 1992, and
section 7.1.1). However, the mechanism of cGMP action in adrenocortical cells is
still unclear. A few groups have implicated cGMP as a mediator of ACTH-
stimulated steroidogenesis in adrenal zf cells (Harrington et al, 1978; Perchellet &
Sharma, 1979), though the increase was transient (Perchellet & Sharma, 1979) and
was often not reproducible.
VIP has been shown to stimulate an increase in cGMP levels, in conjunction
with an increase in cAMP, in rat pinealocytes (section 5.1.4). The possibility that
VIP activates a similar dual signalling system in adrenocortical cells was
investigated. There was no convincing cGMP response within the limits of the RIA
employed. Inclusion of the phosphodiesterase inhibitor, IBMX, in the experimental
media did not alter the amount of either cyclic nucleotide detected. This suggests
that cyclic nucleotide phosphodiesterase activity is intrinsically low in these cells.
Further investigation of a possible VIP-induced effect on cGMP levels in these cells
would be worth pursuing in future experiments.
Turnover of phosphoinositides was investigated in response to VIP and AIL
All is well documented as a stimulant for phosphoinositide turnover leading to
Ins(l,4,5)P3 production. VIP has been shown to affect components of this
intracellular signalling system in some tissues (section 5.1.4), though it is unclear
whether these effects are mediated by VIP receptors (VPAC / PACAP type II
receptors) or via PACAP-specific receptors (PAC1 / PACAP type I receptors).
Indeed, phosphoinositide turnover in rat superior cervical ganglia required much
higher concentrations of VIP than were needed for cAMP production in the same
tissue (Audigier et al, 1986). VIP is capable of activating PACAP type I (PAC1)
receptors but with a greatly reduced potency (section 6.1). VIP had no effect on
phosphoinositide turnover in H295R cells whereas All stimulated a small but
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significant increase, consistent with its weak agonist action in our H295R cells
(chapter 3.0).
Thus, there was no convincing cGMP response to VIP from H295R cells and
VIP also failed to increase phosphoinositide turnover, whereas cAMP appears to be
the major intracellular messenger increased by VIP in these cells. It can be
concluded that VIP regulates steroidogenesis from H295R cells by a cAMP-
dependent mechanism, similar to ACTH. This is consistent with the observation that
the main steroid secreted in response to VIP from this cell-line was Cortisol (see
chapter 4.0). Ehrhart-Bornstein et al (1991a) also detected a greater Cortisol response
than aldosterone response to VIP from perfused, porcine adrenals.
Recently, Mazzocchi et al (1998) demonstrated VIP-stimulated
glucocorticoid secretion and cAMP production from dispersed rat inner zone
adrenocortical cells. Because the effect was anulled by both a VIP-receptor
antagonist ([4-Cl-D-Phe6,Leu17]-VIP) and an ACTH-receptor antagonist
(corticotropin-inhibiting peptide, CIP), they attributed the response to an activation
of ACTH receptors by VIP. This was in accordance with previous work from this
group which indicated that VIP increased basal, but not submaximally ACTH-
stimulated corticosterone secretion from dispersed rat inner zone cells (Mazzocchi et
al, 1994b). The VIP-receptor antagonist ([4-Cl-D-Phe6,Leu17]-VIP) partially
abolished the ACTH-mediated steroid response and CIP completely abolished it
(Mazzocchi et al, 1994b). Li et al (1990) reported that VIP competes for a subtype
of ACTH receptor; those recognising the ACTHn_24 sequence. However, VIP
competitively abolished radiolabeled VIP binding in the rat adrenal cortex and
ACTH was only capable of competing for a subset of these receptors (Cunningham
& Holzwarth, 1989). The effect of VIP on Cortisol secretion from H295R cells is
unlikely to involve ACTH receptor activation because the steroid and cAMP
responses to ACTH from these cells were poor when compared with responses to
forskolin (Rainey et al, 1993). Indeed, maximal stimulation of cAMP production,
P450cl7 activity and Cortisol secretion by forskolin (7-20 pM) was approximately 7,
5 and 4 times greater, respectively, than the maximum responses to ACTH (0.1 pM)
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(Rainey et al, 1993). In the experiments described in this chapter, maximal
stimulation of cAMP and Cortisol by VIP was similar to that produced by forskolin
(10 pM). It has been suggested that the ACTH receptor number on these cells is low,
a theory supported by the finding that, although levels of ACTH receptor mRNA in
this cell-line can be upregulated by cAMP agonists, ACTH was much less potent
than forskolin or dbcAMP at eliciting this effect (Mountjoy et al, 1994).
Alternatively, coupling between the ACTH receptor and the adenylate cyclase-cAMP
pathway may be defective in these cells. Thus, the VIP-induced steroid response
from this human adrenocortical cell-line is unlikely to involve ACTH receptor
activation. A species-specific difference may explain the findings ofMazzocchi et al
(1998). Indeed, Haidan et al (1996) reported that the effects of VIP and ACTH on
steroid secretion from dispersed human adrenocortical cells were additive. In
addition, Bodart et al (1997) indicated a species-specific difference when comparing
the effects of VIP on human adrenocortical carcinoma cells and bovine zg cells.
Although the involvment of ACTH receptors in the VIP-induced steroid response in
vivo cannot be excluded in man, the findings in this chapter indicate that VIP-
induced steroid responses in the human adrenal gland involve a non-ACTH
dependent mechanism.
Controversy surrounding a direct action for VIP on adrenocortical cells arose
because some authors were unable to detect a VIP-stimulated steroid response from
dispersed adrenocortical cells. Most of these studies were performed on dispersed zg
cells (Enyedi et al, 1983; Hinson et al, 1992; Bodart et al, 1997). However,
experiments performed on bovine and rat dispersed inner zone adrenocortical cells
have demonstrated a glucocorticoid response to VIP (Li et al, 1990; Mazzocchi et al,
1994b). Whilst an indirect, catecholamine-mediated action ofVIP is undisputed, the
hypothesis may be advanced that a direct steroid action of VIP is concentrated in the
zfr, whilst the indirect mechanism may be predominant in the zg. This would be in
keeping with the ACTH-like action of VIP in H295R cells in that Cortisol was the
major steroid secreted and that cAMP was the only significant second messenger
response elicited following VIP treatment of the cells.
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Although autoradiographic binding studies for VIP receptors in the rat
showed a predominance of VIP receptors in the zg region of the adrenal gland
(Cunningham & Holzwarth, 1989), a species-specific difference between rats and
humans may exist. A direct steroidogenic action of VIP in the zg is not ruled out but
may be less significant than in the zff. Recently, Hinson et al (1996) demonstrated
an increase in VIP-induced steroid response and VIP binding in the zg following salt
deprivation of rats. Thus the direct action of VIP in the zg is capable of upregulation
in certain circumstances, perhaps providing an extra layer for control of steroid
regulation during changes in electrolyte status. A direct action of VIP on zg cells
could involve growth effects since administration of a VIP receptor antagonist
anulled VIP-induced growth of the zg in rats (with pharmacologically interrupted
HPA axis and RAS) and from zg-like cells of rat adrenocortical autotransplants
(Rebuffat et al, 1994).
In addition, though VIP receptor number may be lower in the zfr, the number
of gap junctions present between zff cells of rodent species has been shown to be
greater than in the zg (Murray & Pharrams, 1997), such that stimulation of a VIP
receptor on one cell may result in activation of a steroid response in several
surrounding cells. Gap junctions provide pathways for direct intercellular movement
of small molecules, including nucleotides (Pitts et al, 1971). In particular, the
involvement of gap junctions was important in increasing steroid responsiveness of
bovine and human zfr cells to low concentrations of ACTH (Munarisilem et al,
1995). Bovine adrenals exhibited a similar distribution of gap junctions in the zg and
the zfr, in contrast with rodent adrenals, though the gap junctions present in each
zone were numerous and large (Murray & Pharrams, 1997). Also, more than one
subtype of VIP receptor exists. The second messenger coupling of receptors in the
zfr may be better than in the zg, thus producing more cAMP for VIP-stimulated
steroidogenesis.
Gallo-Payet & Escher (1985) demonstrated a higher number of ACTH
receptors on rat zg cells than zff cells, yet ACTH produced a higher increment in
steroid output ffom zfr cells than from zg cells (Braley & Williams, 1977). Levels of
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phosphodiesterase are also higher in rat zg cells compared with zfr cells (Gallant et
al, 1974). Thus, a direct action of VIP involving cAMP production could result in a
less pronounced effect of VIP in zg cells, due to more rapid cyclic nucleotide
degradation by phosphodiesterase, despite the presence ofmore receptors. Also, the
presence of spare receptors for ACTH in the adrenal has been suggested (Hornsby &
Gill, 1981). The phenomenon of spare receptors means that not all receptors need to
be activated to obtain a maximal response. Thus, lower numbers of VIP receptors
within the zfr, compared to the zg, do not necessarily equate to a lower potency of
VIP or a lesser steroid response.
In summary, VIP stimulated a concentration-dependent increase in Cortisol
secretion from H295R cells which was accompanied by a concentration-dependent
rise in cAMP acumulation. At this stage one has to conclude that cGMP levels were
unaffected by VIP treatment and similarly a phosphoinositide response to VIP was
absent in H295R cells.
152
6.0 Characterisation of receptor types activated by VIP in
H295R cells
6.1 Introduction
In earlier chapters it was observed that VIP stimulates steroid synthesis from
H295R cells (chapter 4.0) via a mechanism involving increased accumulation of
cAMP (chapter 5.0). The steroidogenic action of VIP could involve activation of a
number of different receptors. Possible mechanisms include: 1) a mechanism
involving (3-adrenoceptors, 2) direct activation of a VIP receptor (currently
comprising the VPAC1 receptor or VPAC2 receptor subtypes), 3) direct activation of
the pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor
(PAC1 receptor). The VIP / PACAP receptor family is introduced in section 6.1.1.
The nomenclature used to refer to these receptors is that suggested by the
International Union ofPharmacology (Harmar et al, 1998).
6.1.1 The VIP /PACAP receptor family
Receptors for VIP belong to a subfamily of the seven transmembrane, G-
protein-linked receptor superfamily (Segre & Goldring, 1993). This subfamily of
receptors is distinct (showing < 12 % sequence identity) from other G-protein-linked
receptors such as rhodopsin. Other receptors in this subfamily include those for the
following peptides: secretin, calcitonin, parathyroid hormone, parathyroid hormone-
related peptide, glucagon, glucagon-like peptide 1, growth hormone-releasing
hormone and PACAP. Due to the high homology between some of these peptides
(Figure 1.7) and also between receptors in the subfamily, many of these peptides are
capable of activating other receptors within the same receptor subfamily. In
particular, VIP and PACAP share a receptor, the VPAC receptor, for which they have
a similar affinity and potency. Two subtypes of the VPAC receptor have been
identified: the VPAC1 receptor and the VPAC2 receptor (sections 6.1.1.1 and
6.1.1.2). Initial indications of these two receptor types came from pharmacological
studies in different tissues and cell-lines (Laburthe et al, 1983; Robberecht et al,
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1988; Luis & Said, 1990) and have since been confirmed by molecular cloning of the
two receptor types and pharmacological characterisation in transfected cell-lines.
Both receptors are bound and activated by PACAP38 and PACAP27 with a similar
potency to VIP (Svoboda et al, 1994; Lutz et al, 1993; Usdin et al, 1994; Ishihara et
al, 1992; Sreedharan et al, 1993) (Table 6.1). However, the VPAC2 receptor differs
pharmacologically from the VPAC1 receptor in that 1) helodermin stimulates cAMP
production with similar potency to VIP (hence, the VPAC2 receptor has been
suggested to be the helodermin-preferring receptor) (Adamou et al, 1995; Lutz et al,
1993; Svoboda et al, 1994), whereas helodermin was less potent than VIP on the
VPAC1 receptor (Ishihara et al, 1992; Gaudin et al, 1996) and 2) secretin is
relatively ineffective at eliciting a cAMP response from the VPAC2 receptor
(Adamou et al, 1995; Lutz et al, 1993; Svoboda et al, 1994; Usdin et al, 1994), but
activates the VPAC1 receptor with approximately 10-100 times less potency than
VIP (Ishihara et al, 1992; Sreedharan et al, 1993; Usdin et al, 1994).
So far, all members of this receptor subfamily have been found to be coupled
to a Gs protein with subsequent activation of adenylate cyclase and increased cAMP
production. Coupling to other G-proteins has also been observed for some members,
for example the PAC1 receptor. Other common features between members of this
subfamily include long amino-terminal extensions with a highly conserved pattern of
cysteine residues and highly conserved sequences for the V, VI and VII membrane-
spanning domains and carboxy-terminal tail (Segre & Goldring, 1993).
6.1.1.1 The VPAC1 receptor
Originally referred to as the VIP receptor, the VIP1 receptor (Lutz et al,
1993), the VIP / PACAP type II receptor (Ciccarelli et al, 1994) or the PVR2
receptor (Rawlings et al, 1995), the VPAC1 receptor (Harmar et al, 1998) was first
isolated and cloned from rat lung by Ishihara et al (1992) using the rat secretin
receptor cDNA as a probe. The rat VPAC1 receptor was found to contain seven
transmembrane segments and to consist of 459 amino acids with a calculated
molecular weight of approximately 52 kDa (Ishihara et al, 1992). The receptor had
48 % sequence identity with the rat secretin receptor and mediated VIP-stimulated
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Relative binding potencies for VIP / PACAP receptors
PAC1a receptor: PACAP38 * PACAP27 »> VIP
PAC1b receptor: PACAP38 > PACAP27 »> VIP
VPAC1 receptor: VIP « PACAP27 > PACAP38
VPAC2 receptor: VIP « PACAP38 * PACAP27
Table 6.1
Relative bindingpotencies of VIP, PACAP38 and PACAP27 on the PAC1 (a and b), VPAC1
and VPAC2 receptors.
Relevent references include: Svoboda et al, 1994; Lutz et al, 1993; Usdin et al, 1994; Ishihara et
al, 1992; Sreedharan et al, 1993; Van Rampelbergh et al, 1996.
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accumulation of intracellular cAMP when expressed in COSGsl cells (Ishihara et al,
1992).
The human VPAC1 receptor was cloned from the HT29 intestinal epithelial
cell-line (Sreedharan et al, 1993) and from jejunal epithelial cells (Couvineau et al,
1994) and comprises a 457 amino acid (Sreedharan et al, 1993) / 460 amino acid
(Couvineau et al, 1994) receptor with an estimated molecular mass of approximately
52 kDa. The sequences for both the rat and human VPAC1 receptor appear to
encode a signal peptide (Couvineau et al, 1994) giving the mature receptor proteins
for both species a predicted molecular weight of approximately 49 kDa (Couvineau
et al, 1994; Ishihara et al, 1992). The human VPAC1 receptor gene contains 13
exons and 12 introns and has been localised to the short arm of human chromosome
3 (3p22) (Sreedharan et al, 1995).
The amino acid sequence for the human VPAC1 receptor shows 84 %
homology with the rat lung VPAC1 receptor (Sreedharan et al, 1993). The human
sequence contains four potential N-linked glycosylation sites (three in the amino
terminus and one in the second extracellular loop) (Couvineau et al, 1994). The
heterogeneity of molecular weights of VIP receptors detected by cross-linking
studies, between tissues and between species (from approximately 51.8 kDa to 68.8
kDa) has been attributed to differences in the size and composition of the
oligosaccharide chains attached (Fabre et al, 1993b). For example, Fabre et al
(1993a) characterised a 68.2 kDa VIP receptor from a human pancreatic cell-line
which contained at least three N-linked oligosaccharide chains and Gaudin et al
(1996) characterised a 67 kDa VPAC1 receptor identified by cross-linking
experiments.
A potential protein kinase A phosphorylation site was predicted in the C-
terminal intracellular tail along with three potential sites for protein kinase C
phosphorylation (two in the N-terminal extracellular segment and one in the second
intracellular loop) (Couvineau et al, 1994).
The amino-terminal domain of the VIP receptor is involved in VIP binding
(Couvineau et al, 1994; Holtmann et al, 1995). In particular, site-directed
mutagenesis studies have indicated that the residues aspartate 68, tryptophan 73 and
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glycine 109 in the N-terminal extracellular domain of the human VIP receptor are
essential for VIP binding (Couvineau et al, 1995) along with six cysteine residues, at
positions 50, 63, 72, 86, 105 and 122, which may form topologically important
disulphide bonds (Gaudin et al, 1995). The significance of these cysteine residues
was confirmed by the finding that the disulphide reducing agent, dithiothreitol,
caused a decrease in specific binding of radiolabeled VIP to vascular VIP receptors
(Huang & Rorstad, 1989). In addition, a disulphide bond between cysteine 215 and
cysteine 285 was found to be important for stabilising the rat VPAC1 receptor in the
correct conformation for ligand binding and receptor activation (Knudsen et al,
1997).
6.1.1.2 The VPAC2 receptor
Originally referred to as the VIP2 receptor (Lutz et al, 1993), the PACAP-3
receptor (Inagaki et al, 1994) or PVR3 (Rawlings et al, 1995), the VPAC2 receptor
(Harmar et al, 1998) was first cloned from the rat olfactory bulb by Lutz et al (1993).
The putative VPAC2 receptor open reading frame was predicted to encode a 437
amino acid protein of molecular mass 49.5 kDa and an amino acid sequence identity
with the rat VPAC1 receptor and PAC1 receptor of 50 % (Lutz et al, 1993).
Potential sites for N-linked glycosylation were observed in the extracellular amino-
terminus at residues 57, 87 and 91 (Lutz et al, 1993; Usdin et al, 1994). As with the
VPAC1 receptor, a highly conserved pattern of cysteine residues was observed in the
amino-terminal tail (Lutz et al, 1993).
The human VPAC2 receptor, originally cloned from SUP-T1 lymphoblasts
(Svoboda et al, 1994) and human placenta (Adamou et al, 1995), is a 438 amino acid
receptor with a predicted molecular weight of 49.5 kDa (including the putative signal
peptide) (Adamou et al, 1995). It contains three potential N-linked glycosylation
sites at residues 58, 88 and 92 and demonstrates an 85-86 % sequence identity with
the rat VPAC2 receptor at the amino acid level (Adamou et al, 1995; Svoboda et al,
1994). The human VPAC2 receptor shows 49 % sequence identity with the human
VPAC1 receptor and 52 % identity with the human PAC1 receptor (Adamou et al,
1995; Svoboda et al, 1994).
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The VPAC2 receptor gene maps to human chromosomal position 7q36.3
(Mackay et al, 1996).
6.1.1.3 Tissue distribution of VIP receptors
A distinct tissue distribution of VPAC1 and VPAC2 receptor expression,
illustrated by in situ hybridisation, is evident (Usdin et al, 1994). VPAC1 receptor
transcripts were detected in a number of tissues, using in situ hybridisation and
Northern blot analysis, including lung, small intestine, liver and placenta, as well as
regions of the brain including the cerebral cortex and hippocampus (Ishihara et al
1992; Usdin et al, 1994; Sreedharan et al, 1993).
Using in situ hybridisation and northern blot analysis, the presence ofVPAC2
receptor mRNA has been detected in areas of the brain and CNS (Lutz et al, 1993;
Usdin et al, 1994), often in regions distinct from those showing expression of
VPAC1 receptor mRNA, for example, the suprachiasmatic nucleus and the
hypothalamus (Usdin et al, 1994). VPAC2 receptor transcripts have also been
detected in peripheral tissues, including the stomach, pituitary and pancreas (Usdin et
al, 1994; Adamou et al, 1995).
Usdin et al (1994) reported the presence ofboth VPAC1 and VPAC2 receptor
transcripts in the rat adrenal gland using in situ hybridisation. VPAC2 receptor
mRNA was found predominantly in the adrenal cortex with VPAC1 receptor gene
expression predominant in the adrenal medulla.
6.1.1.4 PACAP and the PAC1 receptor
In 1989 a group investigating hypophysiotropic factors regulating the anterior
pituitary isolated a 38 amino acid peptide from ovine hypothalamus based on its
ability to stimulate cAMP production from anterior pituitary cells (Miyata. et al,
1989). This peptide was initially named pituitary adenylate cyclase activating
polypeptide (PACAP) (Miyata et al, 1989) and later amended to PACAP38,
following the isolation from ovine hypothalamic extracts of a peptide consisting of
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the N-terminal 27 amino acids of PACAP38, named PACAP27 (Miyata et al, 1990).
The human PACAP gene has also been isolated and cloned (Hosoya et al, 1992).
PACAP38 and PACAP27 have been classified as members of the VIP /
secretin / GHRH family of peptides based on the high sequence homology with these
peptides. Indeed, the 27 N-terminal amino acids of PACAP share 68% homology
with VIP (Miyata et al, 1989).
PACAP has been detected mainly in areas of the central nervous system, such
as the hypothalamus, posterior pituitary and cerebral cortex, but also in peripheral
tissues, including the testis, adrenal and gut (Arimura et al, 1991; Sundler et al, 1992,
Masuo et al, 1993).
Ligand binding studies and receptor autoradiography indicated the presence
of two high affinity binding sites for PACAP (Shivers et al, 1991). One of these
sites had a much greater affinity for PACAP27 than for VIP and was subsequently
named the PACAP type I receptor, later PVR1 (Rawlings et al, 1995) or PAC1
receptor (Harmar et al, 1998). The other binding site showed equal affinity for
PACAP27 and VIP and was named the PACAP type II receptor (Shivers et al, 1991),
subsequently shown to be two receptors which correspond to the VPAC1 and
VPAC2 receptors (Arimura et al, 1992).
The PAC1 receptor was first cloned from a rat pancreatic cancer cell-line
(Pisegna & Wank, 1993) and from a rat brain cDNA library (Hashimoto et al, 1993).
The mature receptor protein was calculated as having 476 amino acids, a predicted
molecular weight of 54.4 kDa and five potential N-linked glycosylation sites
(Hashimoto et al, 1993). So far, a short form of the rat PAC1 receptor has been
identified along with five different splice variants, dependent on whether they
contain either or both of two 84 bp inserts, named hip or hop, of which two hop
forms exist; a 28 amino acid insert called hopl and a 27 amino acid insert, which
lacks a serine residue in the hopl sequence, called hop2 (Spengler et al, 1993). The
splice variants differ in their intracellular signal transduction mechanisms: The short
form and the hopl and hop2 forms are linked to activation of adenylate cyclase and
phospholipase C, the hip form stimulates adenylate cyclase with approximately 10-
fold lower potency and has no effect on phospholipase C, whilst the hiphopl and
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hiphop2 forms possess intermediate characteristics (for review see Journot et al,
1995). More recently, another PAC1 receptor splice variant has been discovered in
the rat (Pantaloni et al, 1996). This variant, the very short (vs) form, is produced
from alternative splicing in the N-terminal extracellular domain and has been shown
to modulate receptor selectivity with respect to PACAP27 and PACAP38 binding
and relative potencies for PLC stimulation (Pantaloni et al, 1996).
The human PAC1 receptor was first isolated from a human pituitary cDNA
library (Ogi et al, 1993). The mature receptor protein was calculated to contain 448
amino acids, to have a predicted molecular weight of 51.4 kDa and to contain six
potential N-glycosylation sites (Ogi et al, 1993). The amino acid sequence showed
92.5 % homology with the rat PAC1 receptor and 55.3 % homology with the human
VPAC receptor (Ogi et al, 1993). Ligand binding studies performed on transfected
cell-lines demonstrated 1000 times higher affinity of the receptor for PACAP than
for VIP (Ogi et al, 1993). VIP was also at least 1000 times less potent than PACAP
in stimulating cAMP production (Miyata et al, 1989; Ogi et al, 1993).
Splice variants of the human PAC1 receptor have also been discovered,
which are closely associated with the four main rat PAC1 receptor splice variants
(Pisegna & Wank, 1996). These four variants, null, SV-1, SV-2 and SV-3, are
formed from alternative splicing between two exons in the third intracellular loop
region, leading to the different insertions of up to two 28 amino acid cassettes, as in
the rat (Spengler et al, 1993; Pisegna & Wank, 1996). Thus, the null, SV-1, SV-2
and SV-3 forms in the human correspond to the short, hip, hop and hiphop forms in
the rat. However, differences exist between the human and rat splice variants in that
all of the human variants bind PACAP27 and PACAP38 with similar affinity and
potency for stimulating adenylate cyclase, unlike the rat variants (Pisegna & Wank,
1996). However, each human splice variant differed in the efficacy (maximal
stimulation) for PLC activation and total inositol phosphate formation, with the order
of efficacy being SV-2 > null > SV-1 > SV-3 (Pisegna & Wank, 1996).
Expression of the PAC1 receptor mRNA, determined by Northern blot
analysis, was abundant in the brain, with little in peripheral tissues (Hashimoto et al,
1993; Ogi et al, 1993) except a relatively weak level of expression in the adrenal
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gland (Hashimoto et al, 1993). A high affinity binding site with the characteristics of
a PAC1 receptor has also been identified on adrenal medullary chromaffin cells by
receptor autoradiography (Shivers et al, 1991).
The aims of this chapter were to determine whether VIP-stimulated Cortisol
and cAMP production from H295R cells required activation of a VIP-specific
receptor or occurred by one of the other mechanisms discussed above.
The rationale for (3-adrenoceptor involvement was based on reports that VIP
induced catecholamine release from chromaffin tissue, with subsequent activation of
P-adrenoceptors on adrenocortical cells, leading to increased steroidogenesis (section
4.1.1). This mechanism was considered unlikely to account for VIP-stimulated
Cortisol release from H295R cells because the cell-line is not known to be
contaminated with chromaffin cells. Nevertheless, it was considered important to
exclude a P-adrenoceptor-mediated mechanism from this transformed cell-line, since
there are no published reports that H295R cell cultures do not contain chromaffin
cells or that they do not contain P-adrenoceptors.
A mechanism involving direct activation of a PAC1 receptor was investigated
because VIP and PACAP share 68% homology in their amino acid sequences
(Miyata et al, 1989) and VIP and PACAP receptors belong to the same receptor
family (see 6.1.1). PACAP is capable of activating VPAC receptors with similar
affinity and potency to VIP itself (Table 6.1). In addition, VIP can activate the PAC1
receptor but with 100-1000-fold less potency than PACAP. If VIP increases Cortisol
production from H295R cells via a PAC1 receptor-mediated mechanism, it would
therefore be predicted that PACAP would stimulate Cortisol secretion and cAMP
accumulation with greater potency than VIP.
Experiments in this chapter were performed using H295R cells which had
been pretreated with forskolin (10 pM, 72 h) in keeping with the conditions used for
the Cortisol and second messenger studies earlier (see chapter 5.0).
The effects of the P-adrenoceptor antagonist, propranolol, on 4 h VIP-
stimulated Cortisol secretion and cAMP production was examined, along with the
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direct effects of the ^-adrenoceptor agonists, adrenaline and isoprenaline, on Cortisol
and cAMP responses. A concentration of 3.3 x 10"8 M VIP was used, unless
otherwise stated, as this concentration resulted in maximal Cortisol secretion and
maximal cAMP production from H295R cells in previous experiments (chapter 5.0).
A comparison was made between the concentration-reponses curves for
Cortisol and cAMP following treatment of cells with either VIP or PACAP38, to
determine whether the PAC1 receptor is involved in these responses from H295R
cells.
The effects of the VPAC1 receptor antagonists, Cl-Phe6, Leu17-VIP and
acetyl-tyr-GRF-amide, on VIP-mediated Cortisol and cAMP responses were also
investigated along with an examination of the direct effects of the VPAC2 receptor
superagonist, RO-25-1553, on Cortisol and cAMP production by H295R cells.
Finally, the gene expression for the VPAC1 receptor, VPAC2 receptor and
PAC1 receptor in H295R cells was studied using RT-PCR.
162
6.2 Results
6.2.1 Effect of propranolol on VIP-stimulated Cortisol and cAMP
production
In order to exclude the possibility that the effects of VIP on Cortisol and
cAMP production by H295R cells were mediated by P-adrenoceptors, cells were
treated with VIP (3.3 x 10~8 M) in the absence or presence of various concentrations
(10~8 M - 10"6 M) of the non-selective P-adrencoceptor antagonist, propranolol.
Propranolol did not alter VIP-stimulated Cortisol or cAMP production at any
concentration used (P>0.05) (Figure 6.1). The effects of propranolol on basal and
forskolin-stimulated Cortisol and cAMP production were also determined to rule out
the possibility of a non-specific or toxic effect of propranolol on Cortisol or cAMP
formation. Propranolol did not affect basal or forskolin-stimulated Cortisol or cAMP
production (P>0.05).
6.2.2 Effect of the d-adrenoceptor agonists, adrenaline and
isoprenaline, on Cortisol and cAMP production by H295R cells
The direct effects of the non-selective and physiological p-adrenoceptor
agonist, adrenaline, on Cortisol and cAMP production by H295R cells was
investigated. Adrenaline failed to stimulate Cortisol secretion or cAMP production
over basal levels at any of the concentrations tested (10~8 M - 1CT6 M) (P>0.05) in
contrast to forskolin (10~5 M) treatment and VIP (3.3 x 10~8 M) treatment (P<0.01)
(Figure 6.2).
Cells were also treated with the synthetic, non-selective, P-adrenoceptor
agonist isoprenaline (10"8 M - 10"5 M), which has a higher potency than adrenaline for
p-adrenoceptor activation. Isoprenaline also failed to increase Cortisol secretion or



















Effect of the non-selective [i-adrenoceptor antagonist, propranolol, on (A) VIP-stimulated
Cortisol secretion and (B) VIP-stimulated cAMP production from H295R cells. Forskolin-
pretreated cells were washed twice and treated with either VIP ('VIP', 3.3 x 10"8 M),
forskolin ('fskn', 10~5 M) or serum-free growth medium alone ('basal') with or without
propranolol ('P', 10~8 M, 10"7 M or 10~6 M) for 4 h. Each treatment was performed in
triplicate within each individual experiment. Medium was assayed for Cortisol and cAMP
content by RIA (Methods, chapter 2.0). Cortisol and cAMP data were corrected with
respect to total cellular protein. Results shown are mean (± s.d.) of triplicate measurements











Effect of adrenaline on (A) Cortisol secretion and (B) cAMP production from H295R cells
compared with basal, VIP-stimulated and forskolin-stimulated Cortisol secretion.
Forskolin-pretreated cells were washed twice and treated with either adrenaline ('Adr',
hatched bars, 10"8 M, 10*7 M or 10"6 M), VIP ('VIP', 3.3 x 10"8 M), forskolin ('fskn', 10"5
M) or serum-free growth medium alone ('basal') for 4 h. Each treatment was performed in
triplicate within each individual experiment. Medium was assayed for Cortisol and cAMP
content by RIA (Methods, chapter 2.0). Cortisol and cAMP data were corrected with
respect to total cellular protein. Results shown are mean (± s.d.) of triplicate measurements











Effect of isoprenaline on (A) Cortisol secretion and (B) cAMPproduction from H295R cells.
Forskolin-pretreated cells were washed twice and treated with either isoprenaline ('Iso',
hatched bars, 10"8 - 10"5 M), VIP ('VIP', 3.3 x 10"8 M), forskolin ('fskn', 10"5 M) or
serum-free growth medium alone ('basal') for 4 h. Each treatment was performed in
triplicate within each individual experiment. Medium was assayed for Cortisol and cAMP
content by RIA. Data were corrected with respect to total cellular protein. Results shown
are mean (+ s.d.) of triplicate measurements from one experiment. Similar results were
obtained from a second experiment.
166
Adrenaline (10"8 M - 10"6 M) also failed to stimulate Cortisol or cAMP
production over basal levels from H295R cells which had not been pretreated with
forskolin (P>0.05) {Figure 6.4).
6.2.3 Effect of PACAP38 on Cortisol and cAMP production from H295R
cells
The Cortisol and cAMP concentration-response curves from H295R cells
following treatment with either PACAP38 (10" M - 10"7 M) or VIP (10"" M - 10"7
M) were compared. PACAP38 and VIP both increased Cortisol secretion and cAMP
production in a concentration-dependent manner (see Figures 6.5 and 6.6 for Cortisol
and cAMP concentration-response curves respectively).
The Cortisol concentration-response curves were similar {Figure 6.5). The
threshold concentrations for Cortisol secretion were 10 " M for both PACAP38 and
VIP, maximal secretion occurring at a concentration of 3.3 x 10"9 M for PACAP38
and 3.3 x 10"8 M for VIP. The pEC50 values (negative logarithm to the base 10 of the
concentration (Molar) producing a half-maximal response) for PACAP38 and VIP
were 9.8 ± 0.06 and 9.4 ± 0.43 respectively (n=3 for both) {Table 6.2).
The cAMP concentration-response curves for PACAP38 and VIP were also
similar {Figure 6.6). Maximal cAMP production occurred at a concentration of
10"8 M for PACAP38 and 3.3 x 10"8 M for VIP. Threshold stimulation for cAMP
production occurred at 10"" M for both PACAP38 and VIP and the pEC50 value for
VIP-induced cAMP production was 8.7 ± 0.46 M (n=3 individual experiments),
compared with a pEC50 value of 9.3 ± 0.05 M (n=3 individual experiments) for
PACAP38-stimulated cAMP production {Table 6.2).
6.2.4 Effect of VPAC1 receptor antagonists on VIP-stimulated Cortisol
and cAMP production
Figure 6.7 shows the effect of the VPAC1 receptor antagonist, Cl-Phe6,
Leu17-VIP (CPLV) (0.05 pM - 5 pM) on VIP-stimulated Cortisol and cAMP
production. Cells were treated with the antagonist for 30 mins prior to the addition
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Fisnre 6.4
Effect ofadrenaline on Cortisol secretion from non-forskolin-pretreated H295R cells (cells
not pretreated with forskolin (10~$ M) for 72 h). The protocol was the same as for
forskolin-pretreated cells except that no forskolin was added to the pretreatment medium.
After 72 h cells were washed twice and treated with either adrenaline ('Adr', hatched bars,
10~8 M, 10-7 m or i0'6 VIP ('VIP', 3.3 x 10"8 M) or serum-free growth medium alone
('basal') for 4 h. Each treatment was performed in triplicate. Medium was assayed for
Cortisol content by RIA. Cortisol data were corrected with respect to total cellular protein.
Results shown are mean (± s.d.) of triplicate measurements from one experiment.
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• log [VIP] (M)
□ log [PACAP] (M)
Figure 6.5
Comparison of concentration-dependent increases in Cortisol secretion from H295R cells
following 4 h treatment with VIP, PACAP38 or forskolin. Forskolm-pretreated cells were
washed thoroughly, then treated with VIP (10*11 - 10*7 •), PACAP38 (10*11 - 10*7 M,
□) or forskolin (10*5 M, bar labelled fskn) for 4 h. Treatments were performed in triplicate
within each experiment. Cortisol content of medium was assayed by RIA and corrected
with respect to total cellular protein. Combined data from n=3 experiments is expressed as
mean (±s.d.) Response Ratios (response to stimulus / basal secretion).
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35 n
• log [VIP] (M)
□ log [PACAP] (M)
Figure 6.6
Comparison of concentration-dependent increases in cAMP production from H295R cells
following 4 h treatment with VIP, PACAP38 or forskolin. Forskolin-pretreated cells were
washed thoroughly, then treated with VIP (10~H - 10~7 M, •), PACAP38 (10~H - 10~7 M,
□) or forskolin (10~5 M, bar labelled fskn) for 4 h. Treatments were performed in triplicate
within each experiment. cAMP content of acidified medium was assayed by RIA and
corrected with respect to total cellular protein. Combined data from n=3 experiments is
expressed as mean (±s.d.) Response Ratios (response to stimulus / basal secretion).
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pEC50 (+/- s.d.) for VIP-induced Cortisol and cAMP production
CORTISOL response cAMP response
Experiment 1 9.533 (0.10) 9.193 (0.1)
Experiment 2 8.921 (0.12) 8.294 (0.33)
Experiment 3 9.640 (0.19) 8.591 (0.21)
MEAN
pEC50 (+/- s.d.)
9.365 (0.43) 8.693 (0.46)
pEC50 (+/- s.d.) for PACAP-induced Cortisol and cAMP production
CORTISOL response cAMP response
Experiment 1 9.863 (0.09) 9.337 (0.03)
Experiment 2 9.786 (0.07) 9.266 (0.08)
Experiment 3 9.746 (0.02) 9.361 (0.03)
MEAN
pEC50 (+/- s.d.)
9.798 (0.06) 9.321 (0.05)
Table 6.2
Comparison of pEC50 values for Cortisol secretion and cAMP accumulation following
treatment of H295R cells with either VIP or PACAP38. Forskolin-pretreated cells were
washed and treated with VIP (10"11 M - 10"7 M) or PACAP38 (10*11 M - 10"7 M) for 4 h.
Medium was collected and assayed for Cortisol and cAMP content as described previously
(see Methods, section 2.2). Concentration-response curves were plotted and the pEC50
(negative logarithm to the base 10 of the concentration (Molar) producing a half-maximal
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Effects of VPAC1 receptor antagonist, Cl-Phe6, Leu^-VIP (CPLV) on VIP-stimulated
production of (A) Cortisol and (B) cAMP. Cells were pre-incubated with CPLV (0.05 - 5
pM) for 30 mins in serum-free growth medium prior to the addition of VIP (1 nM) for a
further 4 h. Cells were also treated with VIP alone (1 nM), forskolin (10 pM, 'fskn'), CPLV
(5 pM) alone and fskn plus CPLV (5 pM) together. Data presented are mean (± s.d.) of
triplicate measurements from one experiment. A statistically significant response compared
with VIP-stimulated response is indicated by **P<0.02. Similar data was obtained in a
second experiment except that 5 pM CPLV did not significantly decrease VIP-stimulated
Cortisol secretion (P>0.05).
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of VIP to allow the antagonist to bind to the receptors before VIP. A sub-maximal
concentration of VIP (1 nM) was used to compete with the antagonist for VPAC1
receptors. CPLV at concentrations of 0.05 pM or 0.5 pM failed to attenuate the
Cortisol and cAMP responses to VIP (P>0.05). A small decrease (34 %) in the
Cortisol response to VIP was seen in the presence of 5 pM CPLV (P<0.02), but this
effect was only observed in 1/2 experiments. A similar experiment was performed
using a different VPAC1 receptor antagonist, acetyl-tyr-GRF-amide (A-T-GRF-A)
(0.05 pM - 5 pM). This antagonist failed to decrease Cortisol or cAMP responses to
VIP (1 nM) at any concentration tested (P>0.05) {Figure 6.8). Neither CPLV (5 pM)
nor A-T-GRF-A (5 pM) altered basal levels of Cortisol secretion or cAMP production
or 10 pM forskolin-stimulated levels of Cortisol secretion or cAMP production.
6.2.5 Effects of VPAC2 superaoonist, RO 25-1553, on Cortisol and
cAMP production by H295R cells
Figure 6.9 shows the effects of the VPAC2 receptor superagonist, RO-25-
1553, on Cortisol secretion and cAMP production by H295R cells. RO-25-1553
(10~9 M, 10~8 M) failed to stimulate either Cortisol or cAMP production over basal
levels (P>0.05). However, 10"7 M RO-25-1553 increased Cortisol secretion and
cAMP accumulation in two out of three experiments (P< 0.01 in each experiment for
both Cortisol and cAMP).
6.2.6 Analysis of VPAC1 receptor, VPAC2 receptor and PACI receptor
gene expression in H295R cells by RT-PCR
Figure 6.10 shows the products of RT-PCR analysis, visualised on an
ethidium bromide-stained 0.8 % agarose gel, of total RNA extracted from H295R
cells. The cells were treated with or without forskolin (10 pM) for 72 h prior to
extraction of the RNA.
A band of the expected molecular weight for the VPAC1 receptor (440 bp)
was not obtained from the VPAC1 receptor positive control material (cDNA obtained
































































Effects of VPAC1 receptor antagonist, Acetyl-Tyr-GRF-amide (A-T-GRF-A) on VIP-
stimulated production of (A) Cortisol and (B) cAMP. Forskolin-pretreated cells were
washed twice then incubated with A-T-GRF-A (0.05 - 5 p.M) for 30 mins in serum-free
growth medium prior to the addition ofVIP (1 nM) for a further 4 h. Cells were also treated
with VIP alone (1 nM), forskolin (10 pM, 'fskn'), A-T-GRF-A (5 pM) alone and fskn plus

















































Effects ofVPAC2 receptor superagonist, RO-25-1553, on production of (A) Cortisol and (B)
cAMP by H295R cells. Forskolin-pretreated cells were washed twice and then treated with
RO-25-1553 (10-9, 10'8 or 10-7 m; «r')> yip (3.3 x 10-8 M) or forskolin (10-5 M, 'fskn')
in serum-free growth medium for 4 h. Cortisol and cAMP contents of medium were
assayed by RIAs and corrected with respect to total cellular protein. Combined data from
n=3 experiments, triplicate incubations performed in each, are expressed as mean (±s.d.)
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Figure 6.10
RT-PCR detection of (a) VPAC], (b) VPAC2 and (c) PAC] mRNA in H295R cells.
Lane 1 corresponds to PCR of positive control material ((a) human lung cDNA
library, (b) human placental cDNA library and (c) human brain cDNA library), lane
2 corresponds to RT-PCR of control H295R cells, lane 3 corresponds to RT-PCR of
cells treated with forskolin (lOpM) for 72 h, lane 4 corresponds to PCR of negative




although bands of the expected weight were obtained following RT-PCR of total
RNA from H295R cells treated without and with forskolin (see lanes 2 and 3,
respectively, ofFigure 6.10(a)).
PCR of cDNA from a human placenta cDNA library (VPAC2 receptor
positive control material) yielded a product of the expected size for the VPAC2
receptor (1563 bp) (lane 1 of Figure 6.10(b)). No equivalent bands were observed
from RT-PCR ofH295R total RNA (lanes 2 and 3 ofFigure 6.10(b)).
PCR of PAC1 positive control material (cDNA from human brain cDNA
library) gave rise to two bands of 335bp and 440bp as expected (lane 1 of Figure
6.10(c)). Corresponding, but relatively very faint, bands were observed from RT-
PCR of total RNA from untreated (control) H295R cells and forskolin-treated H295R
cells (lanes 2 and 3, respectively, ofFigure 6.10(c)).
The negative control (no DNA) lanes were all blank as expected (lane 4 of
Figure 6.10(a), (b) and (c)).
177
6.3 Discussion
Several studies have suggested that VIP exerts an indirect action on the
adrenal cortex via catecholamine release from medullary chromaffin cells and
subsequent activation of P-adrenoceptors on adrenocortical cells, leading to an
increase in steroid secretion (section 4.1.1). Therefore, it was considered important
to determine whether the effects of VIP on Cortisol and cAMP observed in H295R
cells required activation of P-adrenoceptors, either directly by VIP or as a result of
VIP-stimulated catecholamine release from the transformed adrenocortical cells or
from cells of chromaffin lineage. The non-selective P-adrenoceptor antagonist,
propranolol, did not alter the Cortisol or cAMP reponses to VIP, consistent with these
VIP-mediated effects not requiring the activation of P-adrenoceptors. Indeed, both
the physiological catecholamine, adrenaline, and the non-selective P-adrenoceptor
agonist, isoprenaline, failed to stimulate either cAMP production or Cortisol secretion
from H295R cells. Since Bomstein et al (1996) have reported an apparent P-
adrenoceptor-mediated effect on steroid secretion from cultured normal human
adrenocortical cells, this suggests a loss of functional P-adrenoceptors from this cell-
line. To rule out the possibility that the lack of response to adrenaline was due to
cAMP-mediated P-adrenoceptor downregulation during the 72 h pretreatment phase
with forskolin, non-pretreated cells were also treated with adrenaline and VIP. VIP
caused a increase in Cortisol secretion which was diminished but still significant
(P<0.01) compared with forskolin-pretreated cells (consistent with previous findings
in non-pretreated cells). No Cortisol response to adrenaline was observed. This
supports the suggestion that the H295R cell-line lacks functional P-adrenoceptors.
Comparison of Cortisol and cAMP responses following VIP treatment and
PACAP treatment demonstrated similar potencies of the two peptides for both
responses. This observation is consistent with VIP effects being mediated by
activation of a VIP-specific receptor (VPAC receptor) rather than a PAC1 receptor.
Further studies using VPAC1 receptor antagonists and a VPAC2 receptor
superagonist failed to clearly establish which VIP receptor subtype(s) was implicated
in the steroid and cAMP responses from H295R cells. At the time the experiments
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were performed a VPAC2 receptor antagonist was not available. The VPAC2
receptor superagonist, RO 25-1553, did not alter Cortisol secretion or cAMP
accumulation over basal from H295R cells at concentrations of 10"9 M or 10"8 M. RO
25-1553 has been shown to be 3-fold more potent than VIP on the human VPAC2
receptor, 600-fold less potent than VIP on the human VPAC1 receptor and 10-fold
less potent than VIP on the PAC1 receptor (Gourlet et al, 1997c). Whilst a
concentration of 10~7 M RO 25-1553 did increase Cortisol and cAMP levels over
basal in two out of three experiments performed, this effect was much smaller than
that seen in response to VIP and was probably related to the partial agonist action of
RO 25-1553 on human VPAC1 receptors at high concentrations (Gourlet et al,
1997c). These results suggest that VIP-induced steroid and cAMP responses were
not mediated through activation of VPAC2 receptors. The presence of VPAC2
receptors on this cell-line cannot be excluded though data using RO 25-1553 and
from RT-PCR experiments would argue that expression of this receptor subtype in
H295R cells, if any, must be low.
The VPAC1 receptor antagonists used failed to inhibit steroid secretion or
cAMP accumulation from H295R cells. At the time these experiments were
performed, little data was available on the affinity and potency of these antagonists
for human VPAC receptors. However, both of these antagonists exhibited a low
affinity for VIP receptor binding in rat mesenteric artery, anterior pituitary, brain
synaptosomes, liver and bovine coronary artery tissues (Rorstad et al, 1990) and
micromolar concentrations of CPLV were required to antagonise VIP-stimulated
amylase release from guinea pig pancreatic preparations (Pandol et al, 1986). Since
the experiments in this chapter were performed, a highly selective and potent human
and rat VPAC1 receptor antagonist, PG 97-269, has been developed with an IC50
value in the nM range (Gourlet et al, 1997a). Use of this antagonist would help
determine the presence of VPAC1 receptors on the H295R cell-line. In addition, a
high affinity selective human VPAC1 receptor agonist, [K15,R16,L27]VIP(l-7)
/GRF(8-27) has now been described (Gourlet et al, 1997b).
A species-specific difference in VIP receptor subtypes expressed in the
adrenal may exist. Usdin et al (1994) demonstrated a predominance of VPAC1
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receptor mRNA in the rat adrenal medulla with a higher proportion of VPAC2
receptor mRNA in the rat adrenal cortex. However, Adamou et al (1995) noted that
the VPAC2 receptor transcript was highly expressed in human skeletal muscle, in
contrast to rat skeletal muscle where VPAC2 receptor mRNA was not detected
(Usdin et al, 1994).
In an attempt to extend the studies using VPAC1 receptor and VPAC2
receptor antagonists and to further clarify which receptor(s) are present on the H295R
cell-line, RT-PCR experiments were performed to detect the presence of VPAC1
receptor, VPAC2 receptor and PAC1 receptor mRNA transcripts. The suggestion
that the steroid and cAMP responses were mediated mainly through a VPAC receptor
rather than a PAC1 receptor was supported by the RT-PCR data obtained. PAC1
receptor mRNA was barely detectable in H295R cells, indicating a very low level of
expression of this receptor in these cells, if any. The presence of two bands in the
positive control material corresponds to splice variants of the PAC1 receptor,
probably the null form and the SV-1 or SV-2 form.
RT-PCR data indicated that H295R cells expressed transcripts for the VPAC1
receptor but little, if any, VPAC2 receptor mRNA. Unfortunately, the RT-PCR data
obtained in this study was not conclusive. Sequencing of the bands from the PCR
reaction would confirm the identity of the PCR product as VPAC1 receptor mRNA.
However, the presence of VPAC 1 receptors on this cell-line is supported by
studies involving RT-PCR of H295R cell mRNA using degenerate primers for the
VIP / PACAP / PTH receptor family, followed by sequencing of a selection of the
cloned products, which demonstrated a predominance of the VPAC1 receptor
transcript. The VPAC2 receptor transcript was not detected in any of the 9 clones
tested and the PAC1 receptor transcript was detected in 1/9 Clones (Dr. Eve Lutz,
personal communication).
The results from this chapter lend support for a direct action of VIP on
Cortisol secretion from H295R cells by a direct receptor-mediated action, probably a
VPAC receptor rather than a PAC1 receptor and separate from any p-adrenoceptor-
mediated effect. In the light of the discovery that VIP and PACAP share some
receptors, it was necessary to determine whether the actions attributed to VIP so far
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were mediated by VPAC receptors or PAC1 receptors since the presence of PAC1
receptors in a tissue may indicate that PACAP is the more biologically important of
the two peptides for some functions. For example, radioligand binding studies and
autoradiography have indicated that the predominant VIP / PACAP-binding site in
the rat adrenal medulla is a PAC1 receptor (Shivers et al, 1991; Moller & Sundler,
1996), found on chromaffin cells. PAC1 receptor mRNA has also been detected in
the adrenal gland (Hashimoto et al, 1993), in medullary chromaffin cells but not in
the adrenal cortex (Moller & Sundler, 1996). Furthermore, PACAP has been shown
to stimulate catecholamine release from the adrenal medulla of rats (Watanabe et al,
1992), dogs (Gaspo et al, 1997), cultured bovine chromaffin cells (Babinski et al,
1996) and the PC 12 rat chromaffin cell-line (Taupenot et al, 1998) and these effects
appeared to be mediated by a PAC1 receptor. Whilst VPAC receptor mRNA has
been detected in the adrenal medulla of rats (Usdin et al, 1994), the proportion of
VPAC receptors was much lower than PAC1 receptors (Shivers et al, 1991).
Interestingly, PACAP-immunoreactive nerve fibres have been reported in the
medulla but no PACAP immunoreactivity was reported in chromaffin cells or
ganglion cells. In contrast, VIP-immunoreactivity was observed in chromaffin and
ganglionic tissues in rat adrenals whereas VIP-immunopositive nerve fibres were
concentrated in the cortex (Moller & Sundler, 1996). Thus, it is possible that
PACAP is more biologically important in the adrenal medulla than VIP, in terms of
stimulating catecholamine secretion. Hinson et al (1992) obtained catecholamine and
steroid responses from rat zg-capsule preparations using a high concentration (10
pM) of VIP. Although the high concentration of VIP required to stimulate
steroidogenesis may be attributed to the scarcity of chromaffin tissue in the
preparation, it could also be due to an action ofVIP on a PAC1 receptor rather than a
VPAC receptor. Edwards & Jones (1993a) noted that, whilst VIP infusion into
functionally hypophysectomised calves resulted in a Cortisol response equivalent to
that elicited by ACh, VIP was not similarly potent in stimulating catecholamine
secretion. Thus, it may be that an indirect action ofVIP on steroid secretion requires
activation of PAC1 receptors on chromaffin cells and that a direct action depends
upon activation of VPAC receptors on adrenocortical cells. The presence of both
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PACAP and VIP in the adrenal medulla may allow for several levels of control of
steroidogenic regulation. Thus, VIP could be involved in the tonic control of steroid
secretion whilst PACAP, with its greater potency on catecholamine release, may
regulate catecholamine and steroid secretion under increased levels of stress. It
should also be noted that some isoforms of the PACAP receptor are linked to
phosphoinositide turnover, unlike existing VIP-specific receptors. Spengler et al
(1993) observed that the hop isoform of the PAC1 receptor, which predominates in
the rat adrenal gland, stimulates both adenylate cyclase activation and
phosphoinositide turnover. Thus, if specific receptors for both peptides are present in
the adrenal cortex, the types of intracellular signalling systems activated may result
in different patterns of steroid regulation between VIP and PACAP.
It may even be proposed that, in some species, VIP has a relatively minor
function in the adrenal medulla compared with PACAP. Indeed, the PAC1 receptor
has also been implicated in the regulation of chromaffin cell proliferation (Frodin et
al, 1995). One speculation is that activation of PAC1 receptors on chromaffin cells
and ganglion cells could result in the release of VIP as well as catecholamines. The
action of VIP in the adrenal would then become a predominantly cortical one.
However, variations between species cannot be ruled out. Bodart et al (1997)
recently indicated PAC1 receptor-mediated aldosterone secretion from cultured
bovine zg cells. The types of VIP / PACAP receptors present in the human adrenal
have yet to be defined. This study found that VPAC receptors, probably VPAC1
receptors, are predominant on adrenocortical cells of human origin.
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7.0 Steroid responses of H295R cells to a range of putative
paracrine and neuroendocrine agonists
7.1 Introduction
Other agonists, aside from VIP, have been suggested to have potential
paracrine and neuroendocrine actions on steroidogenesis. Many of these have
established indirect effects on adrenal steroid secretion. The discovery of these
substances within the adrenal, either within nerves or chromaffin cells, in parallel
with the demonstration of both neural and chromaffin tissue in the adrenal cortex,
provides indirect evidence for an action for these substances on steroidogenesis. The
investigation of direct effects of these substances on human adrenocortical cells has
been hampered by the lack of easily available human adrenal glands for in vitro
studies, whilst data obtained in vivo is often hard to dissect in terms of direct and
indirect actions.
In this chapter, the steroid responses of the H295R human adrenocortical
tumour cell-line was used to screen a number of putative paracrine and
neuroendocrine agonists for steroidogenic activity. The agonists examined were
atrial natriuretic peptide / hormone (ANP), adenosine 5'-trisphosphate (ATP), 5-
hydroxytryptamine (5-HT / serotonin), arginine vasopressin (VP), acetylcholine
(ACh) and noradrenaline (NA). These factors are introduced below with existing
evidence for paracrine or neuroendocrine effects on the adrenal cortex.
7.1.1 Atrial natriuretic peptide / hormone (ANP)
ANP was first isolated from atrial myocytes by de Bold in 1982 and has been
shown to exert various actions, including vasodilation and natriuresis in the kidney
and inhibition of the renin-angiotensin-aldosterone system (for review see Cantin &
Genest, 1985). Many of these effects antagonise the actions ofAIL
More recently, ANP has been detected in a number of extra-atrial tissues such
as the brain, lung and the adrenal gland. Lee et al (1994) detected ANP-
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immunoreactivity and ANP mRNA in the adrenal medulla of humans. In rats and
guinea-pigs, ANP was localised further to the medullary chromaffin cells (McKenzie
et al, 1985; Wolfensberger et al, 1995).
ANP has been well documented as having a direct inhibitory effect on basal
and All-, potassium- and ACTH- stimulated aldosterone secretion from mammalian
zg cells (reviewed by Ganguly, 1992). These effects have been detected in vivo and
in vitro and can be attributed to both a humoural action and a paracrine action of
ANP on adrenocortical cells.
The action of ANP on zfr cells is more controversial. In most studies, ANP
did not inhibit steroid secretion from inner zone cells (Atarashi et al, 1985; Campbell
et al, 1985; Kudo & Baird, 1984). However, specific receptors have been detected in
bovine zfr cells (Higuchi et al, 1986b) and rat zfr cells (Mulay et al, 1995) and ANP
depressed basal glucocorticoid secretion from cultured inner-zone cells from humans
(Higuchi et al, 1986a; Naruse et al, 1987; Carr & Mason, 1988) and cattle (DeLean
et al, 1984). It has been postulated that ANP may also act indirectly on steroid
synthesis by inhibiting the medullary release of catecholamines in cattle (Fernandez
et al, 1992; Babinski et al, 1995) and rats (Vatta et al, 1994) via specific receptors
found on medullary cells.
7.1.2 Adenosine 5'-trisphosphate (ATP)
ATP is stored in high concentrations in medullary chromaffin cell secretory
granules (Sillero et al, 1994) and is co-released with catecholamines upon
stimulation. A paracrine action of ATP on adrenocortical steroidogenesis from
bovine inner-zone cells has been demonstrated (Hoey et al, 1994) and attributed to a
direct activation of the nucleotide receptor / P2y purinoceptor (Hoey et al, 1994 /
Kawamura et al, 1991) and an increased turnover of membrane phosphoinositides
with a resultant increase in intracellular Ca2+ concentration (Hoey et al, 1994). ATP
treatment was also associated with a small but significant cAMP response (Hoey et
al, 1994).
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In addition, supramaximal electric field stimulation resulted in release of ATP
from rat adrenal capsule-glomerulosa preparations and ATP has been shown to
stimulate steroid secretion in vitro (Juranyi et al, 1997). ATP-containing
noradrenergic nerve endings have been demonstrated in close proximity to rat zg
cells and have been shown to be capable of the co-release of ATP with NA and
dopamine (Szalay et al, 1998).
7.1.3 5-hvdroxvtryptamine / serotonin (5-HT)
5-HT is known to stimulate adrenocortical steroidogenesis indirectly through
an effect on the HPA axis. Specifically, 5-HT causes the release of CRH from the
hypothalamus (Fuller et al, 1992, for review) and ACTH from the anterior pituitary
(Davies et al, 1992).
In addition, there is evidence that 5-HT also exerts a direct action on the
adrenal cortex. Plasma levels of 5-HT are very low, as a result of an active platelet
uptake and storage mechanism (Zinner et al, 1983), so that a direct action on the
adrenal cortex would require local release.
5-HT has been detected immunocytochemically in the adrenal medulla of rats
(Holzwarth et al, 1984; Holzwarth & Brownfield, 1985), mice (Fernandez-Vivero et
al, 1993) and pigs (Kong et al, 1989), though evidence to date has failed to
demonstrate that human chromaffin cells contain 5-HT (Lefebvre et al, 1992).
Instead, 5-HT appears to be restricted to intra-adrenal mast-like cells (Lefebvre et al,
1992, 1996). In addition, serotonergic medullary tissue / nerve fibres have been
detected within the adrenal cortex ofmice (Fernandez-Vivero et al, 1993).
5-HT has been shown to stimulate steroid secretion from both zg and zfr cells
in humans, requiring the activation of 5HT4 receptors (Lefebvre et al, 1992, 1993,
1996). In humans, this effect is associated with an increase in Ca2+ influx (Contesse
et al, 1996) and stimulation of adenylate cyclase (Lefebvre et al, 1992).
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7.1.4 Arainine-vasopressin (VP)
VP has been shown to modulate adrenal function by an action on the HPA
axis. VP is synthesised in the hypothalamus, found co-localised with corticotropin-
releasing hormone (CRH) in parvocellular neurons of the paraventricular nucleus,
and is stored and released from the anterior pituitary. In addition to its function as a
modulator of cardiovascular homeostasis, involving antidiuretic actions in the
kidney, VP stimulates the release of ACTH from the anterior pituitary (Antoni,
1986).
In addition to these indirect, humoural actions of VP on steroid secretion, a
direct effect on adrenocortical cells has been reported. VP stimulated hypertrophy
and hyperplasia of the zg in hypophysectomised rats (Payet et al, 1979) and cell
growth in primary cultures of zg cells (Payet et al, 1984; Hinson et al, 1987)
(reviewed by Gallo-Payet & Guillon, 1998). These growth effects appeared to
involve a VP-specific receptor because growth of rat zg was suppressed following
prolonged infusion with a V,-receptor antagonist (Mazzochi et al, 1993b).
VP also stimulates catecholamine release from chromaffin cells via a Vlb-
receptor mediated mechanism (Gallo-Payet & Guillon, 1998), raising the possibilty
of an indirect stimulation of steroidogenesis.
VP has been shown to increase aldosterone secretion from dispersed rat zg
cells in primary culture (Payet & Lehoux, 1982; Hinson et al, 1987), by activation of
a Vla-receptor (Gallo-Payet et al, 1986, 1991) and subsequent breakdown of
membrane phosphoinositides (Gallo-Payet et al, 1986; Enyedi et al, 1988). In
humans, VP similarly increased aldosterone secretion but also stimulated Cortisol
production by a direct receptor-mediated action (Guillon et al, 1995; Perraudin et al,
1993). VP also stimulated Cortisol secretion, by activation of phospholipase C and
an increase in intracellular Ca2+ in bovine zfr cells (Bird et al, 1990a; Walker et al,
1991). VP did not appear to directly stimulate glucocorticoid secretion in rats
(Gallo-Payet et al, 1986), a species-specific effect that has been theoretically
attributed to the lack of an active phosphoinositide second messenger system in rat
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zff cells. Specific VP receptors of the Vla subtype have been located on both zg and
zfr cells in human and zfr cells in cattle (Guillon et al, 1995).
It has been postulated that the direct action of VP on the adrenal cortex is a
paracrine action of the peptide, following synthesis and release from the adrenal
medulla. VP immunoreactivity has been detected in the adrenal medulla of humans,
cattle and rats (Ang & Jenkins, 1984; Nussey et al, 1987) and further localised to the
medullary chromaffin cells (Ravid et al, 1986; Hawthorn et al, 1987). Perraudin et
al (1993) detected the presence of VP-containing cells in the medulla which were
also scattered throughout the cortex. In addition, Guillon et al (1995) reported VP
release from human chromaffin cells.
7.1.5 Acetylcholine (ACh)
ACh released from sympathetic nerve endings within the adrenal medulla
stimulates the release of catecholamines from chromaffin cells by activation of a
nicotinic ACh receptor. Acetylcholinergic nerve fibres have also been detected
within the adrenal cortex of several species (section 1.6.4.1a)). In 1952, Okinaka et
al showed that stimulation of the splanchnic nerve caused an increase in
corticosteroid secretion from the stimulated adrenal, but not from the contralateral
adrenal, suggesting that the steroidogenic effect of nerve stimulation was
independent of humourally bome agonists. Perfusion of isolated calf adrenals with
ACh resulted in increased 17-hydroxylated steroid secretion (Rosenfield, 1955).
This evidence would support a paracrine action ofACh on the adrenal cortex.
Indeed, ACh has been shown to stimulate the secretion of Cortisol and
aldosterone from isolated bovine adrenocortical cells (Kojima et al, 1986; Walker et
al, 1990) and perfused rat adrenals (Porter et al, 1988). In bovine zff cells, this was
attributed to a direct activation of the M3-muscarinic receptor (Walker et al, 1990;
Clyne et al, 1994) followed by an increase in membrane phosphoinositide breakdown
(Clyne et al, 1992) and mobilisation of intracellular Ca2+ (Clyne et al, 1995).
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7.1.6 Noradrenaline (NA)
The majority of catecholaminergic nerves detected within the adrenal cortex
are noradrenergic (Vizi et al, 1992, 1993), located mainly in the subcapsular-zg
region. Some of these neurons have endings in close contact with zg cells (Vizi et al,
1992). Supramaximal electric field stimulation in superfused rat adrenal capsule-
glomerulosa preparations resulted in the release of noradrenaline (Juranyi et al,
1997). The non-synaptic nature of the nerve terminals (Szalay et al, 1998) favours a
paracrine modulation of zg cell function involving diffusion of noradrenaline from
the nerve ending to the zg cell and subsequent activation of P-adrenoceptors.
Chromaffin cells within the medulla and also the cortex (section 1.6.4.2) also provide
a potential source of noradrenaline which may regulate steroidogenesis in a paracrine
manner. The major source of the catecholamine adrenaline (Adr) appears to be the
medulla. Some chromaffin cells contain both NA and Adr, whilst some are
exclusively adrenergic or noradrenergic.
Although noradrenaline influences steroidogenesis by regulating blood flow
through the adrenal cortex (Vinson et al, 1987), evidence exists for a direct action of
noradrenaline on steroid secretion. In vitro studies in cattle and rats demonstrated
stimulation of glucocorticoids, aldosterone and androstenedione secretion via pr
adrenergic receptor activation (Lightly et al, 1990; Pratt et al, 1985).
The 4 h and 24 h steroid responses of the H295R cell-line to each of these
agonists were examined. In addition, the 4 h responses of the cells to these agonists
following pretreatment of the cells with All or forskolin were investigated. This was
based on findings (in chapter 3.0) which demonstrated an increased steroidogenic
capacity of the cells and also an alteration in the steroid phenotype of the cells
following pretreatment with All or forskolin. Thus, the effects of each of these
agonists on relatively zg-like cells and zfr-like cells could be studied.
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7.2 Results
7.2.1 Cortisol response to 4 h treatment with ANP, ATP, 5-HT, VP, ACh
and NA in H295R cells
Figure 7.1 shows the Cortisol responses to short term (4 h) treatment with
ANP, ATP, VP, 5HT, ACh and NA. Cells were treated with forskolin as a positive
control.
4 h ANP (10~7 M) treatment caused a 40 (±4.5) % decrease in Cortisol
secretion, relative to basal levels (n=3 individual experiments, P<0.05 in 3/3
experiments, calculated from triplicate incubations within each experiment, ofwhich
PO.Ol in 2 of these).
4 h treatment with ATP (10"4 M), 5-HT (10"6 M), VP (10"8 M), ACh (10"4 M)
or NA (10~6 M) did not affect Cortisol levels with respect to basal secretion (P>0.05 in
n=4 experiments, except for VP where n=3 experiments. P-values were calculated
from triplicate incubations within each experiment).
7.2.2 Effect of pretreatment of cells with All or forskolin on subsequent
4 h steroid responses to ANP, ATP, 5-HT, VP, ACh and NA in H295R
cells
Figure 7.2 shows the effects of the different pretreatment conditions on
steroid responses to subsequent 4 h treatment with ANP, ATP, 5-HT, VP, ACh and
NA. Cells were treated with forskolin as a positive control.
In "control" cells (that is, no pretreatment with All or forskolin), 4 h
treatment with ANP (1CT7 M) resulted in a significant decrease in Cortisol secretion
(45 (±4) %, n=3 individual experiments, P<0.02 in 3/3 experiments, calculated from
triplicate incubations within each experiment) and corticosterone secretion (63 (±9)
%, n=3 individual experiments, P<0.01 in 3/3 experiments, calculated from triplicate



















Cortisol secretion in response to short-term (4 h ) treatment with various putative paracrine
and neuroendocrine agonists. Cells were treated with medium alone (basal, dotted line) or
medium containing the agonist to be tested (see Key below) for 4 h. After this time,
medium was removed and assayed for Cortisol content by RIAs. The results from n=4
separate experiments (n=3 for ANP and VP) have been combined and are presented as mean
Response Ratios (response to stimulus / basal secretion) (±s.d.). Statistically significant
changes in secretion compared with basal secretion within individual experiments are noted
by **P<0.02 and *P<0.05, in 4/4 experiments for fskn; in 3/3 experiments for ANP.
Key. fskn=forskolin, 10~5 M; ANP=atrial natriuretic peptide, 10~7 M; ATP=adenosine
triphosphate, 10'^M; 5HT=5-hydroxytryptamine/serotonin, 10~6 M; VP=vasopressin, 10"^
M; ACh=acetylcholine, 10"^M; NA=noradrenaline, 10"^M;
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production (a decrease of 15 (±12) %, n=3 individual experiments, P<0.02 in 2/3
experiments, calculated from triplicate incubations within each experiment), from
"control" cells.
4 h treatment with ATP (10"6 M), 5-HT (10"6 M), VP (10"8 M) or ACh (10"4 M)
had no effect on secretion of Cortisol, corticosterone or androstenedione from
"control" cells (P>0.05 for 3/3 individual experiments, calculated from triplicate
incubations within each experiment).
Following 96 h pretreatment of H295R cells with All (10 nM), the steroid
responses to the substances tested were similar to those obtained from "control" cells.
ANP (10"7 M) suppressed secretion of all 3 steroids (decreases of 47 (±17) %, 64 (±8)
% and 34 (±7) % for Cortisol, corticosterone and androstenedione respectively (n=3
experiments for all three steroids. Within each experiment, P<0.01 for Cortisol and
corticosterone data and P<0.02 for androstenedione data, calculated from triplicate
incubations). ATP (IT6 M), 5-HT (10"6 M), VP (10 8 M) or ACh (10"4 M) had no
effect on secretion of Cortisol, corticosterone or androstenedione from "AII-
pretreated" cells (P>0.05 for 3/3 experiments, calculated from triplicate incubations
performed in each experiment).
Following forskolin pretreatment, none of the agonists tested (apart from the
positive control, forskolin (10 s M), altered steroid secretion with respect to basal. In
particular, forskolin pretreatment abolished the ANP-induced suppression of steroid
secretion seen in "control" and "All-pretreated" cells (P>0.05 with respect to basal
secretion of each steroid in 3/3 separate experiments, triplicate incubations performed
in each) (see Figure 7.2).
7.2.3 Steroid responses to 24 h treatment with ANP, ATP, 5-HT, VP,
ACh and NA in H295R cells
Only ANP (and the positive control agonist, forskolin) caused changes in
steroid secretion after short-term (4 h) treatment. The H295R cells were treated with
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ANP, ATP, 5-HT, VP, ACh and NA for 24 h to see if longer exposure to these
agonists would elicit a Cortisol response.
Figure 7.3 shows the Cortisol, corticosterone and androstenedione responses
to 24 h treatment with ANP, ATP, 5-HT, VP, ACh and NA. Cells were also treated
with forskolin as a positive control.
24 h treatment with ANP (10"7 M) significantly suppressed secretion of all 3
steroids, with respect to basal secretion, with decreases of 19% for Cortisol, 27% for
corticosterone and 35% for androstenedione (P<0.01 for Cortisol and androstenedione
data and P<0.05 for corticosterone data, calculated from triplicate incubations in a
single experiment).
24 h treatment with either ATP (10"4 M), 5-HT (10"6 M), VP (10"s M), ACh
(10"4 M) or NA (106 M) had no significant effect on Cortisol, corticosterone or
androstenedione secretion (P>0.05, calculated from triplicate incubations performed








fskn ANP ATP 5HT VP ACh
Key. fskn = forskolin, 10-5 M (positive control); ANP = atrial natriuretic peptide, 10"^ M;
ATP = adenosine triphosphate, 10~4 M; 5HT = 5-hydroxytryptamine / serotonin, 10~6 M;
VP = vasopressin, 10~8 M; ACh = acetylcholine, 10~4 M; NA = noradrenaline, 10~6 M.
Figure 7.3
Secretion of a) Cortisol, b) corticosterone and c) androstenedione in response to 24 h
treatment with various putative steroidogenic agonists. Cells were treated with medium
alone (basal, dotted line) or medium containing an agonist (see Key) for 24 h. After this
time, medium was removed and assayed for steroid content by RIAs. Results have been
combined and are presented as mean (±range, i.e. max-min) Response Ratios (response to
stimulus / basal secretion) from n=2 individual experiments for Cortisol and corticosterone,
except ANP (where n=l experiment), triplicate incubations performed in each experiment.
Androstenedione data was obtained from n=l experiment, triplicate incubations performed,
for all agonists. Statistically significant changes in secretion compared with basal secretion
within each individual experiment performed are noted by *P<0.05 and ***P<0.01.
195
7.3 Discussion
The steroidogenic actions of various putative paracrine and neuroendocrine
agonists (ANP, ATP, 5-HT, VP, ACh and NA) were investigated in the H295R
human adrenocortical tumour cell-line. Only ANP had any significant and
reproducible effect on steroidogenesis in H295R cells. The steroid responses of the
cells to forskolin (10"5 M) were similar to those presented in chapter 3.0.
Short-term (4 h) treatment with ANP resulted in decreases in basal Cortisol
and corticosterone secretions (45 (±4) % and 63 (±9) % respectively, n=3
experiments for both steroids). Androstenedione secretion was decreased to a lesser
degree (15 (±12) %, n=3 experiments). This inhibitory effect of ANP agrees with
findings following ANP infusion into healthy human volunteers, which resulted in an
inhibition of steroid production from all three zones of the cortex, including
aldosterone, Cortisol and DHEA (Nawata et al, 1991).
Of the three steroids measured in H295R cells, corticosterone was inhibited to
the greatest extent by ANP. ANP is a well-documented inhibitor of aldosterone
synthesis (section 7.1.1 and Ganguly (1992) for review) and the decrease in
corticosterone secretion implies that ANP inhibits the mineralocorticoid pathway at
an earlier stage than corticosterone production in these cells. This would be
consistent with evidence that ANP exerts its action at a very early stage of steroid
synthesis involving cholesterol translocation into mitochondria and conversion to
pregnenolone (Goodfriend et al, 1984). It would be interesting to examine the effects
of ANP on StAR expression in H295R cells. ANP also significantly suppressed
P450scc mRNA in ACTH-stimulated cultured bovine adrenal cells (Nawata et al,
1991). In another study, ANP was shown to inhibit both early and late steps in the
steroid biosynthesis pathway (Campbell et al, 1985).
Androstenedione secretion was unaffected by short-term (4 h) treatment with
ANP. This finding is unexpected if, as has been postulated, androstenedione
secretion is extremely cAMP dependent in this cell-line (chapter 3.0). ANP caused
decreases in cAMP and steroidogenesis in Y1-cells stimulated with ACTH (Heisler
196
et al, 1989) and in dispersed adrenal capsular tissue (Matsuoka et al, 1984, 1985). If
ANP was acting by inhibition of adenylate cyclase, an inhibition of androstenedione
secretion would be predicted.
A previous study on H295R cells showed that ANP failed to inhibit forskolin-
stimulated aldosterone secretion (Bodart et al, 1996). In the present study, forskolin
pretreatment of cells abolished the ANP-induced inhibition of basal steroid secretion.
One possible explanation would be a reduction in the number of ANP receptors
expressed following forskolin pretreatment of the H295R cells. Of relevence is the
observation that the density of cell-surface ANP binding sites is lower on zfr cells
compared with zg cells, as demonstrated by autoradiography (Nunez et al, 1990),
since pretreatment of H295R cells with forskolin results in a zff-like steroid
phenotype (chapter 3.0). In addition, the direct effects of ANP on zfr cells have been
controversial (section 7.1.1).
It has been postulated that ANP can lower cAMP levels in several ways. In
addition to receptor-activated G-protein inhibition of adenylate cyclase (Anand-
Srivastava et al, 1984, 1985, 1987), ANP caused increases in intracellular cGMP and
activated a cGMP-dependent PDE, which subsequently lowered cAMP levels in
primary bovine zg cells (MacFarland et al, 1991). Thus, basal levels of cAMP may
be reduced. Bodart et al (1996) reported ANP-stimulated increases in cGMP in
H295R cells. However, if basal cAMP levels were increased following forskolin
pretreatment of H295R cells, it is conceivable that the subsequent suppression by
ANP may not be sufficient to attenuate basal steroidogenesis in these pretreated cells.
Indeed, ANP only reduced the sensitivity of zg cells to ACTH rather than completely
blocking ACTH-induced steroidogenesis (Ganguly, 1992). This needs to be
investigated further.
Although ATP has been shown to directly stimulate Cortisol secretion from
bovine and rat adrenocortical cells in vitro (Hoey et al, 1994; Juranyi et al, 1997),
this nucleotide failed to elicit a steroid response from the H295R cell-line. The true
situation in vivo in humans is therefore unclear.
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5-HT also failed to stimulate steroid secretion from H295R cells. This
contrasts with studies performed on human adrenals where 10"7 M 5-HT directly
stimulated both Cortisol and aldosterone secretion (Lefebvre et al, 1992, 1993), an
effect mediated via 5HT4 receptor activation and an increase in cAMP formation
(Lefebvre et al, 1992). Since the cAMP second messenger system is intact in this
cell-line, the inference is that the 5HT4 receptor is absent in H295R cells. Lefebvre et
al (1992) observed a partial desensitisation following prolonged exposure (up to 3 h)
to 5-HT on perifused human adrenocortical slices, which was postulated to be due to
a down-regulation of the 5HT4 receptor. Since the H295R cell medium, collected
following 4 h exposure to 5-HT, contains the accumulated Cortisol secreted during
that 4 h period, any stimulation of steroid secretion during that treatment period
should be detected as an increase in total Cortisol content of the medium. Thus,
although the H295R cells were exposed to 5-HT for 4 h, it is unlikely that the lack of
response is due to desensitisation of the receptor in these cells.
Administration of the 5HT4 receptor-specific agonist, zacopride, to human
adrenocortical slices indicated that 5-HT is at least 100 times more potent at
stimulating aldosterone secretion than Cortisol secretion, a finding that was consistent
with in vivo human studies where zacopride infusion resulted in an increase in
plasma aldosterone but not Cortisol (Lefebvre et al, 1993). Thus, a reason for the
apparent lack of steroidogenic action of 5-HT on H295R cells may be due to the
problems experienced in detecting aldosterone in these cells.
Contrary to previous studies performed on primary cultures of human
adrenocortical cells (Perraudin et al, 1993; Guillon et al, 1995), VP failed to
stimulate steroid secretion from H295R cells. Pretreatment of the cells to alter the
steroidogenic phenotype failed to influence the lack of steroid response to VP.
Grazzini et al (1996) recently showed that pretreatment of adrenocortical cells with
the cAMP agonist, ACTH, negatively modulated VP binding and second messenger
activation. Guillon et al (1988) also demonstrated that 2 h exposure to ACTH
decreased inositol phosphate accumulation and VP-receptor binding. Thus,
pretreatment of H295R cells with forskolin, whilst increasing the sensitivity of the
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cells to some steroidogenic agonists, might decrease or inhibit the responsiveness of
these cells to VP.
ACh and NA both failed to stimulate steroidogenesis from the H295R cell-
line, in contrast to in vitro studies performed in other species. A species-specific
difference may account for this observation. Alternatively, the effects observed in
other species could be indirect, involving release of secretagogues, such as
catecholamines, from interspersed chromaffin cells in the primary culture. Indeed,
the effects of ACh on steroidogenesis have been attributed partly to an indirect
mechanism involving increased blood flow to the adrenal (and thus increased rate of
delivery of other stimulatory agonists to the cortex) and partly to release of
catecholamines from the medulla, which subsequently stimulate steroid secretion via
p-adrenoceptors. Studies with this human adrenocortical cell-line were unable to
clarify whether ACh might have a direct action in humans in vivo, but would argue
against this.
In conclusion, the Cortisol, corticosterone and androstenedione responses to a
range of potential steroidogenic agonists (selected on the basis of studies showing an
effect in other systems), were investigated in the H295R cell-line. For most of the
agonists tested in this study, no evidence for a direct action on adrenocortical cells of
human origin was obtained when using the H295R cell-line as a model. This could
be attributed to a species-specific difference. Several of the agonists tested have
previously been shown to affect adrenocortical steroid production in man and yet
failed to do so in this human adrenocortical cell-line. The differences in data obtained
compared with previous human data may indicate indirect actions of these agonists
on steroid secretion, rather than a direct effect on adrenocortical cells. Another
possibility is that receptors for some agonists may have become mutated or down-
regulated in these cells. However, whilst the transformed nature of the cell-line
cannot be ignored, the ability of the cells to produce end-pathway adrenal steroids
and the maintenance of a steroid response to the major physiological regulators of
steroid synthesis (All, K+, ANP) and to activators (or analogues) of the cAMP, PI
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and calcium second messenger pathways (Bird et al, 1993, 1995b; Gazdar et al,
1990; Rainey et al, 1993) is in keeping with properties of normal adrenocortical cells
and indicates that the cell-line is of use in investigating the function of putative
steroidogenic agonists. Of particular interest is the ability to alter the steroid
phenotype of the H295R cells towards a potentially zg-like or zff-like phenotype by
pre-incubation with All or forskolin, respectively.
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8.0 Concluding remarks
The aims of this thesis were to 1) further characterise the time-dependent
effects of All and forskolin on steroid production by H295R cells, 2) examine the
possibility of altering the steroid phenotype of the H295R cell-line, 3) investigate the
direct effects of VIP on steroid production from H295R cells and 4) characterise the
second messenger systems and receptor types involved in VIP-stimulated Cortisol
production (section 1.9). Extensive evidence already existed for an indirect effect but
a direct action of VIP on adrenocortical cells was still controversial. In addition,
little data had been reported relating to the effects of VIP on steroidogenesis in
humans.
In vitro studies, whilst not necessarily reflecting the whole physiological
situation in vivo, are often a useful tool for obtaining an insight into possible in vivo
mechanisms. The difficulty obtaining fresh human adrenal tissue, either normal or
abnormal, has particularly hampered investigations. On this basis, the H295R cell-
line was selected as a useful model for these studies because it was of human origin
and had previously been shown to respond to several physiological regulators of
steroidogenesis, such as All, ACTH and K+ (Rainey et al, 1994). In addition, it was
the first human adrenocortical cell-line characterised as expressing the full
complement of adrenal steroidogenic enzymes with the capability of secreting the
major adrenocortical steroids (Gazdar et al, 1990).
The time-dependent effects of All and forskolin treatment on Cortisol,
corticosterone and androstenedione secretion were studied. The profile of steroids
secreted differed for the two agonists and was dependent on the exposure time to
each agonist (chapter 3.0). Studies performed in this thesis also demonstrated that
the steroid phenotype of the cell-line could be altered by pretreatment with All or
forskolin, resulting in relatively zg-like and zff-like phenotypes, respectively (chapter
3.0). These findings make the H295R cell-line a potentially useful model for
investigating actions in zg-like and zfr-like cells, particularly since primary cultures
of adrenocortical cells quickly revert to a de-differentiated state (Homsby & Crivello,
1983) and often lose steroidogenic capacity altogether (Walker et al, 1988; Williams
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et al, 1989). The fact that the cell-line can be subcultured also obviates the necessity
for a continuous source of new tissue and overcomes problems related to the
variability in results between primary cultures of different tissue origin. The cell-line
would also be potentially useful in investigating factors involved in zonation of the
adrenal cortex.
Against this background, the H295R cell-line was used to investigate a
possible direct action of VIP in human adrenocortical cells. The chronic and short-
term effects ofVIP on the production of steroids from the three major pathways were
examined. Chronic VIP treatment stimulated production of Cortisol and
corticosterone, but not androstenedione, in a time-dependent manner. VIP was more
potent in stimulating Cortisol secretion than corticosterone production, both acutely
and chronically, as evidenced by the increase in the ratio of Cortisol / corticosterone
secretion with time (chapter 4.0). The chronic effects of VIP could involve an
upregulation of steroidogenic enzymes, in particular P450cl7. This would account
for the greater effect ofVIP on Cortisol secretion rather than corticosterone secretion.
Pretreatment of H295R cells with VIP increased Cortisol response to a
subsequent 4 h treatment with VIP, further suggesting an effect of chronic VIP
treatment on steroidogenic enzyme expression and / or VIP receptor expression
(chapter 4.0). Studies into the effect ofVIP pretreatment on the subsequent 4 h VIP-
induced Cortisol / corticosterone and Cortisol / androstenedione secretion ratios may
provide clues as to which steroid pathway chronic VIP treatment preferentially
stimulates. Further experiments to investigate the effect of chronic VIP treatment on
the expression of key steroidogenic enzymes, for example, P450cl7 and 3p-HSD,
would be of interest.
The effects of short-term VIP treatment on steroid production from cells with
a zg-like phenotype and a zfr-like phenotype were also examined (that is, following
pretreatment of the cells with either All or forskolin, respectively, for 96 h). An
interesting observation was that VIP stimulated androstenedione secretion from zff-
like cells (that is, forskolin-pretreated cells) in addition to increasing production of
Cortisol and corticosterone.
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Thus, it is interesting to speculate whether VIP is the putative CASH (section
1.4.3). Recent evidence has strengthened the argument for the existence of an
androgen-stimulating hormone in the regulation of adrenal androgen production,
rather than intra-adrenal factors such as exposure of the inner cortex to high
concentrations of Cortisol (Fearon et al, 1998). One proposed candidate for CASH is
a pituitary-derived factor of, so far, uncertain identity (Brubaker et al, 1982; Hung et
al, 1988; Parker, 1991, review). Immunoreactive VIP is released from perfused rat
pituitaries and cultured rat pituitary cells (Calvo et al, 1990; Carretero et al, 1995)
and VIP gene expression has been detected in the pituitary (Arnaout et al, 1986;
Chew et al, 1992). However, VIP levels in peripheral blood are relatively low
(approximately 50 pg / ml (Said & Porter, 1979 Cugini et al, 1991), whereas
concentrations of VIP in hypophyseal portal blood are 19 times higher (Said &
Porter, 1979)) and VIP is predominantly a neuroendocrine transmitter. Therefore, a
direct stimulation of adrenal androgen secretion by VIP would probably be a
neuroendocrine or paracrine event. The presence of numerous VIPergic nerves in the
zr region of the adrenal cortex as well as within medullary chromaffin cells would
allow for a paracrine / neuroendocrine action of VIP on zr adrenocortical cells
(sections 1.6.4.1c and 1.6.4.2b)). Androstenedione secretion in response to VIP has
also been reported from perfused porcine adrenal and cultured human adrenal cells
(Bornstein et al, 1993, 1996). Stimulation of androgen secretion was found to be
highly cAMP-dependent in this cell-line (chapter 3.0) and VIP was subsequently
shown to increase cAMP production in these cells (chapter 5.0). However, whilst
VIP appears to regulate adrenal androgen secretion, the question as to whether VIP is
a major putative CASH requires further investigation.
To investigate in detail the second messenger systems activated by VIP in
H295R cells, the measurements focussed upon Cortisol production. A concentration-
dependent increase in cAMP accumulation was observed which paralleled the
increase in Cortisol secretion. Changes in cGMP accumulation and PI turnover were
not detected (chapter 5.0). Thus, it appears that VIP stimulates steroid production in
a more ACTH-like manner than All-like manner. Whether this means that VIP could
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modulate adrenocortical responses to All and ACTH in vivo in different ways is
unclear.
VIPergic innervation to the zg appears to be predominantly extrinsic in origin
and may be associated with splanchnic innervation, whilst the VIPergic innervation
of the zfr appears to arise from an intra-adrenal source, with VIP-containing ganglion
cells within the medulla (Hokfelt et al, 1981; Holzwarth et al, 1987; Oomori et al,
1994; Hinson & Kapas, 1996). These two different sources of VIP innervation may
allow a differential regulation of the different zones of the cortex by VIP. To
speculate, it is possible that VIPergic innervation of the zg may be predominantly
involved in the regulation of adrenal blood flow since VIP has been shown to
increase perfusion flow rate through the adrenal (Hinson et al, 1994a) and many
VIPergic nerves have been found in close apposition to blood vessels in the capsular-
zg region (Oomori et al, 1994). In addition, the sub-capsular VIPergic neural plexus
may innervate the numerous chomaffin cells detected within the zg region.
Studies reported here also show that VIP and PACAP stimulate Cortisol
secretion with similar potency from H295R cells, consistent with activation of a
VPAC receptor rather than a PAC1 receptor (chapter 6.0). RT-PCR analysis of
H295R cell mRNA and pharmacological studies with VPAC1 receptor antagonists
and a VPAC2 receptor superagonist provided evidence for an effect mediated by a
VPAC1 receptor (chapter 6.0).
The importance of these findings in relation to the situation in vivo need to be
assessed. The problems with extrapolating data from in vitro studies are difficult
enough since cells in monolayer do not exhibit the same architecture as in intact
adrenal and lack the continuous washout and replenishment of substances by the
blood supply, for example, ACTH. Nevertheless, in vitro studies do provide
important information which can be coupled to existing in vivo data. Although the
H295R cell-line exhibits a transformed phenotype and the cells differ from normal
adrenocortical cells in some respects, many of the cell properties are similar to
normal, non-transformed adrenocortical cells (section 1.8).
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On the basis that the findings obtained within this thesis reflect the in vivo
situation, a physiological rationale for a direct action of VIP on adrenocortical
steroidogenesis must be sought. The acute release of steroids from the adrenal cortex
is a component of the stress response, whether that stress be of a haemodynamic
nature, altered electrolyte status or in response to cold, hypoxia, inflammation or
injury, for example. This response requires activation of several systems including
the sympatho-adrenal system, the immune system and the HPA axis. VIP has been
implicated in the regulation of all these systems.
In particular, VIP may regulate the HPA axis at all levels. Thus, it stimulates
the release of CRH from the hypothalamus and potentiates the effect of CRH on
ACTH release from the pituitary (Alexander et al, 1994). VIP rnRNA has been
detected in the anterior pituitary (Lam, 1991) and VIP may stimulate ACTH directly
from anterior pituitary corticotrophs, though this effect may be more significant in
pathological conditions, such as ACTH-secreting pituitary adenomas (Watanobe &
Takamura, 1994; Oliva et al, 1982).
In the adrenal, VIP directly regulates blood flow. Hinson et al (1994a)
demonstrated an increase in perfusion flow rate in perfused rat adrenals and infusion
ofVIP into functionally hypophysectomised calves also resulted in increased adrenal
blood flow (Bloom et al, 1987). An increase in blood flow indirectly stimulates
steroidogenesis (Vinson et al, 1987). Another possibility is that VIP might be
implicated in the stress-related release of stored steroids within the adrenal as a result
of vascular damming (section 1.6.3). CRH has been suggested to be involved in
release of adrenal venous congestion (Bassett & West, 1997; section 1.6.3).
However, VIP could also be a candidate. A source of VIP exists in the cortico-
medullary boundary (Hokfelt et al, 1981; section 1.6.4.1c) where a vascular dam is
thought to exist and VIP is a potent vasodilator (Said & Mutt, 1970; Lee et al, 1984;
section 1.7). Levels ofVIP increase within the venous outflow following stimulation
of the splanchnic nerve (Bloom et al, 1988; section 4.1.1) and glucocorticoid
secretion is increased in the presence of VIP if the gland architecture is intact
(Hinson et al, 1992; Holzwarth et al, 1987; Bernet et al, 1994a; section 4.1.1). The
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release of dammed steroids by VIP in certain stress conditions may also explain the
apparent VIP-mediated increase in adrenocortical sensitivity to ACTH often
observed in in vivo situations (Bloom et al, 1987, Edwards & Jones, 1993b), though
an actual increase in ACTH sensitivity of adrenocortical cells is not excluded.
Other actions of VIP in the adrenal could include a growth effect on
adrenocortical cells. Whilst a growth action on zff cells has not been shown, VIP
does appear to regulate the growth and secretory capacity of rat zg (Rebuffat et al,
1994).
The indirect effect of VIP on adrenocortical steroidogenesis, involving
catecholamine release from chromaffin cells, is now well documented though it is
unclear whether this effect is more prominant in one zone than another.
With VIP involved in so many different levels of regulation of adrenocortical
steroidogenesis, a key question is whether or not a direct action of VIP exists at the
level of the adrenocortical cell. The recent discovery of VIP receptors in the rat zg
supports such a possibility (Cunningham & Holzwarth, 1989; Hinson et al, 1996;
Hinson & Kapas, 1997). Moreover, these receptors appear to be upregulated by low
sodium status (Hinson et al, 1996) suggesting a more prominant direct action of VIP
in response to stress than a tonic regulation of steroidogenesis. This concept would
also be consistent with a VIP-mediated increase in sensitivity to ACTH, released
during stress. One possibility is that VIP may maintain a level of sensitivity to
ACTH under normal conditions which could be increased during stress by
upregulation of VIP receptors on adrenocortical cells. Thus VIP could increase
sensitivity to steroidogenic agonists, such as ACTH, and also stimulate further
steroid secretion directly.
A function for VIP in the tonic maintenance of adrenocortical sensitivity is
supported by the finding that infusion of a VIP antagonist caused a decrease in
plasma aldosterone concentration in rats (Rebuffat et al, 1994). Maintenance or
increase in adrenocortical sensitivity to ACTH (or other agonists) could involve
putative effects of VIP on steroid enzyme levels, as hinted by the observation that
VIP pretreatment of H295R cells increased the subsequent steroid responses to VIP
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and forskolin (chapter 4.0). This speculation could be investigated by studying the
effects of VIP on adrenocortical steroidogenic enzyme expression, for example, by
Northern analysis of enzyme transcripts from adrenocortical cells. Another
possibility in vivo is that the direct effects of VIP on adrenocortical steroidogenesis
are only apparent in situations where the HPA axis is disrupted, for example, in cases
ofprimary steroid-secreting adrenocortical tumours.
Whilst it is tempting to speculate on a physiological direct action of VIP on
adrenocortical cells, the transformed nature of the H295R cell-line cannot be ignored.
Thus, it is likely that the potency with which VIP stimulates steroid production from
H295R cells is not reflected in vivo, or may only be reflected in pathophysiological
conditions. A large number of tumours secrete VIP, for example, some
phaeochromocytomas (Hassoun et al, 1984; Viale et al, 1985; Said, 1976) as well as
some tumours of the pancreas, thyroid and lung (Said, 1976). Over-production of
VIP in the adrenal medulla could contribute to conditions such as Cushing's
syndrome or hyperaldosteronism associated with secreting phaeochromocytomas. In
addition, some tumours exhibit increased VIP receptor expression (Reubi et al,
1995). An increase in VIP receptor expression in adrenal tumours could result in
excessive steroid secretion, such as that observed in adrenal adenomas.
Further studies on human adrenal tissue are obviously required to determine
the level ofVIP receptor expression in normal human adrenal cortex. Whether or not
these receptors are then upregulated by exposure human to different forms of 'stress'
is of considerable interest. Measurement of the relative levels of VIP receptor
expression in adrenal tumour tissue might also be informative.
Whilst this thesis was in preparation, Haidan et al (1998) published a report
on the expression of VIP receptors in H295R cells. The findings in this thesis
correlate well with the findings of this group; they found dose-dependent increases in
aldosterone, Cortisol and DHEA in the concentration range 10"9 M - 10~6 M, using
non-pretreated cells. They determined the presence of both VPAC1 and VPAC2
receptor mRNAs by RT-PCR. In this thesis, only the VPAC1 receptor transcript was
detected. However, differences in cell culture procedures could account for this. In
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addition, these authors were able to measure aldosterone secretion from these cells,
in contrast to the studies in this thesis.
Finally, the steroidogenic effects of a range of putative paracrine /
neuroendocrine agonists were examined using the H295R cell-line to determine the
existence of a direct action on adrenocortical cells (chapter 7.0). ANP caused a
significant decrease in production of Cortisol, corticosterone and androstenedione,
which was abolished following forskolin pretreatment of H295R cells (that is, cells
with a relatively zfr-like phenotype). Thus, the H295R cell-line could be a good
model for investigating the mechanism of ANP action on zg-like and zfr-like cells.
For example, it would be interesting to examine the relative number of ANP
receptors on zg-like and zfr-like H295R cells.
The work in this thesis provides information on the F1295R cell-line as a
model for investigating the direct action of putative agonists on steroidogenesis
factors involved in the zonation of the adrenal cortex. Also, evidence has been
provided for a direct action of VIP on adrenocortical function. This could be
important in increasing our understanding of mechanisms regulating adrenocortical
steroidogenesis in vivo and perhaps aid the development of potential therapeutic
agents in adrenal diseases associated with an increased response to VIP.
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FORSKOLIN TREATMENT DIRECTS STEROID PRODUCTION TOWARDS
THE ANDROGEN PATHWAY IN THE NCI-H295R
ADRENOCORTICAL TUMOUR CELL LINE
V.J. Cobb, B.C. Williams*, J.I. Mason and S.W. Walker
Department ofClinical Biochemistry, University ofEdinburgh, UK.
*Department ofMedicine, Western General Hospital, Edinburgh, UK
ABSTRACT
The human adrenocortical tumour cell line, NCI-H295, secretes steroids on the
mineralocordcoid, glucocorticoid and adrenal androgen pathways. We have
investigated the effects of 96 h treatment of cells in monolayer culture with either
forskolin (10 pM) (a direct activator of adenylate cyclase), angiotensin II (10 nM)
or no agonist ('control') on the steroidogenic phenotype of this cell line.
Androstenedione, Cortisol and corticosterone secreted into the medium in response
to a subsequent 4 hour treatment with angiotensin II (lOnM) indicated that the
steroidogenic phenotype of NCI-H295 cells changes away from 17-deoxysteroid
biosynthesis towards adrenal androgen production in response to forskolin. The
NCI-H295R cell line therefore serves as a useful model for investigation of the
differential regulation of the steroidogenic pathways in the human adrenal cortex.
INTRODUCTION
The human adrenocortical tumour cell line, NCI-H295, produces more than 30
different steroids characteristic of mineralocorticoid, glucocorticoid and adrenal
androgen pathways (1, 2). The original cell line was established as a suspension to
overcome problems with fibroblast overgrowth (1). Since then, a subpopulation of
cells, designated H295R cells, has been selected that retains attachment during
culture (3). These cells respond to classical adrenocortical agonists such as
545
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angiotensin II (AH), which increases aldosterone secretion (4), and forskolin,
dibutyryl-cyclic AMP and, to a lesser extent, ACTH, all of which stimulate
Cortisol, dehydroepiandrosterone (DHEA), DHEA sulphate and androstenedione in
a dose- and time- dependent fashion (4). Consistent with these observations,
mRNAs encoding P450scc, 3(3HSD, P450cl7; P450c21, P450cl8 and P450cll
(side-chain cleavage enzyme, 3P-hydroxysteroid dehydrogenase, 17-hydroxylase,
21-hydroxylase, 18-hydroxylase and 11-hydroxylase, respectively) have been
detected in H295R cells (2,3,4,5,6) and shown to be regulated in a hormonally-
sensitive manner (2,3,4,7).
To investigate this further we examined the possibility of shifting H295R cells
towards a zona glomerulosa-like phenotype by chronic treatment with AH, the
principal regulator of the mineralocorticoid pathway, or towards a more zona
fasciculata/reticularis-like phenotype by chronic treatment with forskolin, an
activator of protein kinase A.
MATERIALS AND METHODS
NCI-H295R cells (ATCC, Rockville, MD, USA) were seeded into 12-well
plates (5 x 105 cells per well), maintained in DMEM/F12, 2% Ultroser HY (Gibco,
Renfrew, UK), insulin (5 pg/'ml), transferrin (5 ug/ml), sodium selenite (5 ng/ml)
(as 1% ITS, Sigma, Poole, UK) and antibiotics at 37°C with 5% CC>2-95% air.
Cells were preincubated with the above growth medium containing either AQ (10
nM), forskolin (10 pM) or no agonist ('control') for 96 h, replacing medium every
24 h. After 96 h, cells were thoroughly washed with Earle's Balanced Salt solution
(EBS), then treated for a further 4 h with or without All (10 nM) at 37°C.
Androstenedione, Cortisol and corticosterone in the media were measured, using
direct radioimmunoassays, and corrected for protein.
Results.are expressed as mean Stimulation Ratios (SRs i.e. response to
stimulus/basal response) ± s.d. for n=4 experiments. Statisical tests were
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performed using an unpaired, two-tailed, Student's t-test with statistical
significance taken at P<0.05.
RESULTS AND DISCUSSION
96 h treatment with All caused no change in 4 h basal androstenedione
production but significantly increased basal Cortisol (P<0.05 for 4 experiments) and
corticosterone (P<0.05 for 3/4 experiments). In contrast, 96 h forskolin
preincubation significantly decreased 4 h basal production of all three steroids
(P<0.05 in 3/4 experiments) for reasons which remain unclear.
4 h treatment of NCI-H295R cells with All (10 nM) following 96 h
preincubation with All (10 nM) resulted in an SR of 0.9(±0.10) for
androstenedione, 1.3.(±0.21) for Cortisol and 1.7(±0.44) for corticosterone. This
compared with SRs of 1.7(±0.64), 1.5(±0.22) and 1.6(±0.54) for androstenedione,
Cortisol and corticosterone respectively after 96 h preincubation with forskolin (10
pM) (see Figure 1). If the SRs for corticosterone and androstenedione are
expressed as a ratio of increased corticosterone secretion to androstenedione
secretion and these ratios are taken as an indication of shift in steroid production
away from adrenal androgens and towards 17-deoxysteroid secretion or vice versa,
then following AH preincubation the ratio is 1.6 (±0.07) whereas following
forskolin preincubation the ratio is 1.1 (±0.24) (n=4). Statistical comparison of
these ratios is significant with P<0.02 (see table 1).
The cells therefore produce more androstenedione in relation to corticosterone
following forskolin preincubation as compared to AH preincubation. It follows that
chronic forskolin treatment alters steroid production towards the adrenal androgen
pathway and away from 17-deoxysteroid production, favouring a more zona
fascicuiata/reticularis phenotype. Chronic AH treatment markedly increases the
expression of 3[3HSD, P450scc and P450cl8 mRNAs (2, 4). In contrast, forskolin
greatly increases the expression and activity of P450cl7 (3). Thus, the ratio of
3pHSD/P450cl7 mRNA increases following AH treatment (favouring the
548 COBB ET AL.
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96hr preincubation agonist
FIGURE 1
Cells were preincubated for 96 h with growth medium containing either no agonist
('control'), All (10 nM) or forskolin (10 pM). Cells were subsequently treated for
4 h with or without All (10 nM). These graphs show 4 h basal (□) and 4 h AH
stimulated (■) secretions of androstenedione (a), Cortisol (b) and corticosterone (c)
following the different preincubation conditions. *P<0.05. **P<0.01.
(Representative experiment of a set of four experiments).
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table i
Ratio of SRs (mean (+/- std dev.)
96h All preincubation 96h fskn preincubation Stats, (t test)
corticosterone/androstenedione 1.6 (+/- 0.07) 1.1 (+/-0.24) P<0.05
cortisoi/androstenedione 1.3 (+/-0.08) 1.1 (+/-0.45) P>0.05
cortisol/corticosterone 0.8 (+/-0.06) 1.1 (+/-0.57) p>0.05
mineralocorticoid pathway) and decreases following forskolin treatment (favouring
the glucocorticoid/androgen pathway). All is believed to exert these effects via
the protein kinase C signalling pathway (4). The physiological agonist ACTH, in
contrast, activates protein kinase A to mediate its effects on steroidogenesis in
vivo. Forskolin was used to mimic this activation of protein kinase A since H295R
cells show poor response to ACTH, which is possibly related to the low levels of
ACTH receptor mRNA found in these cells (8).
Current theories suggest that cells in the three zones of the adrenal cortex arise
from a common undifferentiated, progenitor cell because transposition of cells
from all zones of the adrenal cortex to in vitro culture results in a loss of their
zone-specific properties (9). Migration of a cell from its origin in an outer stem
cell layer through all three zones of the cortex has been demonstrated by the
appearance of a pattern of radial stripes of a 21-hydroxylase promoter/p-
galactosidase reporter transgene throughout the cortex of transgenic mice (10).
Precisely what determines and regulates the differentiated phenotype of this cell is
still unclear. The ability of the H295R cell line's steroid phenotype to be shifted
from predominantly one pathway to another means that this cell line could be a
useful model for studying mechanisms regulating zonation and the differential
expression of the steroid pathways.
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Direct stimulation of Cortisol secretion from the human
NCI H295 adrenocortical cell line by vasoactive intestinal
polypeptide
Vanessa J. Cobb, Brent C. Williams*, J. Ian Mason and
Simon W. Walker
Objective To investigate a possible direct action of
vasoactive intestinal polypeptide (VIP) on adrenal Cortisol
secretion and to define its mechanism of action.
Design The human adrenocortical carcinoma call line NCI
H295, which is not contaminated by medullary chromaffin
cells, was used to aid distinction between a direct action.
of VIP on adrenocortical cells and an indirect mechanism
involving VIP-stimuiated release of catecholamines.
Methods NCI H295 cells were challenged with
10"11-10"7 mol/l VIP for 4 h, with or without prior
exposure for 72 h to 10 |imol/l forskoiin. Cortisol and
cyclic AMP contents of the overlying media were
measured using in-house radioimmunoassays. Cells were
treated with 10_a-10~6 mol/l adrenaline or 3J x 10"8mol/l
VIP with and without lO^-IO-6 mol/l propranolol to
exclude the possibility that an indirect mechanism of
action involving p-adrenoceptors was operating.
Results VIP treatment produced an increase in Cortisol
secretion without pre-incubation, but this was markedly
enhanced by prior exposure of cells to forskoiin. VIP was
potent with a threshold of 10-" mol/l (n -»4), reaching
a maximum 3.9 ± 0.9-fold increase in effect on cells
Introduction
Elevated plasma Cortisol levels have been associated with
high blood pressure in young people with a familial history
of high blood pressure and may be an indication of a
predisposition to hypertension [1], Amongst subjects of
this group there was also aif increased prevalence of the
AA genotype of the glucocorticoid receptor. It is possible
that higher plasma Cortisol levels result from the presence
of this particular receptor genotype but they may equally
well be an independent event. Thus, factors that increase
Cortisol secretion may also be involved in the pathophys¬
iology of essential hypertension.
There is accumulating evidence to indicate that adreno-
corticotrophic hormone is not the sole regulator of Cortisol
secretion and that neural control mechanisms influence
steroidogenesis in the human and other mammalian
species (for review [2,3]). The adrenal cortex of several
species contains ganglion cells and nerve fibres that
pre-«xposed to forskoiin (n — 4) by 2J3 x 10-* mol/I.
This increase matched the 4 h response to 10 pmol/1
forskoiin. Cortisol secretion was accompanied by a
parallel, dose-dependent increase in accumulation of
cAMP.
Conclusions VIP potently and directly stimulates secretior
of Cortisol from these adrenocortical cells of human
origin via an adenylate cydase-coupied VIP receptor.
These findings raise the possibility of a significant and
direct effect of VIP in the control of steroid secretion
from the adrenal cortex in humans.
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synapse in close apposition to adrenocortical cells as well
as blood vessels within the cortex [4,5].
Several putative neurotransmitters have been implicated
as regulators of adrenal steroidogenesis, including acetyl¬
choline, catecholamines, corticotrophin-releasing factor,
neuropeptide Y and vasoactive intestinal polypeptide
(VIP, for review [3]). In the case of VIP, it has been dem¬
onstrated that rat adrenal cortex contains VlP-immuno-
reactive nerve fibres [4] together with the VIP receptor
messenger RNA being present both in the adrenal cortex
and 'in the medulla [6]. Stimulation of the splanchnic
nerve results in an increase in glucocorticoid secretion, in
the presence of exogenous adrenocorticotrophic hormone,
from the adrenals of conscious hypophysectomized calves
[7], an effect mimicked by infusion of exogenous VEP [8].
Furthermore, stimulation of the splanchnic nerve is
accompanied by the appearance of VIP in the venous
effluent from conscious calves [9]. In other species, VIP
1736 Journal of Hypertension 1997, Vol 15 No 12 (part 2)
was found to stimulate androstenedione secretion from
isolated, perfused porcine adrenals [10] and to increase
steroid production from intact capsule-zona glomcrulosa
preparations from the rat [11].
Controversy has surrounded the question of whether VIP
can stimulate steroidogenesis directly. Hinson et al. [12]
failed to obtain a response of steroid secretion to VIP in
collagenase-dispersed rat adrenocortical cells but observed
an increase in aldosterone secretion to VIP from an intact
capsule-zona glomeralosa preparation. Because adminis¬
tration of VIP can stimulate release of catecholamines
from medullary chromaffin cells [13], it has been postu¬
lated that it might act indirectly by releasing catechol¬
amines from islets of chromaffin cells known to be present
in the cortex [14]. The catecholamines would then stim¬
ulate secretion of steroids by acting on ^-adrenoceptors
present on the adrenocortical cells. In contrast, Mazzocchi
et al. [15] reported that an increase in steroid secretion
occurred with administration of VIP in dispersed rat
adrenocortical cells. Because it is likely that collagenase-
dispersed . rat adrenocortical cell preparations could
contain some contaminating medullary chromaffin cells,
it is difficult to determine whether the response observed
is direct, indirect or both. Bomstein et al. [16] reported
that only an attenuation of VIP-induced secretion of
steroid in response to propranolol treatment occurred in
a primary culture of human adrenal cells (a mixed culture
of adrenocortical and medullary cells) [16], indicating that
two mechanisms of VIP action may be involved.
In order to investigate a possible direct action of VIP on
adrenocortical cells, we studied the steroidogenic effects
of VIP on the human adrenocortical carcinoma cell line
NCI H295. This cell line was originally established from
a primary invasive adrenal tumour in 1980, from a patient
showing signs of mineralocorticoid, glucocorticoid and
adrenal androgen excess [17]. It has since been charac¬
terized and shown to secrete steroids from the three major
pathways in the adrenal cortex [18]. Becauseit is not cont¬
aminated by medullary chromaffin cells, the NCI H295
adrenocortical cell line is the model of choice for exper¬
iments to distinguish direct from indirect effects of VIP
on adrenocortical steroidogenesis.
Materials and methods
NCI H295 cells (ATCC, Rockville, Maryland, USA) were
seeded into 12-welI plates (5 x 105 cells per well) and
maintained in Dulbecco's modified Eagle's medium F12,
2% Ultroscr HY (Gibco, Renfrew, UK), 5 |xg/ml insulin,
5 p.g/ml transferrin and 5 ng/ml sodium selenite (as 1%
ITS; Sigma, Poole, UK) at 37°C with 5% COz-95% air.
Cells were pretreated with the above medium containing
either 10 pjnol/1 forskolin or no agonist ('control') for
72-% h, replacing medium every 24 h. After pretreat-
mcnt, cells were washed with Earle's balanced salt solu¬
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Dose-dependent increases in (a) Cortisol and (b) cyclic AMP
(cAMP) secretions after 4 h challenge with vasoactive intestinal
peptide (VIP) (•). Maximal stimulation occurred in response to
3.3 x 1CT* mot/1 VIP'(a 3.9 ± 0.9-fold increase) and was compara
to that in response to a 4 h challenge with 10 fimol/l forskolin
(fskn). Combined data (expressed as mean n-fold increases relati
to basaJ values ± SD) from four experiments both for Cortisol an*
cAMP.
exposed to fresh serum-free medium with or withe
10~n-10~7 mol/1 VP for 4 h at 37°C. For p-adrcnocep
activation studies, cells were treated in the same mani
but with various doses of adrenaline, propranolol or V
plus propranolol, as stated in the Results.
After 4 h, medium was removed and the Cortisol and eye
AMP (cAMP) content measured, using direct radioi
munoassays. The cell monolayer was washed (in Eagl
VIP-stimulated Cortisol secretion Cobb ef aJ. 173'
*0.2
(b) • 175 :
_ 150 -
.c






•r <o -r to a. <x> to
3. I - 1 > I - I
°
a. a a. a_ a <
Administrations of 10~®, 10~7 and 10~® mol/l propranolol (Pi
failed to inhibit 4 h basal, 4 h forskolin (Fskn and fskn)-stimulated
(10 ixmoi/I) and 4 h vasoactive intestinal peptide (VIP,
3.3 x 10"* mol/l)-stimulated Cortisol (a) and cyclic AMP (cAMP, b)
secretions (■; only 10~° mol/l P data are shown). Representative
experiment from three experiments both for Cortisol and for cAMP.
Four-hour challenges with 10~", 10"' and 10~® mol/I adrenaline (A)
failed to stimulate Cortisol (a) and cAMP (b) secretion above basal
levels (22; only 10-6 mot/I A data are shown). Representative
expenment from a set of three expenments both for Cortisol and for
cAMP.
balanced salt solution alone) and taken up into 0.3 mol/l
NaOH with 0.1% sodium dodecyl sulphate for subsequent
protein determination. The steroid and cAMP measure¬
ments were corrected for cell protein concentration.
Results arc expressed as means of triplicate wells ± SD
for n experiments. Statistical tests were performed using
an unpaired, two-tailed, Student's t test. P < 0.05 was
considered statistically significant.
Results
Administration of 10~"-10~7 mol/l VIP produced a dose
dependent increase in secretion of Cortisol by H295 cells
The stimulation was statistically significant for 'control
cells (no pre-incubarion), in that a dose of 10"8 mol/
VIP resulted in a 2.0 ± 0.3-fold stimulation of cortiso
sfceretion relative to basal values (n - 4). However, thi;
response was greatly enhanced for cells pretreated foi
72 or % h with 10 (xmol/l forskolin, for which 10""8 mol/
VIP elicited a 3.6 ± 0.6-fold increase relative to basa
values (n - 4), the threshold change occurring at 10"'
mol/l (n - 4).
The maximal response to VIP occurred at a dose o
3.3 x 10"8 mol/l both for Cortisol and for cAMP productior
and pEC50 (negative logarithm to the base 10 of the
concentration for half the maximal effect) values were
9.22 ± 0.43 (n - 4) and 8.57 ± 0.45 (n - 4) for Cortisol anc
cAMP production, respectively (Fig. 1).
Administration of the |3-adrcnoceptor antagonist propra¬
nolol did not affect either basal or VIP-stimulated cortiso
or cAMP secretion, which was consistent with the VIF
response occurring through a specific VIP receptor anc
not, therefore, supportive of the hypothesis of there being
an interaction of VIP with ^-receptors (Fig 2). Indeed,
administration of the non-selective fi-receptor agonist
adrenaline failed to elicit an increase either in Cortisol or
in cAMP levels relative to basal values from H295 cells
suggesting that there had been a loss of functiona
(3-receptors on cells of this cell line (Fig. 2).
Discussion
The mechanism by which forskolin pretrcatment en
hances the subsequent response to' VIP is, at present, no
known. Possible explanations include upregulation ofVH
receptors at the cell surface and upregularion of steroid
ogenic enzyme expression (since administration of for
skolin markedly upregulates expression and acrivir
of P450cl7 [19]). The latter explanation is supported br
the fact that pretreatment with forskolin also enhancec
the response of Cortisol secretion to a subsequent 41
further administration of 10 p.moi/1 forskolin. Th<
maximal steroidogenic effect of VIP was equivalent tt
that produced by 10 p.mol/1 forskolin, emphasizing thai
VIP is a very potent stimulus of Cortisol production ir
these cells.
Two subtypes of the VIP receptor, VIP1 and VIP2, have
so far been isolated and cloned [20,21]. Activation of VIP]
and VIP2 receptors increases intracellular cAMP levels vi;
activation of adenylate cyclase in a variety of tissues
Administration of VIP also elicited a dose-dependen
increase in cAMP production in forskolin-pretreated H29.'
cells which paralleled the increase in Cortisol producrioi
(see Fig.l).
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In conclusion, VIP acts directly on H295 cells to stimu- 21 sh—dWJ,w«tkm.mom*,ja.rnk&iwi n> vih3 rmptor mnwculr characterisation of a cONA encode*
late steroidogenesis with an accompanying dose-depcn- ■ nowi receptor for vasoactive intestinal peptide. febs Lett 1005
dent increase in cAMP. These findings do not rule out ssaa-e.
an indirect mechanism of action on adrenocortical cells
m vivo but raise the possibility of an accompanying direct
effect of VIP in the control of steroid secretion from the
adrenal cortex of man.
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